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ABSTRACT
Backgound - This thesis encompasses two main areas of study relating to factors 
predicting survival following resection for pancreatic cancer. The first section 
includes a detailed analysis of various clinico-pathological prognostic factors in a 10- 
year cohort of patients undergoing pancreatic resection at a single regional tertiary 
referral centre (1). The second section comprises a systematic review and meta­
analysis of published literature investigating several key immunohistochemical 
prognostic factors in resected pancreatic cancer (2).
Methods - (1) Retrospective clinical and histopathological data were collected for 166 
patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma and 
entered on to a database. The histopathology slides were retrieved for all resection 
margin negative (RO) cases and re-assessed to conduct an analysis of the prognostic 
relevance of ‘equivocal’ margin involvement (ie. microscopic tumour involvement 
within 1mm of one or more margins without directly breaching the margin itself). 
Survival analyses were undertaken to identify the most important prognostic variables 
with a view to generating a combined prognostic index. (2) p53, smad4, pi6, bcl-2, 
bax, VEGF and EGFR were identified as the most widely investigated and 
biologically important molecular prognostic factors in resected pancreatic cancer. 
MEDLINE, EMBASE and ISI Web of Science were used to search for relevant 
literature and a random effects inverse variance approach was used to analyse the 
pooled data.
Results - (1) Tumour size, differentiation and lymph node ratio were found to be 
significant histopathological prognostic factors for overall survival on multivariate 
analysis. Sub-group analysis of resection margin status indicated no significant 
survival difference between ‘equivocal’ and definitive R1 cases. The preoperative
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platelet-lymphocyte ratio was identified as a novel prognostic factor and was found to 
exhibit strong relationships with both invasive tumour characteristics and likelihood 
of postoperative patient selection for adjuvant therapy. Preoperative serum albumin 
and CA19-9 were also significant independent prognostic factors on multivariate 
analysis. A combined score was found to provide superior prognostic information to 
any individual preoperative or histopathological factor. (2) VEGF (11 studies, n=767), 
bcl-2 (5 studies, n^314), bax (5 studies, n=274) and pi6 (3 studies, n=229) emerged 
as significant immunohistochemical prognostic markers from the pooled data of meta- 
analysed studies while p53 (17 studies, n=925), smad4 (5 studies, n=540) and EGFR 
(4 studies, n=250) returned non-significant results. There was evidence of significant 
heterogeneity in four of the seven study groups.
Conlusions - The findings from this study provide the first clinical evidence to support 
use of the 41mm rule’ in defining resection margin status for pancreatoduodenectomy 
reporting. This issue was found to have a significant impact on the overall number of 
cases classified as Rl. The preoperative platelet-lymphocyte ratio is a newly 
described prognostic marker in resected pancreatic cancer and when analysed 
alongside serum CA19-9 and albumin levels, comparable prognostic information can 
be derived from these routine preoperative haematological and biochemical 
parameters when compared with standard histopathological tumour characteristics. 
The meta-analysis of immunohistochemical prognostic studies indicates that VEGF 
represents the most potentially informative prognostic factor of the seven most widely 
investigated molecular markers identified and should be considered as a comparative 
marker in future prognostic studies utilising microarrayed tissue from adjuvant 
therapy trials for resected pancreatic cancer.
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1. INTRODUCTION
1.1.1. EPIDEMIOLOGY
Over 232,000 new cases of exocrine pancreatic cancer are estimated to occur 
worldwide each year (International Agency for Research on Cancer 2002). Pancreatic 
cancer is the tenth most common malignancy in the United Kingdom, accounting for 
3% of all new cases of cancer each year with 7632 cases diagnosed in 2005 
(http://info.canceiTesearchuk.org/cancerstats). The aggressive nature of the disease is 
underlined by the fact that pancreatic cancer represents the sixth most common cause 
of UK cancer mortality with 7250 deaths per year (Office for National Statistics 2004) 
- ie. a mortality to incidence ratio approximating 1.0.
Having peaked in the 1970s and 1980s, the UK age-standardised incidence of 
pancreatic cancer is believed to have fallen slightly over the past 20 years with a 
consequent similar pattern seen for age-standardised mortality rates (Fitzsimmons et 
al. 2007; Wood et al. 2006).
Gender
Men and women in the UK have a comparable lifetime risk for developing pancreatic 
cancer of approximately 1.0%. However, males have a greater age-standardised 
incidence rate for pancreatic cancer when compared to females (10.1 per 100,000 and 
7.7 per 100,000 respectively [Office for National Statistics 2007]). The male-to 
female ratio of age-standardised incidence rates has gradually decreased over recent 
years in England and Wales (Wood et al. 2006). The pattern of differences in 
incidence rates between males and females is likely to be attributable to changing 
patterns of lifestyle factors due to the association between smoking and pancreatic 
cancer risk.
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Age
Pancreatic cancer incidence rises sharply in patients over the age of 60 years with 
85% of cases occurring in patients within this demographic group. 6.9 cases per 
100,000 are seen in patients aged 45-49 years compared with 50.1 cases per 100,000 
in patients aged 75-79 years (Cancer Research UK 2004).
Socioeconomic status
There is no evidence to suggest that the incidence of pancreatic cancer is higher for 
UK populations in lower socioeconomic groups when compared with more affluent 
groups (Wood et al. 2006; Dutta Roy et al. 2005). Only marginal differences in 
pancreatic cancer incidence between socioeconomic groups have been reported in 
countries elsewhere in Europe (Ji et al 2006; Weiderpass et al. 2006). These findings 
are likely to relate to the influence of potential differences in lifestyle and 
occupational risk factors for pancreatic cancer between different socioeconomic 
strata. Occupational factors reported to be associated with an increased risk of 
developing pancreatic cancer include industries associated with printing and paper 
manufacture, along with petroleum and chemical industries, particularly those 
involving formaldehyde exposure (Keman et al. 1999).
Ethnicity
Previous epidemiological data from North America have suggested that the incidence 
of pancreatic cancer is more common in black populations when compared with 
Caucasian populations (Ries et al. 2002). This finding contrasts with other 
epidemiological data which have demonstrated that the age-standardised mortality 
rates for pancreatic cancer (used as a surrogate marker of incidence) are significantly
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less in African countries when compared with many developed countries 
(International Agency for Research on Cancer 2002). This observation has been 
explained on the basis of lifestyle differences between the different ethnic groups 
(Silvennan et al. 2003). Although Japan and Korea are among the countries with the 
highest age-standardised mortality rates for pancreatic cancer in the world, the 
corresponding mortality rates for China, Indonesia and Malaysia are all significantly 
less (International Agency for Research on Cancer 2002). These differences are 
similarly believed to be attributed to dietary and lifestyle factors rather than 
genetically detennined risk.
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1.1.2. AETIOLOGY
Smoking
Cigarette smoking is believed to be the most significant environmental determinant of 
pancreatic cancer risk. Smokers have been demonstrated to have a two-fold increased 
risk of developing pancreatic cancer when compared to non-smokers with evidence 
for a dose-dependent relationship between smoking and cumulative risk (Silverman et 
al. 1994; Lin et al. 2002), It has previously been proposed that exposure of the 
pancreatic ductal epithelium to cigarette-derived carcinogens excreted in bile results 
in the trigger for carcinogenesis (Wynder et al. 1973). In vitro and animal studies have 
shown that exposure of one of the key carcinogenic tobacco-specific nitrosamines (4- 
(methylnitrosamino)-l-(3-pyridyl)-l-butanone - NNK) to pancreatic epithelial cells 
results in activation of intra-cellular proliferative pathways (Askari et al. 2005; Al- 
Wadei et al 2009). NNK has been shown to exhibit significant biliary excretion in rats 
(Schulze et al. 1992) and has been identified in pancreatic juice from smokers 
(Prokopczyk et al. 2002). Polymorphisms of genes involved in carcinogen- 
metabolising protective mechanisms may also be a significant determinant of 
pancreatic cancer risk in individual smokers (Bartsch et al. 1998; Duell et al. 2002).
Alcohol
Previous studies have suggested that long-standing heavy alcohol consumption may 
be a contributory risk factor in the development of pancreatic cancer (Go et al. 2005; 
Ye et al. 2002). However, the extent to which this effect is exerted as a result of 
alcohol-induced chronic pancreatitis or separate non-pancreatitis related pathways is 
unknown (Whitcomb et al. 2002; Jelski et al 2007). Additional confounding factors 
include the propensity for alcoholics to develop type II diabetes mellitus (which may
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also represent an additional risk factor for pancreatic cancer) along with the fact that 
heavy alcohol consumption is invariably associated with cigarette smoking and 
adverse dietary patterns. In a recent US prospective study including over a million 
participants, excessive consumption of spirits was associated with a significantly 
greater pancreatic cancer risk when compared with excessive beer or wine 
consumption (Gapstur et al. 2011).
Nutrition
As with other malignancies such as colorectal cancer, dietary intake of various 
carcinogens commonly produced as result of food preparation (eg. polycyclic 
aromatic hydrocarbons (PAH), heterocyclic amines, etc) is believed to play a role in 
predisposing to pancreatic carcinogenesis (Silverman et al. 1998; Anderson et al 
2002). Conversely, a high dietary intake of antioxidants may provide a protective 
mechanism against genotoxic hue-radical production and DNA adduct formation 
associated with various carcinogens, whether inhaled or ingested (Woutersen et al. 
1999). The extent to which dietary risk for pancreatic cancer is related to, or 
independent of, smoking and alcohol intake is unknown. However, recent evidence 
has suggested that a high dietary intake of carcinogens derived from cooked meats 
increases the risk of pancreatic cancer synergistically alongside cigarette smoking (Li 
et al. 2007).
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Chemopreventive agents
Given the poor survival rates associated with a diagnosis of pancreatic malignancy, 
much interest has focused on whether potential chemopreventive agents might be able 
to reduce the risk of developing pancreatic cancer. The proposed anti-cancer effects of 
non-steroidal anti-inflammatory drugs (NSAIDs) have been most widely investigated 
in the context of pancreatic cancer prevention and in vitro evidence exists to suggest 
that COX-2 inhibition might influence the progression of carcinogenesis and 
metastatic potential in pancreatic cancer cells (Wenger et al. 2002; Fumkawa et al. 
2003). However, the clinical evidence to support a link between NSAID use and 
reduced pancreatic cancer risk is mixed (Anderson et al. 2002a; Coogan et al. 2000). 
Similarly, conflicting evidence exists with regard to whether regular aspirin use is 
associated with a reduced risk of developing pancreatic cancer (Schemhammer et al. 
2004; Jacobs et al. 2004).
Evidence has been published suggesting that regular statin use (ie. 3-hydroxy-3- 
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors) is associated with a 
reduced likelihood of pancreatic cancer (Khurana et al. 2007). In vitro evidence has 
also demonstrated an association between statin exposure and reduced metastatic 
potential in pancreatic cancer cell lines (Kusuma et al. 2002). However, a meta­
analysis of population-based studies failed to support a significant association 
between long-term statin use and reduced pancreatic cancer risk when taken at levels 
to treat hypercholesterolaemia (Bonovas et al. 2008).
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Recent pre-clinical evidence has emerged with regards to the potential anti-cancer 
effects of beta-blockers in the setting of pancreatic cancer with studies reporting pro- 
apoptotic properties of beta-adrenergic antagonists on pancreatic cell lines (Zhang et 
al. 2011) and chemopreventive effects reported in animal models (Al-Wadei et al. 
2009). No clinical trials have been conducted to date but a recent retrospective cohort 
study suggested adverse survival outcomes associated with beta-blocker use in 
patients with pancreatic cancer (Shah et al. 2011). This study included only a limited 
number of patients with pancreatic cancer (n=140) and the presence of concurrent 
cardiac co-morbidity represents a confounding factor in the interpretation of these 
results.
Curcumin represents a naturally occurring agent derived from the tumeric plant which 
has been widely investigated as both a therapeutic and chemopreventive agent in the 
setting of pancreatic cancer. Curcumin has been shown to inhibit pancreatic cancer 
cell proliferation in vitro (Wang et al. 2006) and has also been shown to sensitize 
pancreatic cancer cells to the cytotoxic effects of gemcitabine in both pancreatic 
cancer cell lines (Lev-Ari S et al. 2007) and animal models (Kumiumakkara et al. 
2007). Its clinical usefulness is potentially limited by its poor bioavailability but a 
number of clinical trials utilising curcumin alongside palliative chemotherapy are 
currently being conducted for locally advanced pancreatic cancer (Stan et al. 2010). 
Several other naturally occurring agents including beta-carotene, vitamin D, vitamin 
E, isothiocyanates (found in broccoli and cabbage), capsaicin (found in red chilli 
peppers), resveratrol (found in grape skins) and genistein (found in soy products) 
represent potential therapeutic or chemopreventive agents for pancreatic cancer (Stan 
et al. 2010).
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Chronic pancreatitis
Chronic pancreatitis is both an aetiological factor and physiological consequence of 
pancreatic carcinogenesis. Pancreatic cancer commonly results in ductal obstruction 
with development of progressive features of secondary chronic pancreatic 
inflammation and fibrosis with consequent exocrine and endocrine insufficiency. 
Several studies have described an association between chronic pancreatitis of 
differing aetiological causes and the development of pancreatic cancer (Whitcomb et 
al. 2002; Maisonneuve et al. 2002). However, the strongest evidence to support a clear 
causal relationship between pancreatic inflammation and malignancy has been 
reported in cases of hereditary pancreatitis (Lowenfels et al. 1997). This condition is 
inherited in an autosomal dominant manner and results from mutations in the cationic 
trypsinogen gene PRSS-1 in around 80% of cases (Whitcomb et al. 1996; Howes et al. 
2005), It has previously been demonstrated that hereditary pancreatitis is associated 
with a lifetime risk for developing pancreatic cancer of approximately 40% (Howes et 
al. 2004) and this patient group represents a significant target population who might 
potentially benefit from pancreatic cancer screening (Vitone et al. 2005).
Diabetes mellitus
As with chronic pancreatitis, the association between diabetes and pancreatic cancer 
may reflect a causal or consequential one. A previous meta-analysis of studies 
investigating the relationship between type II diabetes mellitus and pancreatic cancer 
demonstrated a combined odds ratio for pancreatic cancer of 1.82 in type II diabetics. 
However, significant heterogeneity existed between the studies included in this 
analysis and the effect of other potential confounding factors such as smoking and 
diabetes was not investigated (Huxley et al. 2005). An increased cancer risk was
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identified among patients with a recent diagnosis of type II diabetes when compared 
with patients in whom a diagnosis of diabetes was made greater than five years 
previously. An additional meta-analysis has also demonstrated a similar increased risk 
of pancreatic cancer in patients with early-onset type I diabetes (odds ratio = 2.00). 
However, this finding was based on a smaller number of studies (Stevens et al. 2007).
Genetic predisposition
Several studies have provided significant evidence for familial clustering of 
pancreatic cancer, suggesting that a genetic predisposition is the causative aetiology in 
up to 10% of all cases. A number of hereditary cancer syndromes have been shown to 
be associated with an increased risk of pancreatic cancer. Familial atypical multiple- 
mole melanoma (FAMMM) syndrome is associated with development of multiple 
cutaneous naevi progressing to malignant melanoma and FAMMM kindreds 
exhibiting pi6 mutations have been demonstrated to exhibit a 13-fold increase in the 
risk of pancreatic cancer (Goldstein et al. 1995). Breast-ovarian cancer syndromes 
associated with BRCA1 and BRCA2 mutations and hereditary non-polyposis colorectal 
cancer (HNPCC) caused by mutations in mis-match repair genes including hMSH2 
and hMLHl represent the two other main familial cancer syndromes most commonly 
associated with increased pancreatic cancer risk (Phelan et al. 1996; Peltomaki et al. 
1997). Pancreatic cancer is also variably shown to be associated with less common 
inherited cancer syndromes including Peutz-Jehgers syndrome (Giardello et al. 2000) 
and familial adenomatous polyposis, a condition which has been demonstrated to 
confer a 4.5 fold increased risk of pancreatic cancer when compared with the general 
population (Giardello et al. 1993).
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An additional group of families have been reported in which clustering of pancreatic 
cancer is seen within first-degree relatives in an autosomal dominantly inherited 
pattern in the absence of any existing hereditary cancer syndromes. A diagnosis of 
familial pancreatic cancer (FPC) requires at least two first-degree relatives to have 
had histologically-confirmed pancreatic adenocarcinoma who cannot be categorised 
into an existing hereditary cancer syndrome (Hruban et al. 1998). BRCA2 mutations 
have been identified in up to 20% of FPC families and the pattern of cancer 
inheritance in these kindreds has been shown to exhibit features of genetic 
anticipation with successive generations developing pancreatic cancer at progressively 
earlier ages (McFaul et al. 2006). Large pancreatic cancer family registries have been 
established both in Europe and North America to further investigate inherited 
pancreatic cancer risk in these different groups and to evaluate the potential benefits 
of secondary screening programmes to facilitate earlier detection of pancreatic 
malignancy in high-risk families.
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mi.13. PATHOLOGY
Neoplasms arising from the pancreas can be broadly classified as either exocrine 
(ductal or acinar cell) or endocrine according to their tissue of origin. Table 1 
demonsfrates the World Health Organisation (WHO) classification for malignant 
tumours arising from the exocrine pancreas.
Table 1 - WHO classification of malignant pancreatic exocrine tumours (Kloppel et al. 1996)
Description SNOMed code
Ductal adenocarcinoma (infiltrating ductal carcinoma) M8500
Mucinous noncystic carcinoma (mucinous adenocarcinoma) M8480
Signet-ring cell carcinoma M8490
Adenosquamous carcinoma M8560
Undifferentiated (anaplastic) carcinoma M8020
Mixed ductal-endocrine carcinoma M8154
Osteoclast-like giant cell tumour M8030
Serous cystadenocarcinoma M8441
Mucinous cystadenocarcinoma M8470
Intraductal papillary-mucinous carcinoma M8502
Invasive papillary-mucinous carcinoma M8503
Acinar cell carcinoma M8550
Pancreatoblastoma M8971
Solid-pseudopapillary carcinoma M8452
19
Pancreatic ductal adenocarcinoma and variants
Ductal adenocarcinoma accounts for over 90% of all pancreatic malignancies and is 
taken to be synonymous with the term ‘pancreatic cancer5. Approximately 75% of 
lesions arise in the head of the pancreas and the tumour is frequently associated with 
intense microscopic evidence of desmoplasia reflecting a stromal host inflammatory 
reaction to the tumour mass. Features of intrapancreatic perineural invasion are 
invariably seen which may extend to involve the extrapancreatic nerve plexus. 
Lymphatic, direct and haematogenous spread are common early events in the natural 
history of pancreatic ductal adenocarcinoma which frequently precede the 
development of symptoms resulting in the majority of patients exhibiting locally 
advanced or metatstatic disease at presentation.
Immunohistochemical study of ductal adenocarcinomas demonstrate that these 
tumours characteristically express cytokeratins (CK7,8,18,19) indicating their 
epithelial origin, along with overexpression of the tumour markers CA19-9 and 
carcinoembryonic antigen (CEA). Mucinous (non-cystic) adenocarcinoma, signet-ring 
cell carcinoma and mixed ductal-endocrine carcinomas reflect histological variants of 
pancreatic ductal adenocarcinoma.
Intraductal papillary mucinous neoplasms (IPMNs)
IPMNs account for over 20% of all cystic neoplasms arising from the pancreas and 
represent a group of tumours arising from the main pancreatic duct or side branches 
which exhibit a mucin-producing columnar or papillary epithelium with macroscopic 
cystic appearances. This description encompasses a morphologically diverse array of 
different lesions which have been variably referred to over recent decades (eg.
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mucinous ductal ectasia). However, a standardised definition was published in 1996 to 
classify the description of this category of cystic pancreatic lesions (Kloppel et al. 
1996). IPMNs are known to have malignant potential and previous series have 
demonstrated that approximately 25-40% of resected IPMNs exhibit invasive 
histological features. Malignant transformation results in either a ductal (tubular) or 
colloidal histological sub-type, the latter of which is associated with more favourable 
survival outcomes (Adsay et al. 2003). IPMNs arising from the main pancreatic duct 
have a greater likelihood of malignant transfonnation when compared with those 
arising from side-branches and should be considered for surgical resection over 
surveillance. Other unfavourable characteristics for malignancy include IPMNs 
greater than 3 cm in size, generalised pancreatic duct dilatation and the presence of 
concurrent symptoms (Tanaka et al 2006).
Acinar cell carcinoma
These tumours are uncommon and account for only 3% of all pancreatic 
malignancies. Acinar cell carcinomas characteristically form macroscopic nodular 
lesions and exhibit evidence of enzyme production with consequent positive staining 
for trypsin on iimnunohistochemistry. Acinar cell carcinomas confer a similarly poor 
prognosis when compared with ductal adenocarcinoma.
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1.1.4. PanIN PROGRESSION MODEL
An association between pancreatic cancer and the presence of potential epithelial 
precursor lesions incorporating a spectrum of morphological abnormalities including 
metaplasia, hyperplasia and dysplasia was proposed over 50 years ago (Sommers et 
ah 1954). Since then, subsequent authors have made similar observations (Cubilla et 
al. 1976) but it was not until later that the term PanIN (pancreatic intraepithelial 
neoplasia) was coined (Klimstra et al. 1994). A fonnal classification scheme was 
subsequently proposed by Hruban et al in 2001 {Table 2).
Table 2 - Classification of Pancreatic Intraepithelial Neoplasia,
Description PanIN category
Flat epithelial lesions composed of tall columnar cells with 
basally located nuclei and abundant supranuclear mucin.
PanIN-1A
Epithelial lesions that have a papillary, micropapillary or 
basally pseudostratified architecture, but are otherwise 
identical to PanIN-1 A.
PanIN-IB
Mucinous epithelial lesions that may be flat but are mostly 
papillary. By definition, these lesions exhibit mild or 
moderate nuclear atypia which falls short of those seen in
PanIN-3.
PanIN-2
Usually papillary or micropapillary lesions with severe 
cellular atypia / dysplasia. The lesions resemble carcinoma at 
the cytonuclear level without demonstrable features of
PanIN-3
invasion.
Subsequent studies have provided evidence for a step-wise accumulation of genetic 
abnormalities resulting in transfonnation of normal pancreatic ductal cells into PanlN- 
1 with subsequent progression to PanIN-2, PanIN-3 and eventually invasive 
adenocarcinoma. Mutations of the proto-oncogene K-ras are believed to represent an 
early event triggering the development of hyperplasia and initiation of the PanIN
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pathway. Previous studies have demonstrated a high rate of K-ras mutations in cancer- 
associated PanINs (Lohr et al. 2005). Inactivation of the tumour suppressor gene pi6 
is also believed to be an early event during PanIN progression. Loss of nuclear pi6 
expression has similarly been shown to represent a common finding in cancer- 
associated PanIN-1 and PanIN-2 lesions (Wilentz et al. 1998). Loss of smad4 
expression along with p53 mutation are, in contrast, believed to be relatively late 
events during the PanIN progression model which may contribute to the transition 
from PanIN-3 to invasive malignancy (Maitra et al. 2003; Wilentz et al. 2000).
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1.1.5. PANCREATIC CANCER AND PROGNOSIS
Pancreatic cancer is among the most biologically aggressive of all human 
malignancies with mortality rates approximating incidence. Less than 15 - 20% of 
patients typically present with resectable disease and overall survival for all stages of 
pancreatic cancer is consequently only around 3 to 5 months. Overall 5-year survival 
rates are similarly dismal (0.5% to 3%). Surgical resection is the only potentially 
curative intervention with median postoperative overall survival times of 12 to 18 
months typically quoted and 5-year survival rates in the region of 10%. However, 
adjuvant chemotherapy has been shown to confer a significant survival benefit with 5- 
year survival rates in excess of 20% (Neoptolemos et al. 2004; Oettle et al. 2007).
The identification of factors which are able to predict survival in pancreatic cancer is 
important for a number of reasons. Primarily, factors which are demonstrated to 
directly influence survival (eg. molecular markers expressed in tumour material) may 
provide insight into the underlying disease process and reveal therapeutic targets for 
research into disease-modifying drugs. The identification of standardised prognostic 
factors also allows meaningful comparisons of outcome between different studies 
which may exhibit significant differences in case mix. Furthennore, risk stratification 
as part of clinical trials is important in identifying whether certain sub-groups of 
patients are more or less likely to benefit from specific treatment modalities. Finally, 
being able to provide an accurate and honest appraisal of prognosis is important in 
patient counselling whether in a pre- or postoperative setting.
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1.1.6. MOLECULAR PROGNOSTIC FACTORS
Oncogenes
K-ras belongs to the ras family of proto-oncogenes and is located on chromosome 12. 
Ras proteins bind to GTPase-activating protein (GAP) and regulate signal 
transduction across the cell membrane, thereby regulating a number of cellular 
processes including differentiation and proliferation. In pancreatic cancer, the K-ras 
gene is most commonly affected by point mutations of codon 12 resulting in a number 
of different subtypes of mutation - aspartic acid (GAT), valine (GTT), arginine (CGT) 
and cysteine (TGT). The mutant form of the ras protein results in a GTPase domain 
which is no longer able to be inactivated by GAP, resulting in a constitutively active 
form of ras which predisposes the cell to uncontrolled proliferation and malignant 
transformation.
K-ras mutations are observed in around 80% to 90% of pancreatic adenocarcinoma 
cases (Lemoine et ah 1992; Allison et al. 1998). Most studies investigating the 
prognostic relevance of K-ras mutations in resected pancreatic cancer fail to 
demonstrate a significant relationship between the presence of K-ras mutations and 
survival (Allison et al. 1998). However, it has previously been shown that the subtype 
of K-ras mutation may be more relevant in determining prognosis (Kawesha et al. 
2000; Immervoll et al. 2006).
Tumour suppressor genes
p53 is a tumour suppressor gene located on chromosome 17 which codes for a gene 
product (the p53 protein) with a central role in inducing growth arrest and apoptosis in 
cells which sustain DNA damage. In noimal cells, p53 is bound to MDM2 which
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maintains p53 in its inactive form. DNA damage initiates cell cycle checkpoint 
proteins to phoshphorylate p53 into its active form which also results in a significant 
increase in its half-life. The active fonn of p53 binds to DNA which in turn activates 
expression of p21. p21 is a downstream target of p53 which inhibits cyclin-dependent 
kinases, resulting in cell cycle arrest which either leads to subsequent DNA repair or 
apoptosis. Point mutations of p53 result in a more stable form of the protein which is 
unable to bind to DNA and activate p21, allowing the cell to escape growth arrest.
50% to 75% of pancreatic cancers exhibit p53 mutations, most commonly in exons 5 
to 8 (de Brand et al. 2004). Nuclear accumulation of p53 detected by 
immunohistochemistry has been widely investigated as a potential prognostic factor in 
resected pancreatic cancer. However, only a relatively small number of studies report 
a significant relationship between overexpression of p53 and less favourable survival 
(Linder et al. 1997; Digiuseppe et al. 1994). p21 expression has not been 
demonstrated to have any significant prognostic value in pancreatic cancer (Song et 
al. 1996; Coppola et al. 1998).
pi 6 (CDKN2A) is a tumour suppressor gene located on chromosome 9 which is also 
believed to play an important role in pancreatic carcinogenesis, pi6 is a cell-cycle 
checkpoint protein which binds to cyclin-dependent kinases resulting in cell cycle 
arrest at the Gl/S checkpoint. Around 80% of pancreatic cancers have been 
demonstrated to lack expression of pl6 on immunohistochemistry (Kawesha et al. 
2000). However, the prognostic value of pi 6 expression in resected pancreatic cancer 
is variably reported (Kawesha et al. 2000; Naka et al. 1998).
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The smad4 (or DPC4) gene codes for a protein which is involved in the intracellular 
signalling pathway of transforming growth factor [3 (TGF-(3). The smad4 protein 
forms heterodimers in the cytoplasm with activated smad proteins 1, 2 and 3 which 
translocate to the nucleus activating gene transcription. Loss of smad4 expression, 
therefore, inhibits TGF-p signalling with consequent loss of its inhibitory effect on 
cell proliferation. Loss of smad4 expression is observed in approximately 50% of 
resected pancreatic cancers (Tascilar et al. 2001). Contradictory evidence exists with 
regard to whether loss of smad4 expression in resected pancreatic cancer has an 
adverse (Tascilar et al. 2001) or beneficial effect (Biankin et al. 2002) on patient 
survival.
Apoptotic factors
The ability of cancer cells to evade apoptotic pathways is believed to be an important 
mechanism in the pathogenesis of pancreatic cancer. The bcl-2 family of apoptotic 
genes codes for a number of proteins (including bcl-2, bcl-x, bax and bak) which exert 
either a pro-apoptotic or anti-apoptotic effect. These proteins are believed to mediate 
release of cytochrome C in the cytoplasm which in turn activates the effector 
caspases-3 and 9 which trigger breakdown of the intracellular cytoskeleton and the 
subsequent sequence of events resulting in apoptotic cell death. In pancreatic cancer, 
bcl-2 expression is variably reported to be a predictor of more favourable survival 
following resection (Dong et al. 2005; Bold et al. 1999) and this survival pattern is 
similarly reported for bax immunoreactivity (Friess et al. 1998). In contrast, bcl-x 
expression has been demonstrated to be a predictor of adverse survival in pancreatic 
cancer (Evans et al. 2001).
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Growth factors and receptors
Epidermal growth factor receptor (EGFR) is the cell surface receptor for a family of 
extracellular ligands which include EGF and TGF-a and is coded for by the c-erbBl 
proto-oncogene. Activation of EGFR stimulates intracellular tyrosine kinase 
phosphorylation with downstream activation of a number of signalling cascades 
including the MAPK (mitogen-activated protein kinase) and Akt (protein kinase) 
pathways which promote cell proliferation. Overexpression of EGFR is reported in up 
to 70% of pancreatic cancers. However, the prognostic value of iimnunohistochemical 
EGFR status is variably reported (Smeenk et al. 2007; Bloomston et al. 2006). Studies 
investigating the prognostic relevance of the EGF ligand expression in resected 
pancreatic cancer have demonstrated similar results (Dong et al. 1998, Gansauge et al. 
1998), Transforming growth factor-pi has also been investigated as a potential 
immunohistochemical prognostic marker in pancreatic cancer. However, conflicting 
evidence exists with regard to whether the presence of positive TGF-p expression 
correlates with poorer patient survival (Friess et al. 1993) or more favourable patient 
survival (Coppola et al. 1998; Nio et al. 2005).
Vascular endothelial growth factor (VEGF) represents a family of four signalling 
proteins (isofonns A, B, C and D) which stimulate angiogenesis, promote chemotaxis 
of inflammatory cells and increase vascular peimeability. These ligands have three 
transmembrane receptors (VEGF-1, -2 and -3) which promote intracellular tyrosine 
kinase cascades when activated. Several studies have suggested a significant 
association between VEGF expression in pancreatic cancer and poorer survival 
following resection (Kurahara et al. 2004; Knoll et al. 2001; Bceda et al. 2001).
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1.1.7. HISTOPATHOLOGICAL PROGNOSTIC FACTORS
Although several single-centre studies have reported the prognostic impact of tumour 
histology in the setting of resected pancreatic cancer, relatively few published studies 
incorporate sizeable patient numbers to generate high-powered analyses. Two such 
studies presenting data from the Johns Hopkins School of Medicine (Pawlik et al. 
2007) and the ESP AC-1 trial (Bassi et al. 2005) which have analysed the prognostic 
value of histopathological tumour characteristics in large series of resected pancreatic 
cancer patients (n=905 and n=418, respectively) have demonstrated that tumour size, 
differentiation and nodal involvement represent independent prognostic factors for 
overall survival following surgery. Both studies failed to demonstrate a significant 
independent association between resection margin status and survival on multivariate 
analysis. Although other tumour characteristics are often also reported as potential 
prognostic factors (eg. perineural invasion, vascular invasion, T stage, etc), these 
additional factors are often inconsistently correlated with survival on multivariate 
analysis (eg. Pawlik et al. 2007).
Pawlik et al also demonstrated that the ratio of involved lymph nodes to sampled 
lymph nodes in resected pancreatic cancer specimens provides superior prognostic 
information to overall nodal status (ie. positive vs. negative). This finding has also 
been mirrored in other gastrointestinal malignancies (Berger et al. 2005; Inoue et al. 
2002). These findings indicate that tumour size, differentiation and lymph node ratio 
represent the key histopathological prognostic factors to use when conducting 
comparative multivariate analyses of potential supplementary prognostic factors.
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Two recent studies have indicated that tumour involvement of the resected pancreatic 
cancer specimen on microscopic histopathological examination is commonly under- 
reported in the literature (typically 20% to 40%). These two studies (Verbeke et al. 
2006; Esposito et al. 2008) demonstrated R1 rates of 85% and 76% respectively when 
using the Royal College of Pathologists guidelines (Campbell et al. 2002). These 
guidelines stipulate that tumour involvement within 1 mm of a resection margin 
should result in a R1 classification. However, the rationale for this criterion was based 
on studies investigating circumferential margin involvement in colorectal cancer and 
no evidence exists to suggest that this principle of microscopic margin involvement 
within 1 mm is directly applicable to pancreatic cancer. The prognostic impact of 
multifocal resection margin involvement (ie. where >1 involved resection margin is 
present in a single specimen) and the relevance of individual margin location are also 
unknown. Few studies have investigated how other histopathological tumour 
characteristics influence likelihood of margin involvement (Raut et al. 2007).
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1.1.8. PREOPERATIVE PROGNOSTIC FACTORS
CA19-9
Carbohydrate antigen 19-9 (CA19-9) is a sialyated Lewis blood group antigen 
expressed in normal pancreatic ductal cells and is also secreted in a mucin-bound 
form by the biliary and gallbladder mucosa and excreted in bile. Obstructive jaundice 
will commonly precipitate elevated serum concentrations and around 5% of the 
population are believed to lack the Lewis antigen glycosyl transferase enzyme 
required to synthesize CA19-9 (Itzjowitz et al. 1986). A cut-off level of >37 kU/1 is 
generally used as the optimal point at which pancreato-biliary malignancy can be 
differentiated from benign disease in symptomatic patients (Goonetilleke et al. 2007). 
Normalisation of CA19-9 levels following resection for pancreatic cancer has been 
shown to be associated with a significant improvement in subsequent survival (Sperti 
et al. 1993; Montgomery et al. 1997; Safi et al. 1998), However, relatively few studies 
have investigated the potential role of preoperative CA19-9 levels in isolation as a 
prognostic index (Kau et al. 1999; Lundin et al. 1994; Ferrone et al. 2006).
Lymphocyte count
The immune status of patients is increasingly recognised as a key determinant of 
cancer outcomes. Pancreatic cancer exhibits a number of mechanisms by which the 
tumour can escape immune surveillance and inhibition of lymphocyte function 
secondary to release of the inhibitory cytokines interleukin-10 and TGF-(3 is believed 
to be one such mechanism (Bellone et al. 1999). Only two previous studies have 
investigated the potential prognostic value of low preoperative lymphocyte counts in 
resected pancreatic cancer (Yamaguchi et al. 2000; Fogar et al. 2006). These studies 
included a limited number of patients (n=14 and n=23, respectively). However, both
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suggested a significant association between preoperative 1 ymphocytopaenia and 
poorer survival.
Platelet count
A similarly small number of studies (n=3) have investigated the relationship between 
preoperative platelet count and survival in resected pancreatic cancer. These studies 
are conflicting in that two suggest a relationship between thrombocytosis and adverse 
survival (Suzuki et al. 2004; Brown et al. 2005) while an additional study indicated 
the opposite relationship with lower platelet counts exhibiting an association with less 
favourable survival (Schwarz et al. 2001). However, the latter study did include a mix 
of both pancreatic and periampullary cancers in the survival analysis.
C-reactive protein (CRP)
Although the association between elevated serum CRP levels and adverse survival has 
been widely investigated in advanced pancreatic cancer, only a single study (Jamieson 
et al. 2005) has investigated the potential prognostic value of preoperative CRP levels 
in resected pancreatic cancer. This study demonstrated a significant relationship 
between elevated preoperative CRP and poorer survival on univariate, but not 
multivariate analysis.
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7.1.9. SYSTEMATIC REVIEW & META-ANALYSIS OF PROGNOSTIC STUDIES
A systematic review represents a literature-based project which is intended to 
comprehensively identity and critically review all published and unpublished 
literature relevant to a specific area of interest. This provides the opportunity to 
critique recent developments within a field of research, to highlight and rationalise 
potential contradictory findings between different studies and to identify avenues for 
future research activity. Systematic reviews play an important role in summarising 
and disseminating findings from clinically-oriented research with a view to 
facilitating the process of delivering evidence-based medical practice (Sackett et al. 
1997).
Meta-analysis can be defined as ‘the statistical analysis of a large collection of results 
from individual studies for the purposes of integrating the findings’ (Glass et al. 
1976). Meta-analysis of data from multiple sources (typically randomised controlled 
trials) provides the opportunity to generate pooled statistical analyses which can 
provide comprehensive answers to specific clinical questions and help to resolve 
potential disagreement between individual studies. Meta-analysis can involve 
collation of raw data from multiple trials or studies allowing detailed re-analysis of 
outcome measures (ie. an individual patient data meta-analysis). However, this 
approach is labour intensive and necessitates co-operation from all authors whose 
literature is included as part of the meta-analysis. In practical terms, this is often 
prohibitively difficult to carry out (Lyman et al. 2005). More commonly, data is 
extracted indirectly from published literature to generate pooled results (ie. an 
aggregate patient data meta-analysis).
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The important components of a systematic review / meta-analysis can be summarised 
as follows:
• Clearly-defined study objectives and inclusion/exclusion criteria.
. • Use of a standardised and systematic approach for the identification of 
relevant literature.
• Tabulation of study characteristics and quality assessment of methodology.
• Data extraction from eligible studies where possible (and appropriate) in order 
to combine data to generate more powerful statistical analyses.
• To form appropriate conclusions and generate recommendations or best- 
practice guidelines.
Search strategy
Comprehensive identification of all published medical literature relating to a specific 
study question necessitates use of web-based search engines. Use of multiple search 
engines is recommended in order to maximise the number of potentially eligible 
studies returned. In the context of systematic reviews and meta-analyses targeting 
primary studies as opposed to randomised trials, MEDLINE, EMBASE and IS I Web 
of Science represent the most widely utilised search engines covering US, European 
and International journals. In order to minimise the potential for publication bias, a 
search for non-published studies is also recommended and there are a number of web- 
based resources which allow identification of abstracts presented at conferences and 
meetings which may not have been subsequently published as full papers (eg. ISI 
Proceedings, American Society of Clinical Oncology (ASCO), etc). These strategies 
can be supplemented by checking reference lists of relevant studies and existing 
review articles. Search criteria should be carefully selected to optimise the ability to
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identify a manageable volume of pertinent literature without excluding potentially 
relevant studies. Searches and assessment of study eligibility should ideally be 
performed by more than one researcher.
Quality assessment
Poorly conducted clinical research yields results which are open to criticism. It is, 
therefore, desirable to make an assessment of methodological quality of included 
studies when conducting a meta-analysis to ensure that meaningful conclusions can he 
drawn. With regard to randomised trials, the CONSORT (Consolidated Standards of 
Reporting Trials) guidelines represent an internationally agreed framework for high 
quality trial design and methodology (Moher et al, 2001) and recognised scoring 
systems for assessing trial quality exist (eg. Jadad et al. 1996). Although there are no 
such standardised scoring systems for assessing methodological quality of prognostic 
studies specifically, literature exists which outlines the general prerequisites which 
should be fulfilled for such studies (Hayden et al. 2006).
Data extraction and analysis
As previously outlined, attempting to obtain raw data from a number of authors for 
primary studies identified as part of a meta-analysis is invariably impractical. 
Consequently, it is usually necessary to obtain data from the published results of such 
studies to conduct an aggregate patient data analysis. For the purposes of prognostic 
literature, time-to-event data (ie. survival times) are the end-point of interest and are 
summarised as hazard ratios (HR). This function can be equated to the instantaneous 
relative risk of death associated with one group when compared with a baseline or 
control group and can be estimated from regression models (eg. Cox regression)
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where the HR represents the inverse natural logarithm of the regression coefficient 
(c*3). Where comparative survival data from two patient groups is the outcome 
measure of interest, the logHR and variance are required to pool data for meta­
analysis. This summary statistic is rarely reported in most prognostic studies. 
However, there are a number of reported methods (Parmar et al. 1998) for estimating 
this value indirectly using the summary statistics which are commonly utilised in 
published literature - eg. the HR and 95% confidence interval or the log rank p-value 
and the number of events recorded in each study group. Alternatively, the Kaplan- 
Meier survival curves can be used to record the comparative % survival for set time 
intervals along each survival curve. Along with the sample size of each group, this 
information can be used to obtain an estimate for the logHR and variance ifig.l).
fig.l - Example of indirect method of extracting survival data from K-M curves (Bold et al. 1999).
----- bd-2 Pot: N - 23,
20 'i'5 4Q
FofcMMjp Time (monto)
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Dedicated software is available to generate the indirect estimates of logHR and 
variance from the summary statistics outlined above (www.biomedcentral.com 
/content/supplementary/1745-6215-8-16-S1 .xls).
Once logHR and variance have been calculated for individual studies, these values 
can be pooled in order to generate a weighted average. An inverse variance method is 
commonly employed for aggregated survival data whereby less weighting in the 
pooled estimate is apportioned to studies reporting a greater logHR variance. A fixed 
or random effects approach must be selected based on the assumption of whether the 
true survival effect of the prognostic parameter of interest is uniform or random across 
the included studies. Where there is evidence of significant heterogeneity in the 
direction and/or magnitude of the reported survival effect, a random effects model 
should be utilised which incorporates between-study variation in the calculation of the 
overall result (DerSimonian et al. 1986). Assessment of heterogeneity as part of a 
meta-analysis represents a measure of the consistency or disparity in the true 
treatment effect across studies. Heterogeneity may be assessed with use of Cochran’s 
chi-squared test or the I2 statistic (Higgins et al. 2003). In cases where significant 
heterogeneity is observed across studies included in a meta-analysis, potential reasons 
for disparity should be investigated and use of a random effects approach is required 
if studies can be meaningfully grouped for analysis. A random effects approach is also 
advocated in situations where a limited number of studies are included for meta­
analysis.
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Systematic review and meta-analysis of prognostic studies present a number of 
different challenges (Altman et al. 2001). Some of these potential difficulties are 
common to all systematic reviews and meta-analyses (eg. reliably identifying all 
published and unpublished literature, incomplete reporting of salient survival data, 
etc). However, comparing and collating data from different prognostic studies is also 
associated with several specific problems. These include disparate laboratory 
methodologies for assessing prognostic factors, variation in patient 
inclusion/exclusion criteria used, the prevalence of retrospective study design, non- 
standardised approaches to analysing and reporting survival data along with differing 
methods for analysis of continuous prognostic variables. Adequate consideration 
should be given to all these factors prior to attempting meta-analysis of prognostic 
studies.
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1.2. STUDY OBJECTIVES
Clinico-pathological prognostic factors:
• To conduct a comprehensive analysis of histopathological prognostic factors 
in patients undergoing resection for pancreatic cancer at a high-volume tertiary 
referral centre over a 10-year period.
• To conduct a detailed analysis of how resection margin involvement 
influences postoperative survival and whether the criteria for ‘equivocal’ 
margin involvement (ie. <1 mm) should be considered synonymous with 
margin positivity in pancreatic cancer.
• To identify the potential prognostic value of various preoperative biochemical 
and haematological factors including CA19-9, bilirubin, albumin, CRT, 
lymphocyte and platelet counts with a view to generating an overall predictive 
scoring system.
• To investigate the influence of preoperative markers of systemic inflammation 
on pancreatic and periampullary tumour resectability along with an analysis of 
any relationships between these indices and histological tumour 
characteristics. The implications for patient selection for staging laparoscopy 
were also investigated as part of this analysis.
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Systematic review and meta-analysis of molecular prognostic literature:
• To conduct a detailed systematic review of published and unpublished 
literature assessing the prognostic value of the most widely investigated and 
biologically relevant molecular prognostic markers in resected pancreatic 
cancer.
• To conduct a subsequent meta-analysis of the relevant studies in order to 
estimate the pooled prognostic effect of individual molecular factors analysed 
as univariate prognostic variables.
• To conduct an analysis of methodological quality for the relevant studies in 
order to identify potential reasons for the different survival trends observed 
between individual studies.
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2. CLINICO-PATHOLOGICAL PROGNOSTIC FACTORS
2.1. METHODS
Details of all patients referred to the Pancreatic Unit in The Royal Liveipool 
University Hospital since January 1997 have been prospectively recorded and 
maintained on a Microsoft Access database. All patients undergoing resection for 
pancreatic and peri-ampullary malignancy between January 1997 and December 2007 
were identified from this source. From this list, only cases undergoing pylorus­
preserving partial pancreatoduodenectomy or a classical Kausch-Whipple resection 
were selected for further analysis of histological prognostic factors. This list was 
cross-checked against records of pancreatoduodenectomy specimens kept in the 
Pathology department to ensure no missing cases were omitted.
Clinical data collected from the database included patient demographics, details of 
preoperative biliary stenting, outcome of CT assessment and laparoscopic staging (ie. 
with regard to assessment of tumour resectability). Preoperative blood results 
including CA19-9, liver function and full blood count estimations were separately 
collected from hospital computer records. Overall survival data were collected by 
identifying the recorded date of death from hospital computer records. For living 
patients and the small proportion of cases lost to follow-up, the date of last clinic 
attendance was used to calculate the censored time for survival analyses. All patients 
gave written consent for clinico-pathological data to be used for research purposes.
All patients with potentially resectable pancreatic tumours and obstructive jaundice 
presenting during the study period routinely undenvent biliary decompression at 
endoscopic retrograde cholangiopancreatography (ERCP) where possible. Where
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patients underwent more than one procedure prior to successful stenting, the date of 
definitive biliary drainage was used for analysis. Those in whom endoscopic drainage 
was unsuccessful went on to undergo percutaneous transhepatic cholangiography 
(PTC) or combined procedures with internal stenting. External drainage was required 
in a proportion of these cases. A plastic biliary endoprosthesis was routinely used and 
a covered metallic biliary stent was required in a small proportion. Jaundice was 
defined as a serum bilimbin concentration of >35 pmol/l. This level was selected as 
hyperbilirubinaemia is usually only clinically evident as jaundice when serum 
bilirubin levels exceed this value.
Pylorus-preserving pancreatoduodenectomy (PPPD) was considered the operation of 
choice for pancreatic head and peri-ampullary tumours for the duration of the study 
period due to the associated preservation of gastrointestinal function and comparable 
oncological radicality when compared with a classical approach in previous 
randomised trials (Seiler et al, 2005; Tran et al, 2004). hi cases where the viability of 
the remaining duodenal margin was uncertain or local tumour infiltration into the 
pylorus was present, a classical Kausch-Whipple’s procedure (ie. with concurrent 
distal gastrectomy) was performed. Concmrent cholecystectomy was routinely 
undertaken alongside the pancreatoduodenectomy if the patient still had their 
gallbladder at the time of surgery.
Details of adjuvant therapy received were collected from the Liverpool Cancer Trials 
Unit. A search of case report forms was conducted to identify all participants of 
ESP AC-1 and ESP AC-3 who underwent resection at the Royal Liverpool University 
Hospital. The small number of patients who received neoadjuvant therapy or off-trial
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adjuvant therapy were also identified from departmental records. Patients were 
considered for adjuvant therapy as part of either ESP AC-1 or ESP AC-3 during the 
study period primarily on the basis of their postoperative progress and performance 
status following surgery. Those patients who made a good functional recovery 
following resection were routinely referred to the regional oncology service and 
offered the option of trial participation. Randomisation and commencement of 
treatment was routinely undertaken within 6 to 8 weeks of surgery.
Resectability study
A separate cohort of patients was identified in order to assess the predictive values of 
the preoperative haematological and biochemical parameters for determining tumour 
resectability. Details of all referrals between January 1997 and September 2006 with 
suspected pancreatic/periampullary malignancy were prospectively collected and 
maintained on a database. Patients undergoing contrast-enhanced computed 
tomography (CT) were identified to select a group with radiologically resectable 
disease at presentation. Decision-making regarding resectability was undertaken 
during weekly Multi-Disciplinary Team meetings. The principal CT criteria used to 
determine resectability were based on the presence of intra- or extra-abdominal 
metastatic disease and on vascular encasement or tumour involvement of the superior 
mesenteric-portal vein over >50% circumference and/or >2 cm length. Patients with 
equivocal CT features for resectability (ie. patients with radiological features 
approximating the threshold values outlined above) who went on to undergo further 
staging and subsequent laparotomy were also included in the analysis.
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Only patients who underwent both staging laparoscopy and subsequent attempted 
resection were included in the analysis. This approach was used to retrospectively 
identify what proportion of staging laparoscopies conducted during the study period 
were potentially avoidable in the patient group undergoing surgical exploration. 
Laparoscopic staging included inspection of the peritoneal cavity along with intra­
operative ultrasonographic assessment of the liver parenchyma and tumour 
relationships with local vasculature. Contraindications to laparoscopic staging 
included the presence of co-morbid disease which would preclude consideration for 
further investigation, gastric outlet obstruction requiring surgical bypass or significant 
previous intra-abdominal surgery. Patients with proven metastatic disease from intra­
operative biopsy at laparoscopy were excluded from a trial dissection. Patients with 
equivocal laparoscopic features of resectability who subsequently went on to undergo 
trial dissection were classified as having potentially resectable disease for the 
purposes of the study. Laparoscopy and laparoscopic ultrasonography were in routine 
use throughout the study period.
The operative criteria for unresectable disease at laparotomy were based on the 
finding of any hepatic or peritoneal metastases proven on frozen section, the presence 
of vascular encasement or tumour involvement of the portal/superior mesenteric vein 
precluding the option of local resection. A small proportion of patients underwent 
venous resection (either sleeve or segmental) in cases exhibiting limited tumour 
infiltration into the portal or superior mesenteric vein in order to achieve adequate 
macroscopic tumour clearance where feasible. Extended lymphadenectomy was not 
routinely undertaken as part of the pancreatoduodenectomy during any part of the
44
study period. There were no significant differences between surgeons regarding the 
operative criteria used to determine resectability at laparotomy.
All cases of suspected pancreatic/periampullary cancer (including those with 
subsequently proven benign disease) were included in the analysis of resectability as 
the exact origin and histological nature of the primary is commonly unknown at the 
time of decision-making regarding surgical intervention. Furthermore, the specific 
tumour origin is frequently not established in patients with metastatic disease 
identified at laparotomy. Therefore, this overall patient group reflects a more 
representative sample within which to study the predictive value of biochemical and 
haematological parameters in a clinically meaningful setting.
A preoperative CA19-9 cut-off value of <150 kU/1 (or <300 kU/1 in cases of 
concurrent jaundice) was used to stratify patients for predicting tumour resectability. 
These values were selected in accordance with the previously published literature 
(Connor et al. 2005). On this basis, an adjusted CA19-9 was calculated for analyses of 
continuous data by halving the CA19-9 in cases with concurrent obstructive jaundice 
at the time of CA19-9 estimation (ie, bilirubin levels >35pmol/l). Where concurrent 
bilimbin levels were unavailable, the unadjusted CA19-9 was used for these analyses. 
The platelet-lymphocyte ratio was calculated for all patients in whom a preoperative 
full blood count along with differential white cell count were recorded. Various cut­
off values for the platelet-lymphocyte ratio were used to determine the point at which 
the positive predictive value for resectability was maximised. A value of <150 was 
found to represent this point.
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Histology reports
Pancreatoduodenectomy specimens were processed and reported according to a 
previously defined protocol by a Royal College of Pathologists Working Group 
(Campbell et al. 2002). Specimens were routinely processed according to these 
criteria for the duration of the study period. The complete histology reports for all 
cases undergoing pancreatic resection during the study period were obtained from 
computer records in the Pathology department. A separate Microsoft Access database 
was constructed to collect and analyse the histology data in detail. The following 
information and histological tumour characteristics were recorded from the reports:
Type of specimen
Cases were categorised according to whether the main specimen was from a pylorus­
preserving partial pancreatoduodenectomy or classical Kausch-Whipple procedure.
Additional procedures undertaken
Details of additional specimens received along with the main specimen were also 
recorded (eg. cholecystectomy, splenectomy, venous resection (sleeve or segmental), 
etc).
Site of tumour
Tumours arising from the uncinate process were classified as arising from the 
pancreatic head. Tumour locations were therefore recorded as either head of pancreas, 
ampulla or intrapancreatic bile duct. Only adenocarcinomas of confirmed pancreatic 
origin were analysed.
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Histological tumour type
This was based on the WHO classification system for exocrine pancreatic neoplasms 
(Kloppel et al, 1996). The small number of cases with mucinous adenocarcinoma 
(non-cystic), signet-ring cell adenocarcinoma, mixed ductal-endocrine carcinoma and 
undifferentiated adenocarcinoma sub-types arising from the pancreatic head were 
analysed alongside ductal adenocarcinoma cases.
Size of tumour
The maximum recorded tumour diameter was used as the prognostic variable of 
interest (measured in millimetres). This value was recorded from the microscopic 
tumour report for smaller tumours or the macroscopic tumour dimensions for larger 
tumours.
Tumour differentiation
All tumours were classified as ‘well’, ‘moderately’ or ‘poorly’ differentiated on the 
basis of a previously defined grading system (Kloppel et al. 1996) - Table 1. A 
differentiation grade was allocated according to the least differentiated area. 
Therefore, cases reported as ‘moderate-to-poorly’ differentiated were categorised as 
poorly differentiated. Similarly, cases reported as ‘well differentiated with focal areas 
of moderate differentiation’ were classified as moderately differentiated.
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Table 1 - Grading of pancreatic ductal adenocarcinoma
Differentiation Duct Structures Nuclei Mitotic figures*
Mucin
production
Well Well formed Basal <5 Marked
Moderate Some well fonned
Loss of polarisation, 
anisonucleosis 5-10 Variable
Poor Very irregular or absent
Marked anisonucleosis, 
clumped chromatin >10 Minimal
*per 10 high powered fields (1356pm2)
T stage
T staging was recorded according to the UICC TNM classification for pancreatic, 
ampullary and biliary adenocarcinoma {Table 2).
Nodal staging
Similarly, nodal staging was recorded according to the same UICC TNM 
classification {Table 2). In addition to overall nodal staging, the number of regional 
lymph nodes containing metastatic adenocarcinoma along with the total number of 
lymph nodes sampled were recorded in order to calculate the lymph node ratio (ie, the 
proportion of involved nodes as a ratio of the total number of nodes sampled from the 
specimen). The distribution of regional lymph nodes was further classified as anterior 
pancreaticoduodenal, posterior pancreaticoduodenal, inferior, superior, inffapyloric 
and bile duct where recorded.
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Table 2 - UICC TNM classification for pancreatic adenocarcinoma (Sobin et al. 2002)
Pancreas
T1 Tumour limited to the pancreas, 20mm or less in greatest dimension
T2 Tumour limited to the pancreas, >20mm in greatest dimension
T3 Tumour extends directly into duodenum, bile duct or peripancreatic tissues
T4 Tumour extends directly into stomach, spleen, colon or adjacent large vessels
NO No regional lymph node metastases
N1 Regional lymph node metastasis present
Nla Metastasis in single regional lymph node
Nib Metastasis in multiple regional lymph nodes
Lymph node 8a and 16b sampling
Second order lymph nodes were routinely sampled for resected periampullary 
adenocarcinoma. Nodes from the anterior aspect of the common hepatic artery (LN8a) 
and retroperitoneal nodes posterior to the head of the pancreas (LN16b) were most 
frequently sampled. Nodal stations were identified intra-operatively according to the 
Japan Pancreas Society (IPS) classification (Japan Pancreas Society, 2003). Routine 
extended lymphadenectomy was not employed at any point during the study period.
Resection margins
All pancreatoduodenectomy specimens were serially sliced axially and histopathology 
reporting was conducted according to the Royal College of Pathologists Minimum 
Dataset for pancreatic and periampullary adenocarcinoma (Campbell et al. 2002). The 
reporting criteria in the Dataset were routinely used both before and after their 
publication in 2002. fig. 1 demonstrates an example of an axial slice through the head
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of the pancreas with adenocarcinoma extending close to the posterior (green) 
resection margin and clear of the medial (orange) resection margin. A lymph node is 
seen within the anterior pancreatoduodenal groove (yellow paint).
fig.l - Macroscopic photograph demonstrating example of axial slicing of pancreatoduodenectomy 
specimen.
The guidelines recommend that the status of six discrete resection margins be 
documented by the reporting pathologist - the pancreatic transection margin, the 
medial (or superior mesenteric vessel) margin, the posterior margin, the proximal 
duodenal (or gastric) margin, the distal duodenal margin and the common bile duct 
margin (fig. 2).
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fig.2 - Principal resection margin locations in pancreatoduodenectomy specimens.
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The presence or absence of reported tumour involvement at one or more resection 
margins was recorded by the reporting pathologist and all cases with microscopic 
tumour involvement within 1 mm, without directly breaching one or more margins 
were also documented. In all cases reported as RO, the histopathology slides were 
retrieved and microscopically reassessed alongside a single consultant pathologist 
(FC) in order to confirm RO classification, fig. 3 illustrates an example of an 
‘equivocal' resection margin where tumour can be seen to extend to within 1mm. 
without directly breaching the margin itself, fig.4 shows an example of direct tumour 
involvement at a painted resection margin.
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fig.3 - Light micrograph demonstrating ‘equivocal’ microscopic tumour involvement (ie. within 1mm 
of a resection margin without directly breaching the painted surface).
fig.4 - Light micrograph demonstrating direct microscopic tumour involvement directly breaching a 
painted resection margin.
Isolated tumour involvement of the anterior capsule of the pancreatic specimen was 
not considered as an R1 resection as part of this study. Similarly, the presence of 
PanIN-3 at an otherwise negative transection margin was not considered an R1 
resection. No cases were classified as R1 exclusively on the basis of perineural 
invasion at a resection margin. Similarly, nodal involvement at a resection margin did 
not constitute an R1 classification in the absence of direct tumour involvement. No R2 
resections were reported in this series of patients.
Vascular and perineural invasion
The presence or absence of perineural invasion (ie. tumour invasion involving one or 
more intrapancreatic nerve bundles) on microscopic assessment of the specimen 
documented by the reporting pathologist was recorded. Similarly, the presence or 
absence of vascular invasion (ie. tumour invasion involving one or more 
intrapancreatic blood vessels) was also recorded.
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Statistics
Median, interquartile range and 95% confidence intervals were used to describe 
continuous data. Comparisons of grouped continuous data were conducted using 
Mann-Whitney U testing or Krukal-Wallis testing where data from more than two 
groups were included. Correlation between two continuous variables was evaluated 
using Spearman’s rank correlation. Proportional differences in categorical data were 
analysed using Chi-squared testing with Pearson’s correction where cell frequency 
was greater than 10 and Yates’ correction in cases where cell frequency was 5 to 10. 
Fisher’s exact test was used in cases where cell frequency was <5. Logistic regression 
was used to investigate the effect of one or more continuous or categorical 
independent variables on a categorical dependent variable. Receiver operating 
characteristic curves were generated to compare the predictive value of two 
parameters in determining disease resectability.
Univariate survival data were analysed using Kaplan-Meier cumulative survival 
curves with log rank (Mantel-Cox) testing to demonstrate differences in survival 
between two or more groups from a single categorical prognostic parameter. Where a 
continuous prognostic variable was analysed, univariate analysis was primarily 
conducted with Cox proportional hazards regression on a continuous basis. Because 
of the wide range in preoperative CA19-9 levels recorded, this prognostic variable 
was normalised for Cox modelling by logarithmic transformation (ie. lnCA19-9). 
Only prognostic variables of (or approaching) univariate significance were selected 
for inclusion in subsequent multivariate survival analyses.
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Hazard ratios for continuous variables included in a Cox analysis reflect the 
proportional increase in relative risk of death (hazard) with each incremental increase 
in the continuous prognostic variable of 1 unit. For instance, a hazard ratio of 1.004 
reflects a regression coefficient of 0.004 (ie. e0'004 = 1.004). Therefore, the relative 
hazard associated with a comparative difference of 200 units for this variable would 
be e(200x0004) = 2.226. The Chi-squared statistic gives a further indication of the 
strength of the relationship between the prognostic variable and survival. 
Proportionality was checked for all variables prior to inclusion for Cox regression by 
reviewing the log cumulative hazard plots for each variable when categorised.
Dichotomizing a continuous prognostic variable is associated with potential 
significant bias due to an inflated type I error rate along with the fact that significance 
can be variably seen when using a number of different cut-off points for the parameter 
of interest. This frequently results in an overestimated significance level on univariate 
analysis along with a disproportionate weighting on subsequent multivariate analysis 
(Altman et al. 1994). In order to generate Kaplan-Meier cumulative survival curves 
for continuous prognostic variables, cut-off values were selected either on the basis of 
the nonnal reference range for the parameter of interest or according to the maximum 
degree of risk stratification allowed (three groups where possible). It should be 
pointed out that none of the reported survival relationships for continuous prognostic 
variables were reliant on any data-driven cut-off points as all Cox analyses for such 
variables were conducted on a continuous basis. Hence, cut-off points were only used 
to graphically illustrate the recorded survival trends.
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Statview version 5 (ISAS Institiute, Cary, NC, USA) and Microsoft Excel (Microsoft 
Office 2002) were used to perform the various statistical functions. SPSS version 14.0 
(SPSS Inc. 2005) was used to generate the ROC curves.
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2.2. RESULTS & DISCUSSION
For patients undergoing pancreatoduodenectomy for tumours arising from the 
pancreatic head or uncinate process, the following histological classifications 
recorded by the reporting pathologist were included for analysis:
• pancreatic ductal adenocarcinoma (n= 151)
• ‘adenocarcinoma’ (n=8)
• mucinous (non-cystic) adenocarcinoma (n=4)
• signet-ring cell carcinoma (n=l)
• mixed ductal-endocrine carcinoma (n=l)
• anaplastic (n=l)
• Total = 166
This group of cases was collectively analysed and is subsequently referred to as 
‘pancreatic ductal adenocarcinoma’ for the purposes of this study.
All figures with the suffix ‘A’ (eg. fig.2A) indicate non-significant survival analyses 
and are included in Appendix A for reference.
Publications arising from the content of the following analyses are listed in Appendix 
B, There are some marginal differences in the results when comparing the survival 
analyses in this thesis with the results contained in the various publications. This is a 
result of the fact that the analyses within this thesis included an additional cohort of 
resections undertaken between 2006 and 2007 when compared with some of the 
published papers along with the fact that the survival data was updated at the end of 
this study period.
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2.2.1. Summary survival data
Study group
166 patients identified from the database underwent pylorus-preserving 
pancreatoduodenectomy or classical Kausch-Whipple procedures for pancreatic ductal 
adenocarcinoma during the study period. This group comprised 94 males (56.6%) and 
72 females (43.4%) with a median age of 66.4 (IQR = 60.8 to 72.8) years. 132 
patients (79.5%) died during the follow-up period with 34 (20.5%) censored cases. 
The censored cases had a median follow-up time of 15.3 (IQR = 10.3 to 29.0) months. 
The median survival time for the overall group was 13.9 (95% Cl = 12.4 to 16.1) 
months. There were 4 deaths within 30 days of surgery (2.4%) and 7 deaths prior to 
discharge from hospital (4.2%). Fig.l demonstrates the survival distribution for the 
overall patient group.
fig.l - Kaplan-Meier cumulative survival curve for overall pancreatic ductal adenocarcinoma patient 
group (crosses indicate censored cases).
Time (months)
No. at risk 166 88 38 17 11 8
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Table 1 - Summary table of clinico-pathological characteristics for resected pancreatic ductal 
adenocarcinoma patients.
Total no. of patients identified 166
Gender:
Male 94 (56.6%)
Female 72 (43.4%)
Age: median (IQR) 66.4 (60.8 to 72.8) years
Median overall survival (95% Cl) 13.9 (12.4-16.1) months
No. of censored cases 34 (20.5%)
Median follow-up time for censored cases (IQR) 15.3(10.3-29.0) months
Type of surgery:
PPPD 149 (89.8%)
Classical Kausch-Whipple 17(10.2%)
Venous resections 10(6.0%)
30-day mortalities 4 (2.4%)
In-patient mortalities 6 (3.4%)
Neoadjuvant therapy received 3(1.8%)
Adjuvant therapy received 51 (30.7%)
Chemotherapy 45
Chemoradiotherapy 6
Tumour histology
Median tumour size (IQR) - n=160 30 (22-38) mm
T stage: (n=165)
1 7 (4.2%)
2 17(10.3%)
3 137 (83.0%)
4 4 (2.4%)
Tumour differentiation: (n=165)
well 25 (15.2%)
moderate 85 (51.5%)
poor 55 (33.3%)
Nodal status (n=166):
negative 27(16.4%)
positive 139 (83.6%)
Median lymph node ratio in N+ve cases (IQR): (n=135) 0.23 (0.14-0.37)
Resection margin status: (n=163)
negative 35 (21.5%)
positive 128 (78.5%)
NB, Histological data were incomplete for a small number of cases. IQR = interquartile range. Cl = 
confidence interval.
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2.2.2. Clinical / patient-related factors
No significant difference in median survival was recorded when comparing males 
(13.3 (95% Cl = 10.4 to 16.6) months) and females (14.3 (95% Cl = 12.1 to 22.6) 
months) - log rank, p = 0.289 - fig. 2A (Appendix A). Similarly, Cox regression using 
age as a continuous prognostic variable demonstrated that there was no significant 
relationship between increasing age and overall survival in patients with resected 
pancreatic cancer (HR = 1.000 (95% Cl = 0.970 to 1.021), p = 0.970).
PPPD vs classical Kausch-Whipple’s
149 patients (89.8%) who underwent PPPD had a median survival of 14.3 (95% Cl = 
12.8 to 17.4) months) compared with 8.2 (95% Cl = 5.5 to 16.1) months in 17 (10.2%) 
who underwent a classical Kausch-Whipple procedure - log rank; p = 0.015 - fig.3.
fig.3 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to type of surgery.
PPPD
Classical Whipple's 
Log rank - p=0.015
Time (months)
PPPD 149 82 36 16 10 7
Classical 17 6 2 1 1 1
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This finding is concordant with published results from ESP AC-1 (Bassi et al, 2005) 
and might potentially be explained on the basis that patients with less favourable 
histological tumour characteristics at operation were more likely to require classical 
Kausch-Whipple procedures than those undergoing PPPD. Table 1 demonstrates a 
breakdown of tumour histology according to the type of resection.
Table 1 - Breakdown of tumour histology according to type of pancreatoduodenectomy undertaken.
PPPD (n=159) Classical Kausch- 
Whipple (n=17)
p-value
Median tumour size (IQR) mm 30 (22-38) 30(25-45) 0.743*
Nodal status:
Negative 24 3 0.999
Positive 125 14
Differentiation:
Well/moderate 103 7 0.023**
Poor 45 10
T stage:
1 & 2 22 2 0.999
3 & 4 126 15
Resection margin status:
Negative 34 1 0.197
Positive 113 15
Adjuvant chemotherapy:
No 106 15 0.160
Yes 43 2
Quoted p-values for Fisher’s exact except: 
*p-value for Mann-Whitney test 
**p-value for y2 test
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Venous resection
A total of 10 patients (6.0%) underwent venous resection (either sleeve or segmental) 
as part of their pancreatoduodenectomy in cases exhibiting intraoperative tumour 
infiltration into the portal or superior mesenteric vein in order to achieve adequate 
macroscopic tumour clearance. Patients undergoing venous resection had a median 
survival of 17.4 (95% Cl = 10.4 to 22.1) months compared with 13.8 (95% Cl = 12.3 
to 15.9) months for the remaining group - log rank; p = 0.902 - figAA.
Survival according to study period
An analysis was undertaken to identify whether there was any trend towards more 
favourable survival in patients operated on during the second half of the study period 
when compared with the first. 62 patients (37.3%) who underwent surgery between 
1997 and 2002 had a median survival of 12.8 (95% Cl = 8.5 to 17.0) months while 
104 patients (62.7%) undergoing surgery between 2003 and 2007 had a median 
survival of 14.2 (95% Cl = 12.6 to 17.4) months - log rank; p = 0.647 - fig.5A.
This result suggests that there was no significant difference in survival according to 
timing of surgery during the course of the study period. A significantly greater 
proportion of patients (40/104 - 38.5%) went on to receive adjuvant therapy in the 
second half of the study period when compared with the first half (11/62 - 17.7%) - %2 
= 7.83; p = 0.005. Furthermore, a greater proportion of censored cases are inevitably 
present during the second half of the study (due a shorter overall follow-up period) 
when compared with the first. Despite these potential confounding factors, the data 
suggest that there was no significant overall trend to indicate more favourable survival 
outcomes in patients undergoing surgery in more recent years.
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Adjuvant therapy
Only 3 patients (1.8%) received some form of neoadjuvant therapy - these were cases 
initially staged as locally advanced disease who were subsequently down-staged and 
went on to have a successful resection. 51 patients (30.7%) received adjuvant therapy 
following surgery - 45 received chemotherapy (either 5-FU or gemcitabine) and 6 
received chemoradiotherapy (5-FU based - ESP AC-1 protocol). Patients receiving 
adjuvant chemotherapy had a more favourable median survival (18.2 (95% Cl = 13.8 
to 29.7) months) when compared with patients who did not receive chemotherapy 
(12.8 (95% Cl = 9.9 to 15.4) months) - log rank; p = 0.008 - fig. 6. The limited number 
of patients receiving chemoradiotherapy had comparable survival times to patients 
who received no subsequent adjuvant therapy (log rank; p = 0.754) - fig.7A. These 
results largely mirror the findings from ESPAC-1 (Neoptolemos et al. 2004).
fig. 6 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to adjuvant chemotherapy.
Chemotherapy 
No chemotherapy 
Log rank - p=0.008
Time (months)
No. at risk
Chemo 45 30
No Chemo 121 58
13 6 3 1
25 11 8 7
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2.2.3. Discussion
The overall survival time recorded for the entire study group is comparable with 
reported median survival times recorded for resected pancreatic ductal 
adenocarcinoma patients from previous meta-analyses of adjuvant therapy trials 
(Stocken et al, 2005) and published SEER data (Slidell et al, 2008) given that around 
one in three patients received adjuvant chemotherapy. The marginal gender 
preponderance of males is representative of the overall epidemiological distribution of 
pancreatic adenocarcinoma incidence. The low incidence of operative mortalities 
during the overall study period is also in keeping with operative results from high- 
volume specialist pancreatic units (Neoptolemeos et al, 1997).
Neither age nor gender were demonstrated to have any impact on overall survival and 
this observation is a characteristic finding from previous literature reporting survival 
outcomes following resection for pancreatic cancer (Garcea et al, 2008). The small 
proportion of patients for whom venous resection was required as part of their surgery 
failed to exhibit any adverse overall survival when compared with patients undergoing 
standard resections. Venous resection is appropriate for a sub-group of tumours 
exhibiting involvement of the hepatic portal or superior mesenteric vein providing 
adequate macroscopic tumour clearance can be achieved. Although venous resection 
has the potential to maximise resectability, it has not been demonstrated to have any 
impact on survival (Bold et al, 1999; van Geenan et al, 2001; Nakagohri et al, 2003) 
and the findings from the current study are in keeping with this.
A previous meta-analysis of seven randomised controlled trials comparing outcomes 
following pylorus-preserving pancreatoduodenectomy vs. classical Whipple
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procedures failed to demonstrate any significant differences in operative mortality, 
morbidity or overall survival (Diener et al, 2008). However, the results did suggest 
longer operative times and greater intraoperative blood loss in patients undergoing 
classical Whipple procedures. Pylorus-preserving pancreatoduodenectomy was 
considered as the procedure of choice for resectable tumours of the pancreatic head 
throughout the duration of the study period for the current patient cohort. The limited 
number of patients who required classical Whipple procedures were found to have a 
poorer overall survival and this observation is likely to be explained on the basis that 
those patients for whom classical Whipple procedures were performed exhibited more 
unfavourable tumour characteristics at laparotomy necessitating a more extensive 
resection in order to achieve adequate oncological clearance. The breakdown of 
tumour histology according to type of surgery was indicative of this fact with a 
significantly greater proportion of poorly differentiated tumours in patients requiring 
classical Whipple procedures. Because of this finding, the type of 
pancreatoduodenectomy was not included as a covariate in subsequent multivariate 
analyses.
Patients receiving adjuvant chemotherapy were found to have a significantly greater 
median survival when compared with those patients who received no adjuvant 
chemotherapy and the small number of patients who received adjuvant 
chemoradiotherapy. Most patients who went on to receive adjuvant therapy following 
surgery did so as part of either ESP AC-1 or ESP AC-3. The observation that 
chemotherapy conferred a significantly improved survival mirrors the findings from 
ESP AC-1, a randomized controlled trial conducted between 1994 and 2000, recruiting 
541 patients with resected pancreatic ductal adenocarcinoma from 61 centres in 11
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European countries. 285 patients were formally randomised into a two-by-two 
factorial study design whereby participants received either chemoradiotherapy, 
chemotherapy, chemoradiotherapy with follow-on chemotherapy or observation. 
Chemotherapy consisted of bolus 5-FU and folinic acid given over 5 consecutive days 
every 28 days for six cycles. The CRT regimen consisted of a 20 Gy dose given in 10 
daily fractions over a two week period along with a bolus of 5-FU. The mature trial 
results were published in 2004 (Neoptolemos et al, 2004). A total of 147 patients 
randomized to receive chemotherapy had a median survival of 20,1 months compared 
with 15.5 months in 142 patients who did not receive chemotherapy (p=0.009). CRT 
was shown to be associated with a deleterious survival outcome with 145 patients 
assigned to receive CRT exhibiting a median survival of 15.9 months compared with 
17.9 months in 144 patients not receiving CRT (p=O.05). In order to evaluate the 
findings of ESP AC-1 alongside the existing evidence base for use of adjuvant therapy 
in pancreatic cancer, a meta-analysis of all randomized adjuvant therapy trials was 
undertaken and published in 2005 (Stocken et al, 2005). This analysis included the 
survival data from ESP AC-1, GITSG (Kaiser et al, 1985; Gastrointestinal Tumour Study 
Group, 1987), EORTC (Klinkenbijl et al, 1999), and two studies evaluating adjuvant 
chemotherapy regimens vs. observation (Bakkevold et al, 1993; Takada et al, 2002). 
875 patients were included in the overall analysis. The findings confirmed that 
administration of CRT was associated with no survival advantage while patients 
receiving chemotherapy exhibited significantly more favourable survival times.
Oettle et al published the results of the CONKO-Ol study in 2007, a multicentre 
randomised controlled trial evaluating adjuvant gemcitabine versus no adjuvant 
therapy in 368 patients undergoing radical resection for pancreatic ductal
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adenocarcinoma. A significantly improved disease free interval in the adjuvant 
treatment arm (13.4 months) over the observation arm (6.9 months) was 
demonstrated. However, the difference in median overall survival rates between the 
two groups did not reach significance (22.1 vs 20.2 months respectively - p=0.06). 
Despite this finding, the 5-year survival rates associated with the treatment and 
control groups in this study (22.5% and 11.5% respectively) are consistent with those 
reported in ESP AC-1 (21% and 8% respectively). The more recently published results 
from ESAPC-3 (Neoptolemos et al, 2010) failed to demonstrate any significant 
survival benefit associated with use of adjuvant gemcitabine when compared with 5- 
FU and folinic acid.
Given the significant impact of adjuvant chemotherapy on postoperative survival in 
the current patient cohort along with the existing evidence base, this factor was 
included as a covariate in all subsequent multivariate analyses of prognostic factors. 
No attempt was made to conduct any sub-group analysis based on type of 
chemotherapy received (ie. 5-FU vs. gemcitabine).
The proportion of patients receiving adjuvant chemotherapy following resection in the 
overall study group (30%) was lower than what might be expected given the above 
evidence base. However, the results indicate that the proportion of patients receiving 
chemotherapy increased during the course of the 10-year study period. This pattern 
may in part be explained by evolving oncological practices during this time with less 
restrictive selection criteria applied to assess patient fitness for adjuvant therapy.
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2.3. Histological prognostic factors 
2.3.1. Tumour size
The maximum recorded tumour diameter was obtained for 160 out of 166 cases. The 
median recorded tumour diameter was 30 (IQR = 22 to 38) mm for these cases. Fig.8 
demonstrates that the distribution of tumour size for resected pancreatic ductal 
adenocarcinoma cases approximated a normal distribution.
fig.8 - Distribution of tumour size for resected pancreatic ductal adenocarcinoma cases (n=160).
Tumour size (mm)
The univariate prognostic influence of tumour size on overall survival was assessed in 
160 evaluable patients. The patient group was comparatively analysed by modelling 
tumour size as both a continuous prognostic variable and by dichotomising cases into 
one of two groups based on whether the tumour size was < 20mm or > 20mm ifig.9). 
This standard cut-off value was selected on the basis of existing pancreatic literature 
and the fact that the criteria for histological T stage (ie. T1 vs. T2) is also based on a 
cut-off size of > 20 mm. Cox proportional hazards regression was used to generate 
hazard ratios for both analyses {Table 2). The results from this analysis demonstrate a 
significant relationship between increasing tumour size and poorer survival on a 
univariate basis.
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Table 2 - Univariate prognostic significance of tumour size - Cox proportional hazards (n=160).
Median survival Hazard ratio x! p-value
(95% Cl) (95% Cl)
Tumour size:
<20mm (n=33)
>20mm (n=127)
22.6 (12.4 to 32.4)
13.3(11.1 to 15.4) 1.588 (1.021 to 2.471) 4.213 0.040
Tumour size: _ 1.020(1.005 to 1.036) 6.619 0.010
(continuous)
fig.9 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to tumour size <20mm.
<20 mm 
>20 mm
Log rank - p=0.038
No. at risk
£20 mm 
>20 mm
33 20
127 65
Time (months)
13 7
24 10
6
5
4
4
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2.3.2. Tumour differentiation
Tumour differentiation was recorded in 165 of the 166 pancreatic ductal 
adenocarcinoma cases. 25 cases (15.2%) had a well differentiated tumour, 85 cases 
(51.5%) had a moderately differentiated tumour and 55 cases (33.3%) had a poorly 
differentiated tumour./zg. 70 demonstrates the survival curves associated with each of 
the tumour grades. Table 3 outlines the Cox proportional hazards analysis and median 
survival times for the three differentiation types.
fig. 10 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to tumour differentiation (3 groups).
0 -
0 12 24 36 48 60
Time (months)
No. at risk
well
moderate
25
85
55
14
49
25
21
10
7 2
11
4
2
8 6
poor
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Table 3 - Univariate prognostic significance of tumour differentiation - Cox proportional hazards.
Median survival
(95% Cl)
Hazard ratio
(95% Cl)
x2 p-value
Differentiation (3 groups):
Well (n=25) 22.1 (12.5 to 29.7) - - -
Moderate (n=85) 15.4(13.2 to 19.2) 1.048 (0.620 to 1.772) 0.031 0.860
Poor (n=55) 10.4 (6.4 to 13.3) 1.735 (1.007 to 2.988) 3.948 0.047
Differentiation (2 groups):
well / moderate (n=l 10) 15.5 (13.8 to 21.3) - - -
poor (n=55) 10.4 (6.4 to 13.3) 1.673 (1.167 to 2.399) 7.828 0.005
Given the small numbers of well differentiated tumours observed in the pancreatic 
ductal adenocarcinoma patients, along with the finding that there was no significant 
difference in overall survival between the well and moderately differentiated tumour 
groups (Cox; p=0.860), cases with these two tumour grades were grouped together for 
subsequent analyses. Well/moderately differentiated tumoms (n=110) were associated 
with a significantly more favourable median survival when compared with poorly 
differentiated tumours (JigJl) - log rank; p = 0.005.
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fig. 11 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to tumour differentiation (2 groups).
well/moderate 
poor
Log rank - p=0.005
Time (months)
No. at risk
well / mod 110 63 28 13 10 7
poor 55 25 10 4 1 1
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2.3.3. T stage
T stage was recorded for 165 out of the 166 pancreatic ductal adenocarcinoma cases. 
7 patients (4.2%) had a T1 tumour, 17 patients (10.3%) had a T2 tumour, 137 patients 
(83.0%) had a T3 tumour and 4 patients (2.4%) had a T4 tumour. Due to the small 
numbers of T1 and T4 tumours, T1/T2 tumours and T3/T4 tumours were grouped 
together for analysis. 72 demonstrates the survival curves for these cases. T1/T2 
tumours were associated with a median survival of 16.6 (95% Cl = 12.5 to 31.2) 
months compared with 13.2 (95% Cl = 10.5 to 15.4) months for T3/T4 tumours (Cox; 
HR = 1.503 (95% Cl = 0.937 to 2.409), p=0.091).
fig. 12 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to T stage (2 groups).
T1 + T2 
T3 + T4
Log rank - p=0.088
Time (months)
No. at risk
T1+T2 24 17 10 6 5 3
T3 + T4 141 70 27 11 6 5
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2.3.4. Nodal status
Nodal status (ie. NO, Nla or Nib) was recorded in all 166 patients with pancreatic 
ductal adenocarcinoma. There were 27 (16.3%) NO patients and 139 (83.7%) N1 
patients. The number of lymph nodes containing metastatic adenocarcinoma was 
recorded in 164 cases and the total number of sampled lymph nodes was recorded in 
163 patients. Hence, the lymph node ratio could be calculated for 163 patients from 
the overall group. The total number of sampled nodes included both regional 
peripancreatic lymph nodes along with second order nodes sampled during surgery 
(ie. LN8a, LN16b). Table 4 outlines the distribution of lymph node characteristics 
from within this group of patients.
Separate analyses investigating the prognostic relevance of overall nodal status, 
lymph node ratio and lymph node yield were conducted, fig. IS demonstrates the 
survival curves for pancreatic ductal adenocarcinoma cases according to overall nodal 
status (ie. positive vs negative).
Table 4 - Lymph node characteristics of resected pancreatic adenocarcinoma specimens.
Overall nodal status: 
negative 
positive
Median number of sampled lymph nodes (IQR) 
Median number of positive lymph nodes in N1 cases 
Number of cases with >12 nodes sampled 
Median lymph node ratio in N1 cases (IQR)
27 (16.3%)
139 (83.7%)
17 (12 to 25)
4 (2 to 6)
125 (76.7%) 
0.23 (0.14 to 0.37)
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fig. 13 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
according to overall nodal status (n=166).
NO
N1
Log rank - p=0.006
Time (months)
No. at risk
NO 27 18 10 6 5 5
N1 139 70 28 11 5 3
Patients with nodal involvement had a median survival of 13.3 (95% Cl = 10.5 to 
15.5) months compared with 24.1 (95% Cl = 13.0 to 70.7) months for node negative 
patients (Cox; HR = 2.016 (95% Cl = 1.221 to 3.357), p=0.007).
The lymph node ratio was investigated to identify whether this index represents a 
more informative prognostic marker than overall nodal status. The median lymph 
node ratio recorded for node positive patients (n=136) was 0.23 (IQR = 0.14 to 0.37). 
As with tumour size, the prognostic value of the lymph node ratio was investigated 
both as a categorical and continuous variable. Table 5 outlines the results of the Cox 
proportional hazards analysis, fig. 14 demonstrates the Kaplan-Meier cumulative 
survival curves stratified by three lymph node ratio groups.
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Table 5 - Univariate prognostic significance of lymph node ratio (LNR) - Cox proportional hazards 
(n=163).
Median survival
(95% Cl)
Hazard ratio
(95% Cl)
p-value
LNR (3groups): _ 12.76 0.002
0 (n=27) 24.1 (13 to 70.7) - - -
0 to 0.33 (n=101) 14.3 (11.3 to 17.4) 1.819 (1.079 to 3.069) 5.04 0.025
>0.33 (n=35)
LNR:
9.5 (6.9 to 13.3) 2.969(1.624 to 5.425) 12.51 <0.001
continuous (n=163) - 4.510 (1.938 to 10.494) 12.22 <0.001
fig. 14 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
stratified by lymph node ratio (n=163).
LNR= 0 
LNR>0 to 0.33 
LNR >0.33 
Log rank - p=0.001
Time (months)
No. at risk
NO 27 18 10 6 5 5
LNR >0 to 0.33 101 53 23 9 5 3
LNR>0.33 35 14 4 1 0 0
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An increasing proportion of tumour involved lymph nodes sampled from the surgical 
specimen was found to closely correlate with poorer survival. These results indicate 
that the lymph node ratio provides superior prognostic information when compared 
with overall nodal status. As with tumour size, the lymph node ratio was included as a 
continuous covariate for subsequent multivariate analyses on the basis of these 
findings.
The lymph node yield was also investigated as a potential prognostic index. Previous 
studies have suggested that pancreatoduodenectomy cases with fewer than 12 sampled 
lymph nodes are associated with a poorer survival outcome than those with more than
12 sampled nodes, irrespective of metastatic nodal involvement (Slidell et al, 2008). 
On this basis, a further analysis was conducted using the number of sampled nodes as 
a continuous prognostic covariate for univariate Cox regression in order to assess the 
relationship between lymph node yield and survival.
The median number of lymph nodes sampled in node positive patients was 19 (IQR =
13 to 26). This compared with 15 (IQR = 9 to 18) for node negative patients. A 
logistic regression analysis was conducted using the number of sampled nodes as an 
independent variable and nodal status (ie. positive vs negative) as the dependent 
variable. This result demonstrated an odds ratio of 1.085 (95% Cl = 1.025 to 1.148) - 
p = 0.005 (n=163). This suggests that the likelihood of identifying metastatic lymph 
node involvement increases proportionally as the number of sampled nodes increases. 
When modelling the number of sampled nodes as a continuous variable for Cox 
regression in the overall patient group there was no significant relationship between 
lymph node yield and survival (HR = 1,010 (95% Cl = 0.992 to 1.020), p = 0.269).
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This was equally true when only analysing the NO group (HR = 0.980 (95% Cl = 
0.923 to 1.040), p = 0.501.
An additional analysis was conducted in order to identify whether reporting 
pathologists exhibited a tendency for a greater number of lymph nodes to be sampled 
from pancreatoduodenectomy specimens with less favourable histological tumour 
characteristics in order to provide an alternative explanation for this observation. 
Table 6 outlines the median lymph node yield according to the various histological 
sub-groups. There was no significant correlation between tumour size and the 
corresponding number of sampled lymph nodes (Spearman; rho = 0.140, p=0.090). 
These results did, however, indicate a significant trend towards a greater lymph node 
yield in more locally infiltrative tumours.
Table 6 - Relationship between tumour histology and lymph node yield.
Median lymph node yield (IQR) p-value
Resection margin status: 
R0 (n=35)
R1 (n=126)
17 (10 to 22) 
18(14 to 26)
0.171
(Mann-Whitney)
T stage:
T1 (n=7)
T2 (n=17) 
T3/T4 (n=141)
5(2.5 toll) 
10(7 to 19.5) 
19 (14 to 26)
<0.001
(Kruskal-Wallis)
Tumour differentiation: 
Well (n=23) 
Moderate (n=85) 
Poor(n=55)
17 (13 to 24)
18 (13 to 26) 
17 (12 to 25)
0.883
(Kruskal-Wallis)
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Despite the finding that there was no significant relationship between tumour size and 
the corresponding number of sampled lymph nodes identified within the 
pancreatoduodenectomy specimen, there was a significant relationship between 
increasing tumour size and lymph node ratio - linear regression; R = 0.160, p = 0.047
fig. 15 - Scattergram to demonstrate trend towards increasing lymph node ratio in larger tumours.
Linear regression 
p= 0.047
Tumour size (mm)
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2.3.5. Lymph node 8a status
Lymph node 8a was sampled in 140 cases and was found to be positive in 31 (22.1%). 
Patients with a positive lymph node 8a status had a median survival of 12.6 (95% Cl 
= 7.6 to 17.0) months compared with 14.3 (95% Cl = 12.6 to 17.5) months for those 
with a negative lymph node 8a - log rank, p = 0.040 (fig. 16).
fig. 16 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
stratified by lymph node 8a status (n=140).
LN8a negative 
LN8a positive 
Log rank - p=0.040
Time (months)
No. at risk
LN8a -ve 109 59 27 11 6
LN8a +ve 31 16 2 0 0
4
0
Lymph node 16b status
Lymph node 16b was sampled in 87 cases and was found to be positive in 11 (12.6%). 
Patients with a positive lymph node 16b status had a median survival of 12.5 (95% Cl 
= 7.5 to 27.4) months compared with 15.5 (95% Cl = 12.3 to 22.1) months for those 
with a negative lymph node 16b - log rank, p = 0.261. fig.lVA demonstrates the 
Kaplan-Meier survival curves for this analysis.
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2.3.6. Resection margin status
Following histological microscopic re-assessment of all RO resections, 163 evaluable 
cases were identified. Three cases were omitted due to an inability to reliably classify 
resection margin status from the available slides. Of the 128 cases (78.5%) classified 
as Rl, 57 cases (44.5%) were based on tumour involvement within 1 mm of one or 
more margins, without direct involvement of the margin itself (ie. an ‘equivocal' 
margin).
Table 7 demonstrates a breakdown of resection margin involvement according to the 
number of involved margins per specimen and to the distribution of margin 
involvement. These results indicate that 35.2% of Rl resections exhibit multifocal 
margin involvement (ie. more than one margin involved in a single specimen) while 
the posterior and medial margins were the most commonly involved margin locations.
Table 7 - Distribution of resection margin involvement.
All Rl resections: 128 (79%)
Number of involved resection margins per specimen:
1 83 (65%)
2 37 (29%)
3 7 (5%)
4 1 d%)
Distribution of resection margin involvement:
Posterior 69 (54%)
Medial 64 (50%)
Transection 38 (30%)
Proximal duodenal / gastric 6 (5%)
Common bile duct 4 (3%)
Distal duodenal
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The prognostic relevance of ‘equivocal ’ resection margins
Equivocal R1 cases (<lmm) had a median survival of 15.4 (95% Cl = 11.3 to 18.2) 
months compared with 12.6 (95% Cl = 9.2 to 14.3) months for unequivocal R1 
(direct) cases and 25.4 (95% Cl = 10.5 to 40.8) months for R0 cases. When 
comparing the overall R1 group with R0 cases (fig. 18), a significant difference in 
survival was recorded (log rank, p=0.013).
fig.18 - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients 
stratified by overall resection margin status (n=163).
Log rank
p=0.013
Time (months)
R0 35 19 15 9 6 3
When comparing equivocal with the unequivocal R1 cases (fig. 19), no significant 
difference in survival was recorded (log rank, p=0.102). This was similarly true when 
comparing the equivocal R1 group with the R0 group (log rank, p=0.114). Despite 
this, the survival curves indicated much closer concordance between the equivocal 
and direct R1 cases than when comparing the equivocal and R0 groups. As such, 
equivocal cases were considered as R1 for the purposes of subsequent survival 
analyses.
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fig. 19 - Kaplan-Meier cumulative survival curves for R1 cases stratified by equivocal vs direct tumour 
involvement status (n=128).
<1 mm R1 
Direct R1
Log rank
p=0.102
Time (months)
Direct 71 35 11 3 1 1
dmm 57 33 11 5 4 4
Prognostic relevance of margin location
When analysing only R1 resections, involvement of the transection margin was found 
to exhibit a non-significant trend towards poorer survival (log rank, p=0.085) - fig.20. 
Table 10 demonstrates that neither posterior nor medial margin involvement conferred 
poorer survival within the R1 group.
Table 10 - Prognostic relevance of resection margin distribution in R1 cases (n=128).
Resection margin No. of patients Median survival (95% Cl) p-value (log rank)
Transection:
Negative 90 15.0(12.5 to 17.0) 0.085
Positive 38 11.3 (7.6 to 13.7)
Posterior:
Negative 59 13.3(10.0 to 19.2) 0.259
Positive 69 13.8(10.2 to 15.5)
Medial:
Negative 64 14.2 (8.5 to 15.5) 0.358
Positive 64 13.2(11.1 to 17.4)
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fig.20 - Kaplan-Meier cumulative survival curves for R1 resections stratified by transection margin status 
(n=128).
Transection margin negative 
Transection margin positive
Log rank
p=0.085
Time (months)
TRM positive 38 17 4 1 0 0
TRM negative 90 51 18 7 5 5
When analysing the group of 35 RO resections, 12 cases exhibited isolated tumour 
involvement (either direct or <1 mm) of the anterior pancreatic capsule. There was no 
significant difference in survival between this group of patients and the remaining 23 RO 
resections (log rank, p=0.220) - Jig.21A. Due to the small numbers of cases involving 
duodenal and common bile duct resection margins, the prognostic relevance of these margins 
was not investigated.
Isolated involvement of posterior resection margin vs RO cases
An analysis was undertaken to identify whether the survival of R1 cases with isolated 
posterior margin involvement (either <lmm or direct) was significantly different from RO 
cases. A total of 29 R1 patients (22.7%) had isolated posterior margin involvement with a 
median survival of 15.0 (95% Cl = 10.4 to 17.5) months compared with 25.4 (95% Cl = 10.5 
to 40.8) months for the 35 R0 cases - log rank; p = 0.051. fig.22 demonstrates the Kaplan- 
Meier survival curves for this analysis.
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fig.22 - Kaplan-Meier cumulative survival curves comparing survival between R1 cases with isolated posterior 
margin involvement and RO cases.
isolated posterior RM +ve 
Log rank - p=0.051
Time (months)
No. at risk
RO 35 19 15 9
Post. RM+ve 29 15 5 2
6 3
1 1
Prognostic relevance of number of involved resection margins
A further analysis was undertaken to identify whether an increasing number of involved 
resection margins within an individual pancreatoduodenectomy specimen conferred a poorer 
survival. Within the group of R1 resections (ie. both direct and equivocal), Cox regression 
failed to demonstrate any significant trend towards poorer survival in patients with an 
increasing number of involved resection margins - Cox; HR = 1.145 (95% Cl = 0.914 to 
1.436), = 1-39, p = 0.23S. fig.23A demonstrates that there was no significant survival
difference when comparing R1 cases stratified according to single resection margin 
involvement vs. multiple margin involvement (log rank, p = 0.354).
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Relationship between R1 status and other histological tumour characteristics 
A logistic regression analysis was conducted to identify whether any of the other histological 
tumour characteristics were associated with an increased likelihood of microscopic margin 
involvement. Tumour size and T stage were included as continuous independent variables 
while tumour differentiation (poor vs. well/moderate) and nodal status (positive vs. negative) 
were included as categorical independent variables. R1 likelihood was included as the 
dependent variable in this analysis {Table 11).
Table 11 - Logisitic regression analysis to demonstrate relationship between tumour histology and likelihood of 
resection margin involvement.
Logistic regression
Odds ratio (95% Cl) X2 p-value
Continuous:
Size 1.049 (1.010 to 1.088) 6.205 0.013
T stage 1.644 (0.860 to 3.143) 2.266 0.132
Categorical:
poor differentiation 2.164 (0.874 to 5.356) 2.786 0.095
+ve nodal status 1.187 (0.434 to 3.243) 0.112 0.738
Increasing tumour size (recorded in mm) was associated with a significantly increased 
likelihood of an R1 resection when included as a continuous independent variable (odds ratio 
- 1.049 (95% Cl = 1.010 to 1.088); p=0.013). R0 resections had a median tumour size of 25 
(IQR = 19 to 35) mm compared with 30 (IQR = 25 to 40) mm for R1 resections - fig.24. Poor 
tumour differentiation (p=0.095), increasing T stage (p=0.132) and nodal status (p=0.738) 
failed to exhibit a significant relationship with R1 likelihood in this patient cohort.
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fig'2 4 - Box plot of tumour size according to resection margin status.
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2.3.7. Perineural invasion
The presence or absence of perineural invasion on microscopic assessment was documented 
in 144 of 166 histology reports. Perineural invasion was present in 136 out of 144 cases 
(94.4%). Cases with perineural invasion had a median survival of 13.1 (95% Cl = 10.5 to 
15.0) months while cases with no perineural invasion had a median survival of 100.3 (95% 
Cl = 48.1 to NR) months - log rank, p<0.001. The Kaplan-Meier survival curves for this 
analysis are demonstrated in fig.25.
fig.25 - Kaplan-Meier cumulative survival curves stratified according to the presence of perineural invasion 
(n=144).
no perineural invasion 
perineural invasion 
Log rank - p< 0.001
Time (months)
no peri. inv. 
peri, invasion
8 7
136 25
5
4
2 2 
2 1
1
0
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Vascular invasion
The presence or absence of vascular invasion on microscopic examination was recorded in 
138 of 166 cases. Vascular invasion was present in 104 out of 138 cases (75.4%). Cases with 
vascular invasion had a median survival of 13.1 (95% Cl = 10.4 to 17.0) months while cases 
with no vascular invasion had a median survival of 15.0 (95% Cl = 12.1 to 19.7) months - log 
rank, p=0.809. The Kaplan-Meier survival curves for this analysis are demonstrated in 
fig.26A.
Because of the small proportion of cases who failed to exhibit perineural invasion and the 
lack of any prognostic value of vascular invasion, neither of these histological factors were 
included in any of the subsequent multivariate analyses.
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2.3.8. Multivariate survival analysis of key univariate prognostic factors 
On the basis of the above analyses, the following histological variables of prognostic 
significance according to univariate analysis were considered for multivariate Cox 
proportional hazards regression. Table 12 summarises the results of three multivariate 
analyses. The individual variables were modelled either on a continuous or dichotomised 
basis according to the principles outlined previously:
• Tumour size (continuous)
• Tumour differentiation (poor vs. well/moderate)
• Lymph node ratio (continuous)
• Resection margin status (R1 vs RO)
Table 12 - Multivariate survival analyses of standard histological prognostic factors alongside adjuvant 
chemotherapy in resected pancreatic ductal adenocarcinoma (Cox proportional hazards).
Hazard ratio (95% Cl) x2 P
Model 1 (n=154)
Tumour size 1.018 (1.002 to 1.035) 4.85 0.028
Poor tumour differentiation 1.430 (0.969 to 2.111) 3.24 0.072
Lymph node ratio 3.081 (1.266 to 7.499) 6.15 0.013
Resection margin +ve 1.436 (0.888 to 2.322) 2.18 0.140
Model 2 (n=154)
Tumour size 1.017 (1.000 to 1.033) 4.03 0.045
Poor tumour differentiation 1.428 (0.966 to 2.110) 3.20 0.074
Lymph node ratio 2.984(1.242 to 7.172) 5.97 0.015
Resection margin +ve 1.397 (0.861 to 2.267) 1.84 0.175
Adjuvant chemotherapy 0.598 (0.389 to 0.920) 5.48 0.019
A further analysis was conducted with exclusion of resection margin status as a covariate 
{Table 13),
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Table 13 - Multivariate survival analysis of key prognostic factors in resected pancreatic ductal adenocarcinoma 
excluding resection margin status (Cox proportional hazards).
Hazard ratio (95% Cl) x2 P
Model 3 (n=156)
Tumour size 1.017 (1.002 to 1.034) 4.65 0.031
Poor tumour differentiation 1.551 (1.061 to 2.266) 5.14 0.023
Lymph node ratio 2.987(1.238 to 7.183) 5.93 0.015
Adjuvant chemotherapy 0.580 (0.377 to 0.892) 6.15 0.013
2.3.9. Discussion
The multivariate analysis indicates that the four variables of increasing tumour size, poor 
differentiation, increasing lymph node ratio and lack of adjuvant chemotherapy are all 
independent adverse prognostic factors on multivariate analysis in this patient cohort. These 
key variables were selected for inclusion in all subsequent multivariate analyses undertaken.
Tumour size
Larger tumours were associated with significantly poorer survival outcomes in this cohort of 
pancreatic adenocarcinoma resections. This observation is typical of previous data from 
individual surgical centres (Garcea et al, 2008), adjuvant therapy trials (Neoptolemos et al, 
2004) and meta-analyses (Stocken et al, 2005) of survival data from resected pancreatic 
cancer patients. Tumour size is commonly dichotomised according to a specific cut-off value 
(eg. > 20 mm) as part of these survival analyses which, as previously outlined, can be 
associated with potential bias. The results from the present data indicate that this relationship 
between increasing tumour size and adverse survival is equally time when analysing size as a 
continuous rather than dichotomised variable. Furthennore, tumour size demonstrated a 
stronger relationship with survival when analysed on a continuous basis. For this reason.
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tumour size was modelled as a continuous covariate for subsequent multivariate analyses as 
this was felt to be the most informative method of describing this survival relationship.
Larger tumours were also demonstrated to exhibit a significant association with both the 
corresponding lymph node ratio and an increasing likelihood of a positive resection margin. 
Despite this fact, multivariate Cox regression demonstrated that the relationship between 
tumour size and survival was independently significant of these two factors. This observation 
suggests the presence of more extensive lymphangiogenesis and consequent regional nodal 
infiltration as the primary tumour size increases. Similarly, it follows that larger tumours 
occupying a greater proportion of the overall volume within the pancreatic head are more 
likely to exhibit microscopic tumour involvement at one or more resection margins as one 
might reasonably expect.
Differentiation
Tumour grade or differentiation represents an additional key histological tumour 
characteristic which has previously been shown to have a significant impact on survival 
following resection for pancreatic adenocarcinoma. Survival data from both ESP AC-1 and 
meta-analysed data including other adjuvant therapy trials (Stocken et al, 2005) have 
demonstrated that tumour differentiation is an important determinant of patient survival 
following resection. Due to the limited number of well differentiated tumours in the current 
patient cohort, along with the fact that there was no significant observed difference in 
survival between well and moderately differentiated tumours, these two tumour groups were 
combined for subsequent survival analyses. This was found to result in a significant survival 
difference when comparing the well / moderately differentiated tumour group with the poorly
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differentiated tumour group. This categorisation was used for subsequent multivariate 
analyses.
Lymph node status
The UICC TNM classification for nodal status of resected pancreatic adenocarcinoma 
requires one of three categories be assigned:
• NO - no tumour-involved lymph nodes present
• N1 a - single tumour-involved lymph node present
• Nib - multiple tumour-involved lymph nodes present
Most studies investigating histological prognostic factors in resected pancreatic 
adenocarcinoma report nodal status as simply NO or Nl. The findings from the present study 
provide further evidence to suggest that this simple dichotomised categorisation results in 
restricted prognostic information. A previous large single-centre study (Pawlik et al, 2007) 
has shown that the number of tumour-involved lymph nodes as a proportion of the total 
number of sampled nodes in resected pancreatic cancer specimens provides superior 
prognostic information to overall nodal status (ie. positive vs. negative). This finding has also 
been observed from a recent analysis of SEER data (surveillance, epidemiology and end 
results) from a collective US database of 4005 pancreatic cancer resections (Slidell et al, 
2008). Similar results have also been published for other gastrointestinal malignancies 
including colon (Berger et al, 2005) and gastric cancer (Inoue et al, 2002).
This observation is explained on the basis that patients with a smaller nodal tumour burden 
(eg. 1 of 20 sampled nodes) are more likely to exhibit longer survival times when compared 
to patients with a much greater overall nodal tumour burden (eg. 18 out of 20 sampled nodes)
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who are consequently more likely to experience early regional recurrence. A comparative 
analysis of overall nodal status (ie. N1 vs. NO) against the lymph node ratio (modelled as a 
continuous variable) clearly shows that the latter demonstrates a much stronger association 
with patient survival. This allows additional risk stratification within the N1 group and 
provides significant supplementary prognostic infonnation. For this reason, the lymph node 
ratio was included as a continuous covariate in subsequent multivariate analyses. This finding 
relating to the prognostic relevance of lymph node ratio within the current patient cohort was 
published in 2008 (Appendix B).
The analysis of lymph node yield indicated a significant relationship between the number of 
sampled nodes and the likelihood of an N1 classification and this observation has also been 
made previously (Slidell et al; 2008). The median number of nodes sampled in the overall 
patient group (17) compares favourably with other centres. Sliddell et al (2008) reported that 
in patients undergoing pancreatic resection for cancer a minimum of 12 sampled nodes 
represents the optimum harvest in order to reliably assess nodal status. The median number of 
nodes sampled from the 4005 resections included in their series of patients was seven. The 
number of sampled nodes in the present study was not found to exhibit any significant 
association with survival either in the overall patient group or the NO subgroup. The 
previously reported observed relationship between reduced nodal harvest and poorer survival 
may not have been reflected in the current data by virtue of the fact that only a minority of 
cases (less than one in four) had fewer than 12 lymph nodes sampled. This represents an 
index of high quality pathology processing and reporting throughout the duration of the study 
period.
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When analysing any potential relationships between the lymph node yield and corresponding 
histological tumour characteristics a significant association with T stage was recorded. The 
limited number of T1 and T2 tumours exhibited a smaller median number of sampled lymph 
nodes when compared with T3/T4 tumours. This observation is likely to be explained on the 
basis that patients with more extensive tumours underwent resections encompassing a greater 
amount of peripancreatic tissue in the specimen when compared with smaller tumours.
Resection margin status
The relative prognostic significance of resection margin status is variably reported for 
pancreatic cancer. Although several single centre studies have suggested that resection 
margin involvement has significant prognostic value on multivariate analysis alongside other 
histological tumour characteristics (Benassi et al, 2000; Han et al, 2006; Moon et al, 2006) 
studies including larger patient series typically demonstrate that R1 status either fails to 
maintain significance on multivariate analysis (Raut et al, 2007; Pawlik et al, 2007) or that 
R1 status fails to emerge as a significant univariate predictor of survival (Bassi et al, 2005; 
Jarafe et al, 2004). These results have also been mirrored in a previous meta-analysis of four 
adjuvant therapy trials which failed to demonstrate a significant overall survival difference 
according to resection margin status in a pooled group of 875 pancreatic adenocarcinoma 
resections (Butturini et al, 2008).
Highly variable R1 resection rates for pancreatic cancer are commonly quoted in different 
studies. Large multicentre adjuvant therapy trials have previously reported R1 resection rates 
of 17-19% (Neoptolemos et al, 2004; Oettle et al, 2007). However, these studies do not report 
potential differences in R1 rates between individual surgical centres. Studies reporting results 
from single centre cohorts demonstrate marked variability (17-85%) in R1 rates (Raut et al,
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2007; Winter et al, 2006; Esposito et al, 2008; Verbeke et al, 2006). It is unknown as to what 
extent this heterogeneity in quoted R1 rates may be explained by differences in pathological 
practice rather than operative expertise. However, increasing evidence exists to suggest that 
the standard of histopathological processing and reporting has a significant impact on R1 
resection rates (Esposito et al, 2008; Verbeke et al, 2006).
The previous study by Verbeke et al (2006) demonstrated that utilization of a standardised 
protocol for histological processing and examination of pancreatoduodenectomy specimens 
for pancreatic cancer based on the Royal College of Pathologists guidelines was associated 
with an R1 resection rate of 85%. This study also demonstrated a significant correlation 
between an increasing number of tissue blocks taken from circumferential margins and an 
increasing likelihood of an R1 classification. A more recent study by Esposito et al (2008) 
using a similar standardised histopathology protocol reported an R1 rate of 76%. These 
findings are consistent with the hypothesis that a negative resection margin status may be 
commonly incorrectly assigned to cases with sub-optimal pathological processing. The 
assertion that R1 resections are commonly under-reported is also supported by the 
observation that 60-80% of cases with resected pancreatic cancer develop local recurrence 
(Kayahara et al, 1993; Westerdahl et al, 1993; Sperti et al, 1997), a finding which seems 
incongruous with quoted R1 resection rates of less than 20%. Differences in histological R1 
classification between individual centres may also in part explain the variable reporting of 
resection margin status as a prognostic index for pancreatic cancer.
The present study represents the first attempt to quantify the impact of the ‘<1 mm rule’ in 
defining R1 classification for resected pancreatic cancer and provides further evidence to 
suggest that R1 resections may be commonly under-reported. The R1 resection rate of 79% in
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this study group is comparable with the rates quoted by Esposito et al (76%) and Verbeke et 
al (85%) using standardised pathology protocols based on the Royal College of Pathologists 
guidelines. The results also suggest a similar proportion of multifocal R1 resections (35%) 
when compared with these two studies (32% and 45% respectively).
These findings indicate that the ‘<1 mm rule’ has a significant impact on the quoted R1 
resection rate. In total, 45% of all R1 resections in this cohort of patients were based on 
‘equivocal’ margin involvement (ie. tumour within 1 mm of one or more margins in the 
absence of direct involvement). If these cases had been classified as RO, the R1 resection rate 
would fall significantly from 79% to 44%. Analysis of the survival curves supports the 
previous recommendation made in the Royal College of Pathologists’ guidelines that tumour 
involvement within 1mm of a resection margin should be considered synonymous with 
incomplete excision. The group of‘equivocal’ R1 resections exhibited a comparable survival 
distribution to the ‘unequivocal’ R1 group with no statistically significant difference when 
comparing the two survival curves. Further analysis of the survival data indicate that this 
classification system for R1 resections results in a significant prognostic index on univariate, 
but not multivariate, survival analysis.
When analysing the distribution of margin involvement in R1 resections for pancreatic 
cancer, the finding that posterior and medial margin involvement represent the most 
frequently involved margin locations is also consistent with the existing literature (Esposito et 
al, 2008; Verbeke et al, 2006; Nagakawa et al, 1996). When comparing survival within sub­
groups of the R1 resections according to margin location, only cases with transection margin 
involvement demonstrated a trend (non-significant) towards poorer survival, indicating that
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the transection margin represents the least favourable site for microscopic tumour 
involvement.
The analysis of the RO resections indicates; that the sub-group of patients with isolated tumour 
involvement of the anterior pancreatic capsule had no significant difference in survival when 
compared with the other RO resections. Because of this observation, along with the fact that 
the anterior aspect of a pancreatoduodenectomy specimen represents a peritonealised surface 
as opposed to a true resection margin, the anterior ‘margin* was not considered as a resection 
margin as part of this study. This issue represents an area where there is no clear pathological 
consensus in the literature (Esposito et al, 2008) and this finding requires validation in a 
larger cohort of patients to clarify the prognostic relevance of microscopic anterior tumour 
involvement.
Previous studies have suggested that the presence of poor tumour differentiation 
(Neoptolemos et al, 2001) and increasing tumour size (Raut et al, 2007) may be associated 
with an increased likelihood of resection margin involvement in pancreatic cancer. The 
results from the present study are consistent with regard to these findings. However, this 
observation only reached significance for tumour size. The association between these 
histological tumour characteristics and R1 likelihood may also in part explain why resection 
margin status commonly fails to emerge as a significant independent prognostic index when 
analysed in a multivariate context, as in the present study.
This analysis provides the first clinical evidence to validate the Royal College of 
Pathologists’ guidelines regarding resection margin classification in pancreatoduodenectomy 
specimens for pancreatic cancer. The findings highlight the importance of standardised
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histopathological reporting and provide a potential explanation for the significant 
heterogeneity in reported R1 resection rates quoted by different specialist cancer centres. The 
results also provide further evidence to suggest that histological tumour characteristics may 
be equally important detenninants of R1 resections alongside robust pathological practice. 
These findings have been published {Appendix B) and have also been utilised as part of the 
criteria used to define resection margin status in pending revisions to the Royal College of 
Pathologists minimum dataset for pancreatoduodenectomy reporting (Campbell et al, 2002).
Additional histological tumour characteristics
Perineural invasion is a characteristic feature of pancreatic ductal adenocarcinoma and is 
invariably found on microscopic assessment of resected tumours. In the very small proportion 
of cases for who the pathologist failed to observe any perineural invasion, the observed 
survival times were more favourable. However, due to the limited number of these cases, 
perineural invasion did not represent an infonnative overall prognostic marker and was not 
included in any subsequent multivariate analyses. The presence of microscopic vascular 
invasion failed to exhibit any demonstrable impact on survival in the current patient cohort 
and this is a typical finding from previous large studies (Pawlik et al, 2007). Because no 
significant difference in overall survival was observed when comparing the pancreatic ductal 
adenocarcinoma cases stratified by T stage, along with the fact that a significant majority of 
cases exhibited T3 disease, this variable was not used in subsequent multivariate analyses 
when analysing other prognostic factors alongside established histological tumour 
characteristics.
With regard to the prognostic relevance of second order nodal disease, the results are in 
concordance with previous reports (Connor et al, 2004) which suggest that metastatic tumour
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involvement of the common hepatic artery lymph nodes (8a) confers poorer survival when 
compared with those patients with negative lymph nodes sampled from this region. However, 
when excluding NO cases from this analysis (ie. comparing survival according to LN8a status 
only within the N1 patient group) the result failed to reach significance (p = 0.080). Tumour 
involvement of the retroperitoneal nodes posterior to the head of the pancreas (LN16b) did 
not confer any additional prognostic information. As a result of these findings, along with the 
fact that a significant number of patients had neither second order nodes sampled as part of 
their surgery, these factors were not considered in subsequent multivariate analyses.
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2.4. Preoperative prognostic factors
2.4.1. Preoperative liver function and biliary drainage
Table 14 outlines the distribution of biochemical results for 161 patients for whom 
preoperative liver function tests (LFTs) were available. 136 patients (84.5%) had 
preoperative LFTs recorded within 48 hours of surgery, 21 (13.0%) within 1 week and 4 
(2.5%) within 2 weeks.
Table 14 - Details of preoperative liver function and biliary drainage procedures.
No. (%) of cases with preoperative LFTs recorded: 161 (97.0%)
Bilirubin: median (IQR) 25 (13 to 60) pmol/l
Alkaline phosphatase: median (IQR) 202 (123 to 362) U/l
ALT: median (IQR) 49 (25 to 84) U/l
YGT: median (IQR) 136 (64 to 360) U/l
Albumin: median (IQR)
Intervention for preoperative biliary drainage* (%):
36 (32 to 40) mg/I
none 25 (15.1)
ERCP + stent 129 (77.7)
PTC / combined procedure + stent / drain 12(7.2)
Interval from stenting to surgery: median (IQR) 34 (22 to 49) days
LFTs = liver function tests, ALT = alanine aminotransferase, yGT = gamma-glutamyl transferase, IQR = 
interquartile range, ERCP = endoscopic retrograde cholangio-pancreatography, PTC = percutaneous 
transhepatic cholangiopancreatography.
Four cases undergoing PTC required external drainage. A metal biliary stent was used in 5 
out of 137 cases undergoing internal stenting. A plastic stent was employed in the remaining 
cases.
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The effect of preoperative biliary drainage on survival
ftg.27A demonstrates that there was no significant difference in early or overall survival when 
comparing those patients who did or did not undergo biliary drainage preoperatively (log 
rank, p^O.946). fig.28A demonstrates no significant difference in survival when comparing 
patients who required percutaneous intervention for biliary drainage with those who 
underwent endoscopic stenting (log rank, p=0.290).
The effect of biliary drainage on resolution ofjaundice
Patients requiring PTC exhibited a greater degree of residual jaundice at the time of surgery 
(median bilirubin level = 50 (IQR = 34 to 134) pmol/1) when compared with patients stented 
at ERCP (median bilirubin level = 24 (IQR = 13 to 47) pmol/1) - Mann-Whitney, p=0.042. 
There was a median reduction in bilirubin levels of 73% (IQR = 49% to 92%) in patients 
requiring PTC or combined procedures. However, only 3 of 12 patients (25%) experienced 
complete resolution of jaundice (ie. < 35 pmol/1) at the time of surgery. In total, 64% 
(80/124) of patients undergoing stenting at ERCP had complete resolution of jaundice at the 
time of surgery.
Duration of preoperative biliary drainage and resolution of jaundice
When analysing the overall group of patients undergoing preoperative biliary drainage, there 
was a significant inverse correlation between the duration of biliary drainage and bilirubin 
levels prior to resection (Spearman, rho = -0.704, pO.OOl) - ie. a longer period of 
preoperative biliary drainage resulted in lower bilirubin levels at the time of surgery (fig. 29).
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fig.29 - Plot to demonstrate inverse correlation between duration of biliary drainage and bilirubin levels
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The influence ofpreoperative liver function on overall survival
Table 15 demonstrates the results of univariate Cox regression when modelling the various 
preoperative liver function parameters as continuous prognostic variables in the overall 
patient group undergoing resection for pancreatic cancer. The hazard ratios quoted for each 
variable reflect the increase in the relative hazard associated with each unit increase in the 
prognostic variable of interest.
Table 15 - Univariate Cox proportional hazards regression of preoperative liver function parameters.
Hazard ratio (95% CE) 2X P
Bilirubin 1.001 (0.999 to 1.003) 1.07 0.302
Albumin 0.958 (0.931 to 0.986) 8.53 0.004
Alkaline phosphatase 1.001 (1.000 to 1.001) 7.45 0.006
ALT 1.001 (0.998 to 1.004) 0.29 0.590
yGT 1.000 (1.000 to 1.001) 3.78 0.052
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Univariate Cox analysis demonstrated a significant inverse association between preoperative 
albumin levels and postoperative survival (p=0.004) while elevated alkaline phosphatase 
levels were also associated with a significant trend towards poorer postoperative survival 
(p=0.006). Preoperative y-glutamyl transferase levels were associated with a borderline 
significant result (p=0.052) while alanine aminotransferase exhibited no significant 
relationship with survival (p=0.590). Table 16 demonstrates the results of a multivariate Cox 
analysis including albumin, alkaline phosphatase and y-glutamyl transferase as covariates. 
This result demonstrates that of the three biochemical parameters, only preoperative albumin 
levels continue to exhibit a significant relationship with survival (p=0.039).
Table 16 - Multivariate Cox proportional hazards regression of preoperative liver function parameters.
Hazard ratio {95% Cl) 21 P
Albumin 0.965 (0.933 to 0.998) 4.27 0.039
Alkaline phosphatase 1.000 (0.999 to 1.001) 0.30 0.583
yGT 1.000 (0.999 to 1.001) 0.46 0.497
fig. 30 demonstrates the results of a Kaplan-Meier survival analysis dichotomising albumin 
according to a cut-off value of >33 g/1 (ie. the lower limit of the normal reference range for 
serum albumin concentrations). Patients with a preoperative albumin >33 g/1 had a median 
survival of 15.4 (95% Cl = 13.1 to 22.1) months compared with 10.2 (95% Cl = 6.9 to 14.3) 
months for patients with an albumin of <33 g/1 (Cox; HR = 1.722 (95% Cl = 1.202 to 2.468) - 
log rank, p = 0.003.
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fig.SO - Kaplan-Meier cumulative survival curves according to preoperative hypoalbuminaemia.
Albumin >33 
Albumin <33 
Log rank - p=0.003
Time (months)
No. at risk
Albumin >33 106 60 27 14 8 6
Albumin <33 55 24 8 2 2 2
The influence of preoperative jaundice on early postoperative sunival 
Although preoperative bilirubin levels were not found to exhibit a significant relationship 
with overall survival when modelled as a continuous variable, 37 demonstrates a clear 
trend towards less favourable early survival in jaundiced patients (ie. bilirubin levels >35 
pmol/1) at the time of resection (Breslow-Gehan-Wilcoxon, p=0.019). A cut-off of >35 
pmol/1 was selected as this represents the serum concentration at which hyperbilirubinaemia 
is clinically apparent as jaundice.
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fig.31 - Kaplan-Meier cumulative survival curves according to preoperative jaundice.
no jaundice 
jaundice
Log rank - p=0.082 
Breslow-Wilcoxon - p=0.019
Time (months)
No. at risk
nojaundice 95 56
jaundice 66 28
24 10 6
116 4
4
4
Table 17 demonstrates the results of a multivariate Cox analysis including serum albumin as 
a continuous covariate alongside tumour size, differentiation, lymph node ratio and adjuvant 
chemotherapy (n=152). The results indicate that low preoperative serum albumin levels 
continue to exhibit an adverse relationship with overall survival (p = 0.002) alongside the 
other prognostic factors of relevance.
Table 17 - Multivariate Cox analysis of preoperative albumin alongside tumour histology / chemo.
(n=152) Hazard ratio (95% Cl) 2X P
Albumin 0.952 (0.923 to 0.983) 9.32 0.002
Tumour size 1.019(1.003 to 1.036) 5.34 0.021
Poor differentiation 1.598(1.090 to 2.344) 5.76 0.016
Lymph node ratio 4.415 (1.717 to 11.354) 9.49 0.002
Adjuvant chemotherapy 0.612(0.391 to 0.959) 4.60 0.032
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Discussion
There is currently no general consensus regarding whether preoperative biliary drainage prior 
to surgical intervention represents the optimal management approach in patients presenting 
with potentially resectable pancreatic cancer. A meta-analysis has suggested that preoperative 
intervention for biliary drainage is associated with an increased risk of early postoperative 
morbidity, principally relating to wound infection (Sewnath et al, 2002). However, no overall 
association between biliary drainage and perioperative mortality was identified in this study. 
This meta-analysis was based on level 1 evidence from five randomised trials comprising 302 
periampullary cancers in total. Less than half of these patients had pancreatic 
adenocarcinoma and a similar proportion of the overall group actually underwent resection. 
These five trials encompassed a mix of both endoscopic and percutaneous procedures and 
included cases undergoing both internal and external drainage. The median bilirubin level at 
the time of surgery for the pooled patient group undergoing preoperative biliary drainage was 
recorded as 157 pmol/1. This represents a significantly greater value than the result recorded 
in the present study (25 pmol/1). Given the mix of periampullary tumours and the inclusion of 
both resected and unresected cases in the above meta-analysis, the overall findings from this 
study might not be reliably extrapolated to the specific setting of resected pancreatic cancer. 
Nevertheless, the results of the present study are concordant with the above findings in that 
biliary stenting per se was not shown to have any adverse effect on early or late survival in 
the overall patient group undergoing pancreatoduodenectomy for pancreatic cancer.
One of the main obseivations from the above analysis was the association between residual 
jaundice at the time of surgery and less favorable early survival. A previous study has also 
suggested that preoperative jaundice may represent a significant predictor of postoperative 
survival in a cohort of 281 resected periampullary cancers (Schmidt et al, 2004). hi the
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present study, separation of the survival curves was evident primarily for the first 12 
postoperative months resulting in a significant p-value when using the Breslow-Gehan- 
Wilcoxon test, but not the log rank (Cox-Mantel) test. The Breslow-Gehan-Wilcoxon test is 
calculated according to the number of patients at risk along each point of the survival curve 
and provides a better discriminator of differences in early survival between two groups - ie. 
the follow-up period during which the majority of patients are still alive. In comparison, the 
log rank test, which is calculated according to equal weighting at each point along the 
survival curve, provides a better indication of differences in overall and late survival.
The results demonstrate that the majority of patients with resectable pancreatic cancer who 
present with obstructive jaundice can undergo successful preoperative biliary drainage at 
ERCP. The findings also demonstrate that a longer period of preoperative biliary drainage 
was inversely correlated with bilirubin levels at the time of surgery as one might expect. This 
suggests that a balance exists with regard to the optimal timing of definitive surgery for this 
patient group, in order to allow for resolution of jaundice where possible without 
compromising the window of opportunity for tumour resectability. This issue is particularly 
relevant for patients where borderline features of resectability are present on initial imaging 
or where resolution of jaundice is protracted, even following percutaneous intervention. The 
decision-making process regarding the optimal timing of surgery is clearly a multifactorial 
one which may need to incorporate a number of additional logistical issues and should be 
considered on an individual patient basis. However, the observations from the present study 
indicate that early survival outcomes may be adversely influenced by inadequate resolution of 
preoperative jaundice.
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These findings were published in 2008 {Appendix B). The recently published multicentre 
DROP-trial randomised 202 jaundiced patients with pancreatic head and peri-ampullary 
cancers to undergo either preoperative biliary drainage prior to resection or early surgery (van 
der Gaag et al. 2010). The results indicated a greater degree of perioperative sepsis-related 
morbidity in the patient group undergoing biliary drainage. However, a further sub-group 
analysis of this data (Eshuis et al. 2010) found that there was no difference in resectability 
rates or overall postoperative survival when comparing the stented patients with those 
undergoing early surgery. Despite these results, they also observed a significant trend towards 
a lower operative mortality rate in patients with a longer time interval between randomisation 
and surgery for the overall study group. This observation is in agreement with our finding 
that patients with complete resolution of jaundice following biliary stenting had improved 
early survival when compared with those who remained jaundiced at the time of their 
operation. This suggests that the issue of perioperative morbidity is only one of a number of 
factors to consider when evaluating whether preoperative biliary drainage or expeditious 
resection represents the optimum management strategy for these patients.
Preoperative albumin levels were found to be a significant predictor of overall survival in the 
present study. Although previous studies have demonstrated that hypoalbuminaemia is 
associated with less favourable survival outcomes in patients with inoperable pancreatic 
cancer (Glen et al, 2006) and higher morbidity and mortality rates following 
pancreatoduodenectomy (Winter et al, 2007), no previous study has shown that pre-resection 
albumin levels are also associated with overall postoperative survival following resection for 
pancreatic cancer (Jamieson et al, 2005). Hypoalbuminaemia is often associated with a 
systemic inflammatory response and the observed survival association may simply reflect the 
fact that preoperative albumin levels represent an additional index of inflammation.
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Alternatively, low albumin concentrations may represent a multifactorial surrogate marker of 
general ill-health prior to surgery (ie. poorer overall nutritional status, impaired liver 
function, cancer cachexia, etc) which adversely affects survival. This finding raises the 
possibility that preoperative measures to counteract hypoalbuminaemia may influence 
postoperative outcome. A recent study has suggested that the introduction of immuno- 
enriched nutritional supplements in the preoperative setting yields significant improvements 
in early postoperative outcomes for patients undergoing major pancreatic resections (Giger et 
al, 2007).
110
2.4.2. Preoperative serum C-reactive protein (CRP)
Preoperative serum CRP levels were recorded in 131 patients (81.4%). The median time 
interval from the date of CRP estimation to date of surgery was 2 (IQR = 1 to 12 days). The 
median preoperative CRP recorded was 10 mg/1 (IQR = 5 to 27). Where a CRP level was 
recorded as <5 mg/1, a value of 4 mg/1 was used for subsequent analyses.
fig.32 demonstrates a percentile plot of the distribution of preoperative CRP levels. This 
suggests that over 90% of cases had CRP levels less than 100 mg/1 with 10 cases in whom 
levels of >100 mg/1 were recorded.
fig.32 - Percentile plot of preoperative CRP results recorded (n=131).
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A univariate Cox proportional hazards regression analysis was conducted using preoperative 
CRP as a continuous prognostic covariate. Table 18 demonstrates the results of this analysis 
when including all patients for whom CRP levels were recorded and when excluding the 10 
cases for whom levels of >100 mg/1 were recorded.
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Table 18 - Univariate Cox analysis of preoperative CRP levels as prognostic index (continuous).
Hazard ratio (95% Cl) 2 PX
All patients
Excluding cases with CRP >100
0.998 (0.994 to 1.002) 
1.011 (1.001 to 1.020) 5.12
1.14 0.287
0.024
This result suggests that there is a significant underlying relationship between preoperative 
CRP levels and subsequent survival following resection for pancreatic ductal adenocarcinoma 
on a univariate basis. However, it also implies that the presence of CRP levels >100 mg/1 
(which is more likely to reflect concurrent infective complications (eg. cholangitis) rather 
than the host inflammatory response to tumour) has a marked confounding effect when 
analysing the prognostic value of CRP levels in this setting.
fig. 33 demonstrates the Kaplan-Meier cumulative survival curves when stmtifying patients 
according to a preoperative CRP of >10 mg/1 (excluding patients with levels >100 mg/1). A 
cut-off value of 10 mg/1 was selected on the basis that this value is commonly used to define 
the upper limit of normal for serum CRP in a clinical setting.
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fig.33 - Kaplan-Meier cumulative survival curves according to preoperative CRP levels.
CRPclO mg/I 
CRP >10 mg/I 
Log rank - p=0.008
Time (months)
No. at risk
CRP<10 mg/I 61 36 15 9 6 4
CRP £10 mg/I 60 27 9 2 0 0
Patients with a preoperative CRP <10 mg/1 had a median survival of 17.0 (95% Cl = 12.8 to 
22.1) months compared with 12.3 (95% Cl = 9.8 to 13.7) months for patients with a CRP of 
>10 mg/1 (log rank, p = 0.008). Table 19 outlines the results of a multivariate Cox 
proportional hazards analysis including preoperative CRP levels (included as a continuous 
covariate) alongside the histological prognostic factors of relevance.
Table 19 - Multivariate Cox analysis of preoperative CRP alongside tumour histology / chemo.
(n=114) Hazard ratio (95% Cl) 2X P
CRP 1.012(1.002 to 1.023) 5.19 0.023
Tumour size 1.014(0.994 to 1.033) 1.86 0.173
Poor differentiation 1.358 (0.866 to 2.127) 1.78 0.182
Lymph node ratio 5.477(1.656 to 18.116) 7.77 0.005
Adjuvant chemotherapy 0.603 (0.370 to 0.981) 4.15 0.042
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The relationship between preoperative biliary drainage and CRP
Preoperative CRP levels were found to be more significantly elevated in those cases requiring 
PTC (median (IQR) = 29 (22 to 107) mg/1) when compared with those stented at ERCP - 
(median (IQR) = 9 (4 to 21) mg/1); Mann-Whitney, p=0.006 {fig.34).
fig. 34 - Box plot of preoperative CRP levels according to type of biliary drainage.
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Discussion
Elevated CRP levels were found to be associated with adverse survival when excluding 
patients with preoperative CRP values >100 mg/1. Cholangitis represents the most common 
cause for acute sepsis preoperatively in patients undergoing biliary decompression and 
stenting has also been shown to be associated with positive bile cultures at laparotomy 
(Jagannath et al. 2005; Jethwa et al. 2007). Several studies have demonstrated that pre­
resection CRP levels represent a potential prognostic factor in other gastrointestinal 
malignancies (Nozoe et al. 2001; Hashimoto et al. 2005; Crozier et al. 2007). In the single 
previous study in resected pancreatic cancer (n=65), an adverse association between elevated 
preoperative CRP and survival was shown on univariate but not multivariate analysis 
(Jamieson et al. 2005).
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The results from the present study demonstrate that the relationship between elevated 
preoperative CRP levels and poorer survival is only evident when excluding a small number 
of outlying patients with a significantly elevated CRP. It was not possible to determine which 
patients in this study had preoperative clinical features of cholangitis on a retrospective basis 
and the selection of a CRP cut-off value of 100 mg/1 for exclusion was a pragmatic one rather 
than being based on any pre-defined diagnostic criteria. However, when analysing the 10 
excluded patients with CRP levels >100 mg/1, 9 underwent preoperative intervention for 
biliary drainage and the median concurrent bilimbin level at the time of CRP estimation was 
92 (IQR = 33 to 160) pmol/1. This observation is concordant with the only other study which 
has investigated the relationship between preoperative CRP levels and postoperative survival 
in resected pancreatic cancer (Jamieson et al, 2005). This study also reported that patients 
with cholangitis were excluded from their analysis. However, they failed to elaborate on any 
specific criteria with regard to how this was defined. It was, therefore, felt to be reasonable to 
conclude that the disparity in the survival analyses outlined above was principally due to the 
confounding effect of cholangitis in the group of patients with significantly elevated CRP 
levels. Tumour size and differentiation lost significance with inclusion of CRP in the 
multivariate analysis. This is likely to reflect a type II error as a result of the smaller number 
of patients included within this model and this finding is similarly true for the subsequent 
analysis of CA19-9.
Preoperative percutaneous intervention for biliary drainage was associated with higher CRP 
levels at the time of surgery. Percutaneous access to the biliary tree is a more invasive route 
than that associated with ERCP and patients who required PTC or combined procedures 
would have already undergone one or more unsuccessful attempts at endoscopic biliary 
stenting. Therefore, the association between elevated CRP levels and PTC is likely to reflect
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the increased tissue damage associated with percutaneous access in addition to increasing the 
degree of bactobilia and consequent likelihood of biliary sepsis due to the cumulative effect 
of previous endoscopic biliary instrumentation prior to successful drainage. The results 
suggest that while elevated preoperative CRP levels exhibit an association with overall 
survival, the presence of cholangitis and the requirement for percutaneous biliary 
decompression are likely to represent significant confounding factors when interpreting the 
prognostic value of preoperative CRP levels in this patient group. These findings were 
published in 2008 {Appendix B).
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2.4.3. Preoperative serum CA19-9
Preoperative serum CA19-9 levels were recorded for 138 patients. In cases where more than 
one preoperative value was recorded, the result taken nearest to the date of surgery was used 
for analysis. The median preoperative CA19-9 level was 236 (IQR = 68 to 681) kU/1. The 
median time interval from the date of preoperative CA19-9 estimation to surgery was 26 
(IQR = 17 to 36) days. 19 of the 138 patients did not undergo preoperative biliary drainage. 
In the remaining group, CA19-9 levels were recorded prior to stenting in 46 (38.7%) and 
following stenting in 73 (61.3%).
Due to the wide range of CA19-9 results recorded (from 2 kU/1 to 90,000 kU/1), the natural 
logarithm was used for subsequent regression and correlation analyses. /?g. 35 demonstrates 
that the preoperative CA19-9 results were approximately normally distributed when 
calculating the natural logarithm (ie. lnCA19-9).
Jig-35 - Distribution of preoperative CA19-9 results normalised by logarithmic transformation.
lnCA19-9
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A significant association between preoperative lnCA19-9 and concurrent bilirubin levels was 
demonstrated in 131 cases where both results were available - fig.36.
fig.36 - Scatterplot to demonstrate relationship between preoperative lnCA19-9 and bilirubin levels.
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CA19-9 and univariate survival
Preoperative CA19-9 exhibited a significant relationship with overall survival when analysed 
as a continuous prognostic variable. Table 20 outlines the results of univariate Cox 
proportional hazards regression. The strong association between lnCA19-9 and survival 
allowed three discrete risk groups to be defined, fig.37 demonstrates the Kaplan-Meier 
cumulative survival curves for lnCA19-9 according to these three categories (ie. <5, 5 to 7.5, 
>7.5).
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Table 20 - Univariate survival analysis of preoperative lnCA19-9 as a continuous and categorical prognostic 
variable (n=138).
Median survival
(95% Cl) months
Hazard ratio
(95% Cl)
X2 p-value
lnCA19-9 (Bgroups): _ 21.56 <0.001
<5 22.1 (15.4 to 31.2) - - -
5 to 7.5 12.3 (9.5 to 15.0) 2.065 (1.352 to 3.155) 11.25 <0.001
>7.5
lnCA19-9:
8.5 (5.5 to 12.4) 4.227(2.202 to 8.115) 18.77 <0.001
continuous - 1.245 (1.119 to 1.385) 16.13 <0.001
fig.37 - Kaplan-Meier cumulative survival curves according to three preoperative lnCA19-9 groups.
lnCA19-9>7.5 
lnCA19-9= 5 to 7.5 
lnCA19-9<5 
Log rank - p<0.001
Time (months)
No. at risk
>7.5 16 4
5 to 7.5 64 30
<5 58 38
0 0 0 
10 2 2 
20 10 6
0
2
4
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CA19-9 and midtivariate survival
Table 21 outlines the results of a multivariate Cox regression analysis including preoperative 
lnCA19-9 as a continuous prognostic variable alongside the histological prognostic factors of 
relevance. The results indicate that elevated preoperative CA19-9 levels continue to exhibit a 
strong adverse relationship with survival (p=0.005).
Table 21 - Multivariate Cox analysis of preoperative lnCA19-9 alongside tumour histology / chemo.
(n=130) Hazard ratio (95% Cl) 2z P
lnCA19-9 1.185 (1.052 to 1.336) 7.74 0.005
Tumour size 1.014(0.996 to 1.031) 2.43 0.119
Poor differentiation 1.532 (0.999 to 2.350) 3.83 0.050
Lymph node ratio 3.747 (1.182 to 11.878) 5.04 0.025
Adjuvant chemotherapy 0.565 (0.346 to 0.923) 5.20 0.023
Relationship between CA19-9 and tumour histology
Table 22 outlines the association between preoperative CA19-9 and associated tumour 
histology. The results indicate that CA19-9 levels are generally greater in patients with larger 
tumours and those patients with lymph node involvement. Spearman’s rank correlation also 
indicated a significant association between increasing tumour size and elevated lnCA19-9 
(rho = 0.204, p = 0.022). There was no significant correlation between the lymph node ratio 
and lnCA19-9 (Spearman, rho = 0.075, p=0.400).
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Table 22 - Relationship between preoperative CA19-9 and histological tumour characteristics.
Median CA19-9 level kU/l (IQR) p-value*
Tumour Size;
<20mm 122 (35 to 324) 0.010
>20mm 356 (90 to 859)
Nodal Status:
negative 128 (30 to 384) 0.056
positive 280 (85 to 750)
Resection margin:
negative 136 (55 to 492) 0.325
positive 236 (73 to 785)
Differentiation:
well / moderate 172 (52 to 630) 0.099
poor 315(134 to 860)
p-values for Mann-Whitney test
Discussion
The results from the present study confirm that greater preoperative CA19-9 levels are 
associated with a significantly reduced overall survival following resection for pancreatic 
ductal adenocarcinoma. Normalisation of CA19-9 levels following resection for pancreatic 
cancer has been shown to be associated with more favourable subsequent survival in patients 
undergoing resection for pancreatic cancer (Sperti et al, 1993; Montgomery et al, 1997; Safi 
et al, 1998). However, only a small number of studies have investigated the potential value of 
preoperative CA19-9 levels in isolation as a prognostic index (Lundin et al, 1994; Kau et al, 
1999; Ferrone et al, 2006). These studies characteristically dichotomise the number of 
patients into high- and low-risk groups according to a single cut-off value for CA19-9 
without any attempt to correct for the potential bias associated with this approach. The results 
from the present study indicate that CA19-9 exhibits a strong relationship with survival both
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as a continuous and categorical prognostic variable, thereby avoiding any potential bias 
associated with categorising continuous prognostic data (Altman et al, 1994).
Preoperative serum CA19-9 levels demonstrated a significant association with concurrent 
bilirubin levels in the present patient cohort. CA19-9 is secreted in a mucin-bound form by 
the biliary and gallbladder mucosa and excreted in bile (Ker et al, 1991; von Ritter et al, 
1997; Brockmann et al, 2000) and existing studies have demonstrated that obstructive 
jaundice will commonly precipitate elevated serum concentrations in the absence of 
malignancy (Duraker et al, 2007). Given the previous findings indicating that preoperative 
bilirubin levels had no significant effect on overall survival when analysed on a continuous 
basis, there was no evidence to indicate that concurrent jaundice exerted any significant 
confounding effect to explain the strong association between preoperative CA19-9 and 
survival. These results are also consistent with the findings from a previous study (Kim et al, 
1999) which demonstrated that, in the context of diagnosing pancreatic malignancy in 
symptomatic patients, the presence of concurrent obstructive jaundice did not significantly 
affect the sensitivity or specificity of CA19-9 when using a standard diagnostic cut-off value 
of 37 kU/1.
The deleterious survival outcome observed for cases with elevated preoperative CA19-9 
levels is likely to be explained on the basis that elevated CA19-9 was observed for larger 
tumours and cases exhibiting nodal involvement. There was also a non-significant trend 
towards elevated CA19-9 in patients with poorly differentiated tumours. These findings 
support the assertion that preoperative CA19-9 levels are not only indicative of tumour 
burden, but also that CA19-9 may act as a marker of biological 'aggressiveness’. This 
hypothesis is borne out by the finding that preoperative CA19-9 was a more significant
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variable when compared to tumour size or nodal status alone. Given that the presence of local 
or distant micrometastates at the time of surgery is believed to be the most significant factor 
in limiting long-term survival for the majority of resected pancreatic cancer patients 
(Bogoevski et al, 2004), it is reasonable to hypothesise that preoperative CA19-9 levels may 
also act as a marker of disseminated micrometastatic disease. These findings have been 
published in 2008 {Appendix B).
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2.4.4. Platelet-lymphocyte ratio
A complete preoperative full blood count (FBC) was available in 147 (88.6%) evaluable 
cases and the results taken nearest to the date of surgery were used for analysis. The median 
time interval from the date of preoperative FBC to date of surgery was 1 (IQR = 1 to 2) days.
fig.38 demonstrates the distribution of preoperative lymphocyte counts. The median 
lymphocyte count was 1.9 (IQR = 1.3 to 2.4) xl09/l. Lymphocytopaenia (ie. a lymphocyte 
count less than 1.0 xl09/l) was present in 10 patients (6.8%).
Jlg.38 - Distribution of preoperative lymphocyte counts.
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fig. 39 demonstrates the distribution of preoperative platelet counts. The median recorded 
platelet count was 323 (IQR = 265 to 404) xl09/l. Thrombocytosis (ie. platelet count >400 
xl09/l) was present in 40 patients (27.2%).
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fig.39 - Distribution of preoperative platelet counts.
Platelet count (x10E9/l)
fig.40 demonstrates the distribution of preoperative neutrophil counts. The median recorded 
neutrophil count was 5.3 (IQR = 4.1 to 7.1) xl09/l. Neutrophilia (ie. neutrophil count >7.0 
xl09/l) was present in 38 patients (25.9%).
fig.40 - Distribution of preoperative neutrophil counts.
Neutrophil count (x10E9/l)
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There was a significant inverse relationship between the preoperative neutrophil and 
lymphocyte counts (Spearman, rho = -0.196 (95% Cl = -0.347 to 0.035), p = 0.018) - fig. 41. 
This result demonstrates the expected trend towards lower lymphocyte counts in patients 
exhibiting greater neutrophil counts indicating that a relative lymphocytopaenia represents an 
additional index of the host inflammatory response to tumour.
Jlg.41 - Scatterplot to demonstrate inverse correlation between preoperative lymphocyte and neutrophil counts.
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A significant association between increasing platelet and neutrophil counts was also observed 
(Spearman, rho = 0.321 (95% Cl = 0.168 to 0.459), p < 0.001) - fig.42. Similarly, this 
observation suggests that the platelet count reflects a further potential marker of systemic 
inflammation in this patient group.
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fig.42 - Correlation between preoperative platelet and neutrophil counts.
CT>
LLI
O
C
D
Oo
CLol—
3
0)
20 -i
15
10 -
5 ■
0
Spearman - rho = 0.321 
P<0.001
4 4 *
4
**4 *4
4#- 4 44 ^ 4 
*4 v 4
100 200 300 400 500 600
Platelet count (x10E9/l)
700 800
Univariate survival according to preoperative haematological parameters 
The results of univariate survival analysis using Cox proportional hazards regression for each 
of the haematological parameters (ie. lymphocyte, neutrophil and platelet counts) are shown 
in Table 19.
Table 23 - Univariate survival analysis of preoperative haematological parameters as continuous prognostic 
covariates (Cox proportional hazards).
Hazard ratio (95% Cl) Chi-square p-value
Lymphocyte count (xl09/l) 0.819 (0.665 to 1.009) 3.51 0.061
Neutrophil count (xl09/l) 1.047 (0.988 to 1.110) 2.42 0.120
Platelet count (xl09/l) 1.002(1.001 to 1.004) 7.56 0.006
N/L ratio 1.019(0.977 to 1.062) 0.78 0.377
P/L ratio 1.003 (1.001 to 1.004) 10.81 0.001
N/L ratio = neutrophil-lymphocyte ratio, P/L ratio = platelet-lymphocyte ratio
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Lower lymphocyte counts exhibited a borderline significant relationship with poorer survival 
(p=0.061) while increasing platelet counts were significantly associated with adverse survival 
(p=0.006). The platelet-lymphocyte ratio (PLR) was demonstrated to be a superior prognostic 
index when compared with either parameter in isolation (p=0.001). Neither the neutrophil 
count nor the neutrophil-lymphocyte ratio (NLR) was demonstrated to confer significant 
prognostic information in this patient cohort. Table 24 outlines the survival of three patient 
sub-groups stratified according to the preoperative PLR. The corresponding Kaplan-Meier 
cumulative survival curves for these three patient groups are shown infig.43.
Table 24 - Univariate survival analysis of preoperative platelet-lymphocyte ratio as a continuous and categorical 
prognostic variable (n=147).
Median survival
(95% Cl) months
Hazard ratio
(95% Cl)
x2 p-value
PLR (3 groups): 8.48 0.014
<150 18.2(13.3 to 26.5) - - -
150 to 300 13.2 (10.4 to 16.6) 1.626 (1.077 to 2.455) 5.35 0.021
>300
PLR:
7.6 (5.5 to 14.3) 2.025 (1.188 to 3.451) 6.73 0.010
continuous - 1.003 (1.001 to 1.004) 10.81 0.001
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fig.43 - Kaplan-Meier cumulative survival curves according to three platelet-lymphocyte ratio groups.
PLR <150 
PLR 150 to 300 
PLR >300
Log rank - p=0.013
Time (months)
No. at risk
<150 56 36 17 9 6 3
150 to 300 64 33 12 3 1 1
>300 27 8 3 1 1 1
Platelet-lymphocyte ratio and multivariate survival
Table 25 outlines the results of a multivariate Cox regression analysis including preoperative 
PLR as a continuous prognostic variable alongside the histological prognostic factors of 
relevance. The results indicate that elevated preoperative PLRs continue to exhibit a strong 
adverse association with survival (p=0.002).
Table 25 - Multivariate Cox analysis of preoperative PLR alongside tumour histology / chemo.
(n=137) Hazard ratio (95% Cl) 2X P
PLR 1.003(1.001 to 1.005) 9.69 0.002
Tumour size 1.020(1.003 to 1.037) 5.21 0.022
Poor differentiation 1.522 (1.016 to 2.281) 4.14 0.042
Lymph node ratio 6.100(1.887 to 19.716) 9.13 0.003
Adjuvant chemotherapy 0.679 (0.430 to 1.074) 2.74 0.098
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Relationship between platelet-lymphocyte ratio and tumour histology
Table 26 outlines a breakdown of median platelet-lymphocyte ratios according to the various 
histological tumour characteristics. The results demonstrate a trend towards greater platelet- 
lymphocyte ratios being associated with more invasive histological tumour characteristics (ie. 
the presence of T3/T4 tumours and vascular / perineural invasion).
Table 26 - Relationship between preoperative PLR and histological tumour characteristics.
Median PLR (IQR) p-value*
Tumour Size:
<20mm 151 (111 to 244) 0.597
>20mm 181 (124 to 256)
T stage:
T1/T2 139 (95 to 216) 0.063
T3/T4 181 (123 to 261)
Vascular invasion:
negative 139 (96 to 187) 0.004
positive 182(131 to 270)
Perineural invasion:
negative 106 (97 to 117) 0.038
positive 171 (125 to 256)
Nodal Status:
negative 187(131 to 258) 0.658
positive 162 (117 to 251)
Differentiation:
well / moderate 158 (116 to 240) 0.150
poor 193 (139 to 289)
*p-values for Mama-Whitney test
Platelet-lymphocyte ratio and preoperative biliary stenting
There was no overall difference in preoperative platelet-lymphocyte ratios when comparing 
stented vs unstented patients (Mann-Whitney, p = 0.857). However, patients requiring 
percutaneous biliary drainage had a significantly greater preoperative platelet-lymphocyte 
ratio (290 (IQR = 227 to 341)) when compared with patients stented endoscopically (158 
(IQR = 117 to 219)) and those who did not undergo biliary stenting (157 (IQR = 112 to 335)) 
- Kruskal-Wallis, p < 0.001 - fig.44. There was no significant difference between the latter 
two groups (Mann-Whitney, p = 0.617).
fig.44 - Box plot to illustrate relationship between preoperative platelet-lymphocyte ratio and biliary stenting.
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Discussion
Systemic inflammation is associated with release of a number of inhibitory immunological 
mediators, most notably interleukin-10 (IL-10) and transforming growth factor-p (TGF-P), 
which can result in a significant immunosuppressive effect with consequent impaired 
lymphocyte function (Salazar-Onffay et al, 2007). Pancreatic cancer cells directly secrete 
these two inhibitory cytokines (Bellone et al, 1999) and lower circulating serum levels of 
TGF-p2 have been shown to be associated with a more favourable survival outcome in 
pancreatic ductal adenocarcinoma (Bellone et al, 2006). Lymphocytopaenia has previously 
been demonstrated to be more strongly associated with pancreatic adenocarcinoma when 
compared with gastric and colorectal cancer (Romano et al, 2004) suggesting that pancreatic 
malignancy is associated with a more marked host inflammatory response than other 
gastrointestinal cancers. In addition to pancreatic cancer commonly exhibiting reduced 
circulating lymphocyte populations, a reduced number of tumour-infiltrating lymphocytes in 
resected pancreatic adenocarcinoma specimens have also been found to be associated with 
poorer survival rates following surgery (Fukunaga et al, 2004). Lymphocyte trapping within 
peritumoral fibrous tissue is believed to be an additional factor by which pancreatic cancer 
cells evade immune surveillance (von Bemstorff et al, 2001).
Pancreatic cancer commonly causes a hypercoagulable state resulting in a predisposition to 
thromboembolic events (Khorana et al, 2004). This is largely attributable to tumor expression 
of tissue factor which binds to factor Vila, activating the clotting cascade and promoting 
thrombin production (Haas et al, 2006). Pancreatic cancer exhibits significant over-expression 
of tissue factor when compared with normal pancreatic tissue along with upregulation of 
vascular endothelial growth factor expression, thereby potentiating tumour angiogenesis
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(Khorana et al, 2007). Tissue factor expression has also been linked with an adverse 
prognosis in pancreatic ductal adenocarcinoma (Niton et al, 2005).
The significance of tumour-platelet interactions within this context is incompletely 
understood. A number of pro-inflammatory mediators (notably IL-1, IL-3 and IL-6) are 
known to stimulate megakaryocyte proliferation (Klinger et al, 2002; Alexandrakis et al, 
2003), therefore, the association between a relative thrombocytosis and adverse overall 
survival in pancreatic cancer might be explained on the basis that the platelet count reflects 
an additional index of systemic inflammation elicited by the tumour. Platelet aggregation and 
degranulation along with the consequent release of platelet-derived pro-angiogenic mediators 
within the microvasculature of the tumour could also be an important detenninant of tumour 
growth (Sierko et al, 2004). It has previously been suggested that anti-platelet agents might 
have an inhibitory effect on the invasive potential of pancreatic cancer cells in vitro by down­
regulating tumour secretion of matrix metalloproteinase-9 (Suzuki et al, 2004).
The preoperative systemic host immune response as a prognostic factor in resected pancreatic 
cancer has not previously been extensively evaluated. It has been reported that a more 
marked pre- and postoperative systemic inflammatory response (as evidenced by an elevated 
serum C-reactive protein (CRP) level >10mg/l) is associated with a poorer survival following 
resection for pancreatic ductal adenocarcinoma (Jamieson et al, 2005). Elevated preoperative 
CRP levels have also been shown to be associated with poorer survival following surgery in 
other gastrointestinal malignancies (Canna et al, 2005; Crumley et al, 2006). In addition to an 
elevated CRP, the presence of a neutrophilia and relative lymphocytopaenia are recognised 
features of the systemic inflammatory response. Few studies to date have investigated the 
potential prognostic role of preoperative lymphocytopaenia in resected pancreatic cancer
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(Yamaguchi et al, 2000; Fogar et al, 2006). A similarly small number of studies have 
investigated the potential utility of the preoperative platelet count as a prognostic marker in 
resected pancreatic cancer and the results from these studies have been conflicting (Schwarz 
et al, 2001; Suzuki et al, 2004a; Brown et al, 2005).
The present study provides further evidence to support the assertion that the preoperative 
lymphocyte and platelet counts confer significant prognostic information in resected 
pancreatic ductal adenocarcinoma. The expected inverse correlation between neutrophil and 
lymphocyte counts was observed, suggesting that a significant proportion of patients with 
pancreatic ductal adenocarcinoma exhibit some degree of systemic inflammation prior to 
surgery. Furthermore, the positive correlation between neutrophil and platelet count points 
towards the preoperative platelet count reflecting an additional index of systemic 
inflammation. This is perhaps also evidenced by the fact that a preoperative neutrophilia and 
thrombocytosis were recorded in a similar proportion of the overall patient group.
The results of the preliminary univariate survival analysis indicated that the pre-operative 
platelet count earned the most significant prognostic information of the three recorded 
haematological parameters when modelled as a continuous variable within this patient cohort, 
with the lymphocyte count displaying borderline significance. The platelet-lymphocyte (P/L) 
ratio was a superior prognostic marker when compared with either individual parameter or 
the neutrophil-lymphocyte ratio. When categorizing the overall number of patients into three 
groups according to the preoperative platelet-lymphocyte ratio, Kaplan-Meier analysis also 
demonstrated a consistent pattern of progressively poorer survival associated with larger 
platelet-lymphocyte ratios. The median survival associated with a value of >300 appeared to
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be comparable with that which would be expected for locally advanced disease (Sultana et al, 
2007).
Preoperative intervention for biliary drainage represents a potential confounding factor given 
the previously described association between CRP and percutaneous biliary procedures. The 
results also indicated elevated platelet-lymphocyte ratios in the small number of cases 
requiring PTC. However, there was no significant overall difference in platelet-lymphocyte 
ratios between stented and unstented patients and given the previous findings indicating no 
association between stenting and subsequent survival, it is unlikely that that the issue of 
preoperative biliary drainage is a significant factor in explaining the strong association 
between preoperative platelet-lymphocyte ratio and overall postoperative survival. The 
results are consistent with the hypothesis that greater preoperative platelet-lymphocyte ratios 
reflect a marker of an enhanced host inflammatory response to more locally invasive tumour 
biology. These results have been published in 2008 {Appendix B).
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2.5. The predictive value of the platelet-lymphocyte ratio in determining resectability of 
suspected pancreatic and peri-ampullary adenocarcinoma
The finding that the preoperative platelet-lymphocyte ratio exhibited a significant association 
with invasive histological tumour characteristics prompted an additional analysis in order to 
ascertain whether this index may represent a marker of tumour resectability alongside CA19- 
9 in guiding patient selection for staging laparoscopy (Connor et al, 2005). In order to assess 
this, a cohort of 336 patients with suspected pancreatic or peri-ampullary neoplasms 
undergoing staging laparoscopy were identified between January 1997 and September 2006. 
263 patients from this group went on to laparotomy with a resection rate of 72% (190/263). 
The median interval between laparoscopy and surgery was 14 (IQR = 7 to 28) days. The 
histological diagnoses recorded in this group are shown in Table 27. 149 patients were male 
(57%) and the median age was 65 (IQR = 58 to 71) years.
Table 27 - Frequency of tumour type in patients with resectable disease according to CT assessment.
Histology Frequency
Pancreatic ductal adenocarcinoma 119
Ampullary adenocarcinoma 48
Cholangiocaricnoma 34
Other malignancy 24
Metastatic adenocarcinoma (unconfirmed primary) 25
Presumed peripancreatic malignancy 4
Benign tumours 9
Total 263
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A preoperative full blood count with differential white cell count was available in 225 of 263 
patients. 188 (84%) of these cases had a full blood count recorded within 2 days of surgery, 
22 (10%) within 2-7 days and 15 (6%) within more than 7 days prior to surgery. 216 of 263 
patients had preoperative CA19-9 levels recorded. The median interval from the preoperative 
CA19-9 to date of surgery was 26 (IQR = 15 to 39) days. CA19-9 levels were adjusted for the 
presence of concurrent obstructive jaundice as previously described. Concurrent bilirubin 
levels were available in 142 of these cases, 94 (66%) of whom had bilirubin levels of >35 
pmol/1. The unadjusted CA19-9 was used in cases where bilirubin data was missing.
The median adjusted CA19-9 levels and platelet-lymphocyte ratios recorded for patients with 
resectable disease compared with locally advanced and metastatic disease at laparotomy are 
shown in Table 28. Preoperative CA19-9 levels were greatest in patients with metastatic 
disease at laparotomy while preoperative platelet-lymphocyte ratios were greatest in those 
with locally advanced disease.
Table 28 - Comparison of median preoperative adjusted CA19-9 and platelet-lymphocyte (P/L) ratios in 
resected and inoperable pancreatic and peri-ampullary neoplasms (Kruskal-Wallis).
Preoperative CA19-9 levels (kU/l) Preoperative P/L ratio
n Median CA19-9(IQR) P n Median P/L ratio (IQR) p
Resected tumour 157 144 (27 to 569) 158 147 (113 to 208)
Locally advanced 36 413 (106 to 4546) 0.001 43 202 (146 to 265) <0.001
Metastatic 19 1350 (232 to 2554) 22 176 (139 to 363)
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ROC curves for preoperative adjusted CA19-9 and platelet-lymphocyte ratios in predicting 
tumour resectability are shown in fig.45. The areas under the curve (AUC) recorded for the 
two prognostic indices were very similar: AUC = 0.67 (95% Cl = 0.58 to 0.76) for CA19-9 
and AUC = 0.68 (95% Cl = 0.60 to 0.77) for platelet-lymphocyte ratio. Using various cut-off 
values for the platelet-lymphocyte ratio, a level of 150 was found to result in a comparable 
positive predictive value and specificity when compared with a CA19-9 cut-off value of 150 
kU/1.
fig.45 - Receiver operating characteristic (ROC) curves to compare the predictive values of preoperative CA19- 
9 and platelet-lymphocyte (P/L) ratio in determining peri-ampullary tumour resectability at laparotomy.
Source of the Curve
a Reference Line
a P/L ratio
adjusted CA19-9
1 - Specificity
The predictive values of CA19-9 levels <150 kU/1 in determining tumour resectability at 
laparotomy are shown in Table 29. A positive predictive value, negative predictive value, 
sensitivity and specificity of 83%, 36%, 51% and 73% were recorded respectively (n=216). 
The predictive values for platelet-lymphocyte ratios <150 were broadly comparable with 
values of 81%, 38%, 51% and 72% respectively (n=225) as shown in Table 30.
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Table 29 - Contingency table for preoperative CA19-9 levels <150 kU/1 (or <300 kU/1 in jaundiced patients) in 
predicting periampullary tumour resectability at laparotomy (n=216).
Resectable Unresectable
Preoperative <150 kU/l (n=96) 80 16
CA19-9 levels >150 kU/1 (n=120) 77 43
Predictive values of CA19-9 <150 kU/1 in determining resectable disease at laparotomy: 
Positive predictive value = 83%
Negative predictive value = 36%
Sensitivity = 51%
Specificity = 73%
Table 30 - Contingency table for preoperative platelet-lymphocyte ratios <150 kU/1 in predicting periampullary 
tumour resectability at laparotomy (n=225).
Resectable Unresectable
Preoperative P/L <150 (n=100) 81 19
ratio >150 (n=125) 77 48
Predictive values of P/L ratio <150 in determining resectable disease at laparotomy: 
Positive predictive value = 81%
Negative predictive value = 38%
Sensitivity = 51%
Specificity = 72%
The predictive values of using the combined requirement for both CA19-9 and platelet- 
lymphocyte ratio to be <150 are shown in Table 31 with respective values of 95%, 35%, 28% 
and 96% (n=183). These combined criteria resulted in a significantly improved specificity 
over using CA19-9 in isolation (Fisher’s exact - p<0.001) and a borderline significant 
improvement in the positive predicitive value for resectability (Fisher’s exact - p=0.065).
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Table 31 - Contingency table for combined requirement of preoperative platelet-lymphocyte (P/L) ratio <150 
along with CA19-9 levels <150 kU/1 (or <300 kU/1 in jaundiced patients) in predicting periampullary tumor 
resectability at laparotomy (n=183).
Resectable Unresectable
Combined CA19-9 £150 for both (n=38) 36 2
and P/L ratio >150 for either (n=145) 94 51
Predictive values of combined score in determining resectable disease at laparotomy: 
Positive predictive value = 95%
Negative predictive value = 35%
Sensitivity = 28%
Specificity = 96%
If using both CA19-9 and platelet-lymphocyte ratio to guide decision-making regarding the 
requirement for preoperative laparoscopic staging, 21% (38/183) of laparoscopies would 
have been avoided with a false positive rate for resectability at laparotomy of only 5% (2/38).
The relationship between the preoperative platelet-lymphocyte ratio and tumour histology in 
resected pancreatic and peri-ampullary adenocarcinoma
The relationships between the platelet-lymphocyte ratio and tumour resectability and were 
investigated in a group of 204 resected pancreatic and periampullary adenocarcinomas 
undergoing pancreatoduodenectomy from this cohort in whom a preoperative full blood 
count result was recorded. This group comprised 113 patients with pancreatic ductal 
adenocarcinoma, 53 with ampullary adenocarcinoma and 38 with intra-pancreatic bile duct 
adenocarcinoma.
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Platelet-lymphocyte ratio and origin of primary
There was no significant difference in the median recorded preoperative platelet-lymphocyte 
ratio when comparing adenocarcinomas arising from the ampulla, intrapancreaic bile duct 
and head of pancreas (Kruskal-Wallis, p=0.228) - fig.46.
fig.46 - Box plot of preoperative platelet-lymphocyte (P/L) ratios in the resected peri-ampullary adenocarcinoma 
groups (n=204).
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The previously observed association between preoperative platelet-lymphocyte ratio and 
invasive histological tumour characteristics was further investigated in this cohort of resected 
pancreatic and periampullary cancers.
Platelet-lymphocyte ratio and vascular invasion
The presence of absence of vascular invasion was recorded in 178 of the 204 resected peri­
ampullary adenocarcinoma cases, fig. 4 7 demonstrates that patients with evidence of vascular 
invasion on microscopic histological assessment (n=116) had significantly greater
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preoperative platelet-lymphocyte ratios than those with no evidence of vascular invasion 
(n=62) -Mann-Whitney, p<0.001.
Jig.47 - Box plot of preoperative platelet-lymphocyte ratios recorded in peri-ampullary adenocarcinoma cases 
according to vascular invasion (n=178).
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Platelet-lymphocyte ratio and perineural invasion
The presence or absence of perineural invasion was recorded in 181 of the 204 resected peri­
ampullary adenocarcinoma cases, fig. 48 similarly demonstrates that cases with perineural 
invasion (n=149) had a significantly greater median preoperative platelet-lymphocyte ratio 
when compared with cases with no evidence of perineural invasion (n=32) - Mann-Whitney,
p=0.008.
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fig.48 - Box plot of preoperative platelet-lymphocyte ratios recorded in peri-ampullary adenocarcinoma cases 
according to perineural invasion (n=181).
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Platelet-lymphocyte ratio and T stage
T stage was recorded in 203 of the 204 resected peri-ampullary adenocarcinoma cases. T1 
tumours accounted for 15 cases (7%), T2 tumours accounted for 26 cases (13%), T3 tumours 
accounted for 154 cases (76%) and T4 tumours accounted for 8 cases (4%). fig.49 
demonstrates that increasing T stage was strongly associated with a greater median 
preoperative platelet-lymphocyte ratio (Mann-Whitney, p=0.005).
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fig.49 - Box plot of preoperative platelet-lymphocyte ratios recorded in peri-ampullary adenocarcinoma cases 
according to T stage (n=203).
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Discussion
Laparoscopic staging has been demonstrated to influence decision-making regarding surgical 
intervention in approximately 15% of patients with radiologically resectable periampullary 
malignancy (Minnard et al, 1998; Doran et al, 2004). Use of staging laparoscopy can 
minimise potentially unnecessary surgical intervention in cases of locally-advanced and 
metastatic disease missed by CT imaging and facilitate earlier administration of the most 
appropriate palliative therapy (Nieveen van Dijkum et al, 2003; Ellsmere et al, 2005; 
Thomson et al, 2006; Doucas et al, 2007). Although endoscopic ultrasound represents a 
potential alternative staging modality to image tumour relationships with local vasculature 
along with regional adenopathy (Dewitt et al, 2006), the ability to visually inspect the 
peritoneal cavity and liver surface to exclude small metastatic deposits represents the 
principal advantage of laparoscopy over other staging modalities. Staging laparoscopy has
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also been demonstrated to be as useful in influencing operative decision-making for 
periampullary tumors of non-pancreatic origin (Brooks et al, 2002).
Significantly elevated CA19-9 levels have been shown to represent a reliable marker of 
metastatic disease (Schlieman et al, 2003), but CA19-9 is believed to be relatively less 
effective at identifying locally advanced disease (Connor et al, 2005). Low preoperative 
CA19-9 levels have previously been investigated as a potential means of reliably identifying 
patients with resectable periampullary tumours at laparotomy, thereby avoiding the 
requirement for supplementary staging in all patients (Schlieman et al, 2003; Connor et al, 
2005; Karachristos et al, 2005;). This presents the opportunity to make more judicious use of 
staging laparoscopy, which is particularly relevant in centres where laparoscopic staging is 
routinely conducted on separate theatre sessions prior to laparotomy.
The results of the present study indicate that the preoperative platelet-lymphocyte ratio 
correlates with features of local tumor invasiveness in cases of resected peri-ampullary 
adenocarcinoma. Increasing T-stage along with the presence of vascular and perineural 
invasion were associated with a trend towards greater median preoperative platelet- 
lymphocyte ratios in the overall patient cohort. This finding further indicates that the platelet- 
lymphocyte ratio is more significantly influenced by local tumour infiltration rather than 
overall tumour burden. This observation is also supported by the fact that a greater median 
platelet-lymphocyte ratio was observed in patients with locally advanced periampullary 
tumors when compared with those with metastatic disease. This contrasts with the results 
seen for CA19-9 which demonstrated greater median CA19-9 values in patients with 
metastatic disease at laparotomy, a finding consistent with previous studies (Schlieman et al, 
2003).
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Analysis of the ROC curves indicates that the overall predictive value of the preoperative 
platelet-lymphocyte ratio is comparable with that seen for CA19-9 levels. The contingency 
tables for CA19-9 and platelet-lymphocyte ratio also resulted in a broadly comparable 
positive predictive value and specificity for both. The combined use of CA19-9 levels <150 
kU/1 (or <300 kU/1 in jaundiced patients) and a platelet-lymphocyte ratio <150 resulted in a 
significant improvement in the ability to identify a low-risk group for unresectable disease at 
laparotomy with a positive predictive value for resectability of 95% and a specificity of 96%. 
Use of these combined criteria for selective use of staging laparoscopy would have resulted in 
38 of 183 laparoscopies (21%) being avoided with a false positive rate of only 5% - ie. only 
5% of patients going straight to laparotomy with unresectable disease. The poor negative 
predictive value and sensitivity for CA19-9 and platelet-lymphocyte ratios indicate that 
neither parameter can reliably predict unresectable periampullary tumors and, as such, 
investigating the predictive values of these parameters in the patient group with convincing 
evidence of advanced disease diagnosed at CT or laparoscopy would not result in any 
information which would alter decision-making regarding surgery.
It has previously been estimated that less than 5% of the overall population lack the Lewis 
antigen glycosyl transferase enzyme required to synthesize CA19-9 (Itzjowitz et al, 1986). 
This represents a potential confounding factor in interpreting the predictive values associated 
with CA19-9. However, only 5 out of 216 cases (2.3%) in the present study for whom a 
preoperative CA19-9 was recorded had unrecordable CA19-9 levels (<2 kU/1). These cases 
were included in the analysis in order to avoid potential bias, but this issue is unlikely to have 
a significant impact on the validity of the CA19-9 predictive values recorded in this study.
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In summary, this is the first study to report an association between preoperative inflammation 
and periampullary cancer resectability. The preoperative platelet-lymphocyte ratio was found 
to be associated with both macroscopic and microscopic features of periampullary tumor 
invasiveness and appears to be a more effective marker of locally advanced disease than 
CA19-9. Use of both CA19-9 and platelet-lymphocyte ratio in risk stratifying patients with 
suspected peri-ampullary malignancy for staging laparoscopy resulted in a significant 
improvement in the ability to identify those patients in whom supplementary staging can be 
safely avoided. The results of this study suggest that the preoperative platelet-lymphocyte 
ratio merits prospective evaluation alongside CA19-9 in this setting. These findings have 
been published in 2008 {Appendix B),
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2.6. Combined prognostic score
The four preoperative parameters of univariate significance (ie. albumin, CRP, CA19-9 and 
platelet-lymphocyte ratio) were included in a multivariate Cox regression analysis {Table 32). 
Due to incomplete data for each variable, this analysis included a total of 98 patients.
Table 32 - Multivariate Cox analysis of preoperative prognostic factors.
(n=98) Hazard ratio (95% Cl) %2 p
albumin 0.955 (0.908 to 1.005) 3.17 0.075
CRP 0.996 (0.983 to 1.009) 0.33 0.567
lnCA19-9 1.182 (1.031 to 1.355) 5.74 0.017
Platelet-lymphocyte ratio 1.003 (1.001 to 1.005) 6.83 0.009
The preoperative CA19-9, platelet-lymphocyte ratio and albumin were used to generate a 
combined preoperative prognostic score according to the following formula (Piantadosi, 
2005):
p
Vi — risk score
j = number of covariates
i = number of patients
X= individual value for covariate j
pj = Cox regression coefficient for co variate j
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Data for the CA19-9, platelet-lymphocyte ratio and albumin were complete for 122 cases. 
Within this patient group, the combined score exhibited a stronger relationship with survival 
on a continuous basis than any of the individual parameters {Table 53).
Table 33 - Univariate comparative Cox analysis of combined preoperative prognostic score.
(n«122) Hazard ratio (95% Cl) 2X P
albumin 0.945 (0.908 to 0.983) 7.90 0.005
platelet-lymphocyte ratio 1.002(1.001 to 1.004) 8.40 0.004
lnCA19-9 1.228(1.087 to 1.386) 10.92 0.001
Combined preoperative score 2.020 (1.476 to 2.764) 19.29 <0.001
The same principle was used for the three histological variables of significance (ie. tumour 
size, differentiation and lymph node ratio) to generate a combined histological score. The 
histological data were complete for 157 cases within this group {Table 34).
Table 34 - Univariate comparative Cox analysis of combined histological prognostic score.
(n=157) Hazard ratio (95% Cl) 2X P
tumour size 1.021 (1.006 to 1.037) 7.08 0.008
poor differentiation 1.663 (1.149 to 2.407) 7.26 0.007
lymph node ratio 4.631 (1.916 to 11.195) 11.59 <0.001
Combined histological score 2.305 (1.620 to 3.281) 21.54 <0.001
An overall prognostic index was calculated on an additive basis using both scores {Table 35). 
This overall score allowed a superior degree of risk stratification into four groups (fig. 50).
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Table 35 - Univariate survival analysis of combined overall prognostic score as a continuous and categorical 
variable (n=122).
(n=122)
Median survival
(95% Cl) months
Hazard ratio
(95% Cl)
x2 p-value
Overall score (4 groups): _ 36.84 <0.001
Group A 30.4 (15.0 to 49.8) - - -
Group B 19.2 (12.6 to 25.8) 2.124(1.069 to 4.219) 4.63 0.032
Group C 12.6 (8.2 to 15.5) 3.463(1.872 to 6.404) 15.68 <0.001
Group D 5.8 (4.7 to 10.4) 9.598 (4.507 to 20.443) 34.38 <0.001
Combined overall score:
continuous 2.050(1.590 to 2.643) 30.66 <0.001
fig.50 - Kaplan-Meier survival curves stratified according to combined overall prognostic score.
GroupA
Group B 
Group C 
Group D
Log rank - p< 0.001
Time (months)
No. at risk
Group A 29 21 12 7 5 3
Group B 26 17 7 1 0 0
Group C 49 21 6 1 0 0
Group D 18 4 0 0 0 0
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Using the formula outlined on page 148, the combined prognostic score was calculated for 
each patient. This score ranged from -1,42 to 2,39 with a median of 0.64. The overall 
prognostic score was used to divide patients into four groups according to the maximum 
degree of risk stratification possible {fig, 50). The cut-off values used to categorise patients 
from this combined score to generate the above survival curves were as follows:
• Group A = < -0.05
• Group B = -0.05 to 0.60
• Group C = 0.61 to 1.60
• Group D = >1.60
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2.7. Preoperative factors and patient selection for adjuvant therapy
Ail additional analysis was undertaken in order to identify any potential preoperative factors 
which were predictive of patient selection for adjuvant therapy following resection. This 
included patients randomised to ESP AC-1 or ESP AC-3 (to either treatment or observation 
arms) and the small number of patients who received off-trial adjuvant treatment. Table 36 
outlines the results of univariate logistic regression with patient selection for adjuvant therapy 
as the dependent variable. All factors with the exception of gender were included as 
continuous variables. Hence, an odds ratio of 0.930 for patient age (regression coefficient of- 
0.073) indicates a reduced likelihood of selection for adjuvant treatment by a factor of 0.930 
for each increase in age by one year. Therefore, a 60-year old patient would be 4 times more 
likely to be selected for adjuvant treatment than an 80-year old patient (ie. 1 + e((80"60) x '0'073-) = 
4.307).
Table 36 - Logistic regression analysis of factors predictive of patient selection for adjuvant therapy.
Odds ratio (95% Cl) 2X P
Univariate
age 0.930 (0.892 to 0.970) 11.60 <0.001
gender(M) 1.100 (0.572 to 2.114) 0.08 0.776
albumin 1.115 (1.045 to 1.190) 10.79 0.001
bilirubin 0.999 (0.995 to 1.003) 0.27 0.603
platelet-lymphocyte ratio 0.994 (0.990 to 0.998) 8.03 0.005
lnCA19-9 0.905 (0.755 to 1.086) 1.14 0.285
Multivariate
age 0.925 (0.877 to 0.975) 8.25 0.004
platelet-lymphocyte ratio 0.995 (0.990 to 1.000) 4.61 0.032
albumin 1.085(1.001 to 1.171) 3.98 0.046
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This analysis indicates that patient age, preoperative platelet-lymphocyte ratio and albumin 
levels were significant independent predictors of patient selection for adjuvant therapy 
following resection. Younger patients were significantly more likely to be selected (ie. odds 
ratio < 1), while patients with lower preoperative platelet-lymphocyte ratios and higher 
albumin levels were also significantly more likely to be selected for adjuvant treatment. 
These factors were independent on multivariate logistic regression.
Patient’s age, their overall recovery from surgery and functional performance status within 
the first 4 to 6 postoperative weeks are the main factors which determine patient selection as 
potential candidates for adjuvant treatment. The results from the above analysis indicate that 
the preoperative host inflammatory response, as measured by the platelet-lymphocyte ratio, 
may be a significant contributory factor to patient’s initial postoperative recovery as well 
their overall subsequent survival as evidenced from the observation that patients with 
increasing preoperative platelet-lymphocyte ratios were proportionally less likely to go on to 
receive adjuvant therapy. The association between albumin levels and selection for adjuvant 
treatment suggests that the preoperative nutritional status of patients may also be a significant 
factor in influencing early postoperative recovery (Giger et al, 2007). Furthermore, die 
previous multivariate Cox analyses demonstrated that the associations between these two 
preoperative parameters and postoperative survival were mutually independent of adjuvant 
treatment received. These observations merit prospective evaluation in a larger cohort of 
patients.
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3. SYSTEMATIC REVIEW & META-ANALYSIS OF MOLECULAR MARKERS 
3.1. METHODS
Search Strategy
From a preliminary analysis of existing review articles of molecular prognostic studies in 
pancreatic cancer, the most widely investigated molecular markers were selected for analysis. 
Literature was searched using the MEDLINE, EMBASE and Web of Science search engines. 
Search criteria were based on the relevant marker selected and included appropriate 
synonyms:
• eg. (pi6 OR pl6INK4a OR pi6*) AND (pancreas OR pancreatic) AND (survival OR 
prognostic OR prognosis).
In addition, the ISI Proceedings search engine was also searched in order to identify 
unpublished studies presented at international conferences / meetings. This was supplemented 
by conducting an abstract search of the American Society of Clinical Oncology (ASCO) 
website, the American Association of Cancer Research (AACR) website and the British 
Society of Gastroenterology (BSG) websites for relevant unpublished studies.
Selection criteria
A standardised eligibility form was generated to detennine which studies were eligible for 
selection for potential meta-analysis. All searches were conducted in December 2009. This 
process was conducted by two independent reviewers (Richard Smith and Paula Ghaneh). 
Where part or all of the same patient series was included in more than one publication, only 
the more recent or most complete study was included in the analysis in order to avoid 
duplication of the same survival data. In studies where reported survival data were 
incomplete but the other relevant inclusion criteria were fulfilled, supplementary survival
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data were requested from the authors of the relevant study. The criteria for selection are listed 
below:
• only resected pancreatic adenocarcinoma cases included in prognostic analysis.
• only studies conducting immunohistochemical analysis of resected primary tumour 
material.
• only studies where a univariate survival analysis was conducted for the relevant 
prognostic marker (overall survival).
• only studies where the marker of interest was dichotomised (ie. positive vs. negative 
immunostaining). Studies with three or more risk groups were excluded.
Quality assessement
An assessment of methodological quality was also performed for each piece of literature 
selected. A standardised form was used which assessed the important components of a well- 
conducted prognostic study. These criteria were adapted from existing literature (Hayden et 
al. 2006; Steels et al. 2001) and were used to define 20 individual study characteristics which 
were deemed to be key factors to report in an immunohistochemical prognostic study {Table 
1). For any criterion not fulfilled according to the information outlined in the article, one 
point was deducted from a maximum of 20 and the final score was recorded as a percentage. 
The eligibility criteria and quality scoring were assessed by two independent investigators 
(RS and PG). Any disagreement was resolved by discussion.
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Table 1 - Methodological scoring criteria used.
Study group
• Study population adequately described:
o Gender/Age 1 point
o Histology 1 point
• Period of recruitment: 1 point
• inclusion / exclusion criteria used: 1 point
Study attrition
• >90% of cases identified included in final analysis: 1 point
• Reasons for attrition / loss to follow-up given: 1 point
• Peri-operative mortality details: 1 point
Scientific methodology
• IHC methodology outlined;
o Details of l0/2° Abs used: 1 point
o Concentration of 1° Abs used: 1 point
o Positive / negative controls outlined: 1 point
• Description of scoring technique:
o >1 independent scorer: 1 point
o Scorers blinded to clinical data: 1 point
o Criteria for positivity clearly outlined:
■ Distribution (cytoplasm vs. membranous vs. nuclear): 1 point
■ % positive cells for immunostaining classification: 1 point
Confounding factors considered
• Adjuvant therapy details provided: 1 point
• Histological breakdown according to IHC staining: 1 point
Statistical analysis
• HR (confidence interval) provided: 1 point
• Exact p-value quoted: 1 point
• Numbers at risk for Kaplan-Meier curves: 1 point
• Number of censored cases recorded: 1 point
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Data extraction
Data were extracted by RS. A study was considered significant if the p-value for the 
statistical comparative test used (eg. log rank) was less than 0.05. Studies were also 
categorised according to the direction of the survival relationship observed (ie. whether 
positive staining of the marker of interest conferred an adverse or more favourable survival 
outcome). The primary outcome measure was overall survival (ie. date of resection to date of 
death). Additional details were also collected in order to identify potential sources of 
heterogeneity. These included the specific primary antibody (and dilution) used for 
immunohistochemistry, the scoring criteria used to define positive staining and relevant 
clinico-pathological data. The relationships between positive staining and resected 
histopathological tumour characteristics were also recorded as a secondary end-point. A 
standardised data extraction form was used in order to obtain the relevant survival data 
required for either direct or indirect calculation of the log hazard ratio and variance {Table 2).
As few studies directly quote the log hazard ratio and variance (or standard error) for survival 
analyses, an indirect approach is usually required in order to estimate these values for 
quantitative aggregation of survival data (Parmar et al. 1998, Tierney et al. 2007, Williamson 
et al. 2002). Where the HR and 95% confidence interval were quoted, these values were used 
to generate the log hazard ratio and variance. If not reported, the log rank p-value (or 
associated chi-squared statistic) and the number of reported events were instead used to 
calculate these values. If survival data were only presented graphically, Kaplan-Meier 
survival curves were used to estimate these values (Parmar et al. 1998, Tierney et al. 2007). 
In a small number of studies, raw survival data were presented in a tabulated fonnat allowing 
direct estimation of the log hazard ratio and variance using standard statistical software 
(Statview). If insufficient survival data were presented to allow any indirect estimation of log
hazard ratios in an otherwise eligible study, the authors of the relevant paper were contacted
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in order to request supplementary data. The HR calculation Excel spreadsheet developed by 
Tierney et al was used to generate the HR and variance from the available survival data 
(www.biomedcentral.com/content/supplementaiy/1745-6215-8-16-Sl.xls). The logHR and 
variance for individual studies were entered into RevMan 4.2 (Cochrane collaboration, 
Oxford, UK) and pooled using an inverse variance approach. Hazard ratios were calculated 
for positive expression of each molecular marker (ie. a HR > 1 reflecting adverse survival 
associated with positive immunostaining while a HR < 1 reflects favourable survival 
associated with positive staining).
Heterogeneity and Bias
Heterogeneity was assessed using a % test for heterogeneity with a p-value of < 0.10 taken to 
reflect the presence of significant heterogeneity. The I2 statistic was calculated to quantify the 
degree of heterogeneity (Higgins et al, 2002). A p-value of <0.050 was taken to reflect 
significance for all other analyses. Due to the relatively limited number of studies included in 
each analysis, a random-effects approach was used in all cases. Potential sources of 
heterogeneity between studies were explored (ie. variation in IHC methodology, differences 
in resected histological tumour characteristics, etc). Publication bias was assessed by analysis 
of the inverted funnel plots generated in RevMan 4.2. An inverted funnel plot represents a 
plot of the HR against the standard error of the log HR for each included study. Significant 
asymmetry about the pooled HR estimate is indicative of publication bias. A visual inspection 
of each plot was supplemented by calculation of the p-value for Egger’s regression 
(StatsDirect). Funnel plots were not generated when the total number of included studies was 
small (less than five). Continuous data were compared using Spearman’s rank correlation 
with two-sided Mann-Whitney testing for categorical data.
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3.2. RESULTS & DISCUSSION
3.2.1 VEGF Studies
Selection Criteria
The following search criteria were used:
• (‘VEGF5 OR ‘vascular endothelial growth factor, OR ‘VEGF*’) AND (‘pancreas’ 
OR ‘pancreatic’) AND (‘survival’ OR ‘prognosis’ OR ‘prognostic’).
Abstracts were initially checked for relevance and the full article was retrieved for all 
potentially eligible studies. Where the same patient series was included in more than one 
publication, only the more recent or most complete study was included in the analysis in 
order to avoid overlap. Only studies investigating the prognostic value of VEGF-A 
expression were included (this represents the most widely investigated and biologically 
relevant VEGF isofonn).
Results
The initial search returned a total of 255 studies. Following review of these abstracts, 20 
potentially relevant studies were identified with publication dates ranging from 1997 to 2008. 
No relevant unpublished abstracts were identified. Following review of the full papers, nine 
were excluded for the following reasons: duplicated series of patients (Ikeda et al, 1999; 
Niedergethmann et al, 2000; Tang et al, 2001), only VEGF-C and/or VEGF-D analysed 
(Kurahara et al, 2004; Zhang et al, 2007), no dichotomised univariate survival analysis 
reported (Ellis et al, 1998; Fujioka et al, 2001), mix of resected and unresected cases included 
in survival analysis (Chimg et al, 2006), only VEGF receptor status analysed (Btichler et al, 
2002). None of the eligible studies described a prospective design and archived paraffin- 
embedded primary tumour material was utilised for immunohistochemistry in all cases.
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The 11 eligible studies included a total of 767 patients with a median number of 62 patients 
per study (range = 19 to 142). Table 3 outlines the demographic, clinico-pathological, 
methodological and outcome characteristics of these studies. Five studies reported a 
significant adverse association between VEGF expression and suivival on univariate analysis. 
The median quality score was recorded as 70% (range = 60% to 95%). There was no 
significant difference in median quality scores between significant and non-significant studies 
(Mann-Whitney, p=0.516). Similarly, there was no significant correlation between study size 
and quality scores (Spearman, rho = 0.139, p=0.698).
Meta-analysis
fig.l illustrates the Forrest plot for the survival data. Significant heterogeneity was 
demonstrated according to Cochran’s chi-squared test (x = 22.08, p=0.01). The combined 
HR was recorded as 1.51 (95% Cl = 1.18 - 1.92) indicating that positive immunostaining for 
VEGF was significantly associated with adverse survival in the pooled patient group. When 
assessing the funnel plot for this analysis {fig. 2), the data points approximated a symmetrical 
distribution indicating that publication bias is unlikely to be a significant confounding factor 
in describing this relationship. Egger’s regression for this analysis demonstrated a non­
significant p-value (p = 0.269).
160
Ta
bl
e 3
 - 
M
et
ho
do
lo
gi
ca
l a
nd
 cl
in
ic
o-
pa
th
ol
og
ic
al
 d
at
a 
fo
r e
lig
ib
le
 V
EG
F 
stu
di
es
.
to
CO CO2; 2 ^ O ro CO m
CO 11 2 w
'O CO ^ 'O cn CN
<N. —< co,
CS
'O CO 00 trt co
co <N COoo wo vi in 
On On in cs
no in no
CN On 04
04 (NNO NO VO NO
—< NO NO
NO ©O ON
in on in cn in oo Oncn n in n rj- c^-
O CO NO CN Ocn cn n cn ■'^r
NO NO NO NO NO NO
no no no m m m
nl cn On m no^ cn ^ no cn m
m ^
A A
xO
A A
vo m oo o —< (N 'OlO lO VO
cn ov m m oo ovCN rn CN
I)
a.
in <n vo
f ^ 
i g
Q SS) t/}&
S g 
^ o
§ s
% "z
oo -st o r4 o oo cn on vn ooni in nd in rn ni rn
3 3 3 (N (M CNOO CN •—<
fN CO NO
(N (N (N <N
3 .3
<Nn4<NCNl(NCN0sl<N
H <
'O
o43
A
N=0s*
f‘g
-1
 - 
Fo
rre
st 
pl
ot
 to
 as
se
ss
 ov
er
al
l e
ffe
ct
 o
f V
EG
F 
ex
pr
es
sio
n o
n s
ur
vi
va
l.
or'CMiO'^rcrioocriOLno
•^roooocriLnocooo'^ocM
•^•M''XioooooiHrroo<N'q'
oo<NiCNio^D'X)oo'^,r'C»M'
■53'rocrioor''Xi'i)'j'ooor)<Ni
rHoninooococrior^in
r-CMoo'sDCNrnr'CDr'CNj^o
crivoM’Oooco.-iino'^CM
cNCNic\jcNC\i<-ioocMknroro
iDLoro^^'^r'^i’CNjcTiroo
OOOOOOCMCDOOOJOOJOOOO
csirHTHCMo^ror^ooooo^o
N CO
%
I5
9
I
(NVO
Jig.2 - Inverted funnel plot to assess potential publication bias.
0.0 SE(log[Haza-d Ratio])
0.2
o.4 Egger’s regression 
p = 0.269
0.6
0.8
------------------------ y-
0.1 0.2
H--------------------- 1----------- 1--------- h
0.5 1 2
H-------------------- 1
5 10
Hazard Ratio (fixed)
Potential sources of heterogeneity
The median proportion of patients classified as VEGF positive in the included studies was 
recorded as 60% (range = 32% to 71%). The proportion of VEGF positive cases reported in 
each study failed to exhibit any correlation with the assessment of methodological quality 
(Spearman, p=0.491) or the % cut-off used to define positive immunostaining (Spearman, 
p=0.388). No automated immunohistochemical scoring was described in any of the included 
studies.
Only two studies (Lim et al, 2004; Fujimoto et al, 1998) reported an opposite survival trend 
associated with VEGF expression (ie. more favourable survival in VEGF positive tumours). 
However, neither of these studies approached statistical significance (p=0.448 and p=0.400 
respectively). Only six studies reported the proportion of patients who received any form of 
adjuvant therapy {Table 2) and administered treatment modalities included a mix of both
chemotherapy and chemoradiation. Importantly, no studies reported any policy of selection of
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patients for adjuvant therapy based on VEGF tumour expression as immunohistochemical 
evaluation was undertaken retrospectively in all cases. No studies reported use of any 
neoadjuvant therapy and only a single study reported use of intra-operative radiotherapy 
(Ikeda et al, 2001).
Most studies included a breakdown of VEGF staining according to histological tumour 
characteristics. Table 4 outlines the cumulative data to describe the relationship between 
VEGF expression and nodal status, T stage and tumour grade in the meta-analysed studies 
where available. These results suggest a significant relationship between positive VEGF 
immunostaining and an increased likelihood of T3/T4 tumours (%2 = 5.63, p=0.018). Despite 
a similar trend towards a greater proportion of N1 tumours associated with positive VEGF 
expression, this finding did not reach significance (x2 = 2.67, p=0.102).
Table 4 - Pooled data to demonstrate association between VEGF expression and resected 
histopathological tumour characteristics.
VEGF positive VEGF negative P
Nodal status:
NO 132 115 0.102
N1 237 158
T stage:
T1/T2 77 72 0.018
T3/T4 136 76
Tumour grade:
Well 75 54 0.622
Moderate 136 121
Poor 60 50
Pooled data was available for nodal status in 9 studies (n=642), for tumour grade in 8 studies (n=496) and T 
stage in 6 studies (n=361).
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Of the five studies which reported positive VEGF expression as a significant adverse 
prognostic variable, only three conducted some form of multivariate analysis. These three 
analyses included a variety of disparate covariates alongside YEGF. However, each reported 
that VEGF status retained statistical significance. Due to the lack of studies reporting 
multivariate analyses, no attempt was made to use any adjusted survival data as part of this 
meta-analysis.
Discussion
Previous meta-analyses of studies investigating the immunohistochemical expression of 
VEGF as a marker of prognosis have been published for various malignancies including head 
and neck (Kyzas et al, 2005), colorectal (Des Guetz et al, 2006) and lung cancer (Delmotte et 
al, 2002), all reporting a significant correlation between VEGF expression and poor survival 
when pooling data from individual studies. To date, no such meta-analysis has been 
undertaken for prognostic studies evaluating VEGF in pancreatic cancer.
The results from the present study demonstrate that, despite variability between eligible 
studies as to the relative prognostic impact of VEGF expression in resected pancreatic 
adenocarcinoma, the overall observed survival trend is concordant with that reported for 
other malignancies as outlined above. When comparing the value for the pooled HR 
identified in the present study (1.51 (95% Cl = 1.18 to 1.92)) with the studies referenced 
above, the order of magnitude for this effect is also broadly comparable for that quoted for 
both lung cancer (1.48 (95% Cl - 1.27 to 1.72)) and colorectal cancer (1.65 (95% Cl - 1.27 
to 2.14)). The analysis of the pooled data indicated that there was no difference between 
significant and non-significant studies when comparing the allocated scores for
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methodological quality. This finding indicates that a meaningful aggregation of survival data 
can be conducted for both significant and non-significant studies.
When considering the nine studies which were excluded from the analysis, three were 
removed due to a duplicated cohort of patients included elsewhere and a further three were 
removed due to VEGF-C, VEGF-D or VEGF receptor status being the immunohistochemical 
markers of interest. Therefore, the outcomes of these six studies cannot be meaningfully 
compared with the 11 pooled studies. When evaluating the remaining three studies excluded 
due to either the lack of a dichotomised univariate survival analysis (Ellis et al, 1998; Fujioka 
et al, 2001), or mix of resected and unresected cases (Chung et al, 2006), all three studies 
reported a non-significant relationship between VEGF expression and survival. However, two 
of these three studies reported the direction of the survival effect to favour lower levels of 
VEGF immunostaining, in keeping with the general survival trend observed for the 
aggregated data.
Significant heterogeneity was observed when analysing the logHR estimates from the eligible 
studies. When evaluating the relevant methodological and clinico-pathological characteristics 
of each study, a number of potential sources of heterogeneity in study methodology were 
observed. Nine studies reported use of commercially available anti-VEGF primary 
antibodies, all of which exhibit broadly comparable binding characteristics with the common 
splice variants of VEGF-A. One study (Itakura et al, 1997) reported use of a non-commercial 
VEGF-A specific primary antibody and one study (Tang et al, 2006) did not elaborate on the 
origin of the anti-VEGF-A antibody used. When analysing the concentrations of primary 
antibody utilised, most studies reported comparable dilution ratios. However, the 
concentration was not specified in two studies. This issue is potentially relevant for the study
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reporting use of the lowest primary antibody dilution (Lim et al5 2004) as this was one of only 
two studies which indicated a contradictory prognostic effect (non-significant) when 
compared with the overall group (ie. a trend towards adverse survival with negative VEGF 
immunostaining).
When reviewing the immunohistochemical criteria used for VEGF scoring, the majority of 
studies reported a scoring system based on cytoplasmic staining of tumour cells. Where the 
distribution of immunostaining used for scoring was not explicitly stated in the text (ie. 
cytoplasmic, membranous, nuclear, stromal, etc), the figures of representative VEGF staining 
presented in the relevant studies were strongly indicative of cytoplasmic staining being used 
to define positive VEGF expression in cancer cells. All studies with one exception utilised a 
system of dichotomising patients according to the percentage of positively-stained cells 
present. The % cut-off values ranged from >1% to >50% of cancer cells. However, six out of 
ten studies utilised a standard cut-off value of >10%. Despite the range of values used to 
define VEGF positivity across the included studies, there was no evidence of any significant 
association between the % cut-off value used and the corresponding proportion of VEGF 
positive patients reported. Furthermore, if only including the six studies using a standardised 
cut-off value of >10% for meta-analysis, the significance of the association between VEGF 
staining and adverse survival was unchanged (HR = 1.62 (95% Cl = 1.09 to 2.40) - random 
effects). These observations suggest that differences in the specific scoring criteria used for 
immunohistochemical classification are unlikely to have a significant confounding effect in 
describing the underlying relationship between VEGF expression and survival obseived for 
the overall group.
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The combined analysis to investigate the relationship between reported VEGF positivity and 
histological tumour characteristics {Table 3) indicated a significant association between 
VEGF expression and likelihood of more invasive tumours (ie. T3/T4). This finding was also 
reported by two individual studies (Itakura et al, 1997; Tang et al, 2006). However, only six 
of the eleven eligible studies (representing less than half the overall patient group) presented 
sufficient data to detennine the exact proportion of T3/T4 tumours stratified by VEGF 
expression and consequently, this result should be interpreted with caution. There was no 
demonstrable association between VEGF expression and either tumour grade or nodal status 
when analysing the available pooled data. Of the three studies identified which investigated 
VEGF-C and/or VEGF-D alongside VEGF-A expression (Tang et al, 2006) or in isolation 
(Kurahara et al, 2004; Zhang et al, 2007), all three demonstrated a significantly greater 
proportion of N1 cases associated with positive VEGF-C/D expression. In contrast, none of 
these studies found a significant association between tumour stage and VEGF-C/D positivity. 
These findings are generally consistent with the accepted roles for VEGF-A in mediating 
growth and local tumour infiltration and VEGF-C/D in promoting lymphatic invasion (Achen 
et al, 2008).
The eleven studies which fulfilled the eligibility criteria exhibited a comparable mix of 
significant and non-significant studies. When analysing the funnel plot for the pooled 
survival data, the distribution of data points was approximately symmetrical. These findings 
indicate that publication bias is unlikely to represent a significant confounding factor in the 
interpretation of this meta-analysis.
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3.2.2. bcl-2 studies
Selection Criteria
The following search criteria were used:
• (‘bcl-2’ OR ‘bcl2’ OR ‘bcl’ OR ‘bcl*) AND (‘pancreas’ OR ‘pancreatic’) AND
(‘survival’ OR ‘prognosis’ OR ‘prognostic’)
Results
The initial search returned a total of 232 abstracts of which 16 potentially eligible articles 
were retrieved. A total of 11 were rejected for the following reasons; duplicated series of 
patients (Nio et al, 2001), mix of resected and unresected cases included (Ohshio et al, 1998; 
Makinen et al, 1998; Gansauge et al, 1998; Hu et al, 1999), inclusion of ampullary tumours 
(Sinicrope et al, 1996), no dichotomised univariate survival analysis conducted (Evans et al, 
2001; Stipa et al, 2002; Sun et al; 2002), insufficient survival data reported for indirect 
estimation of logHR and variance (Friess et al, 1998; Campani et al, 2001). The latter two 
authors were contacted to request supplementary survival data. However, this information 
was either unavailable (Friess et al, 1998) or no response was received (Campani et al, 2001).
The five eligible studies included a total of 314 patients with a median number of 63 patients 
per study (range = 52 to 70) - Table 5. Three studies reported a significant prognostic effect 
of bcl-2 expression on univariate analysis and all studies reported the direction of the survival 
effect to favour bcl-2 positivity. The median quality score was recorded as 75% (range = 65% 
to 85%) and the median proportion of bcl-2 positive cases was 33% (range = 12% to 67%).
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Meta-analysis
fig. 3 illustrates the Forrest plot for the pooled survival data. There was no evidence of any 
significant heterogeneity (x = 1.19, p = 0.88). The combined HR was recorded as 0.51 (95% 
Cl = 0.38 to 0.68) indicating a significant association between positive bcl-2 immunostaining 
and more favourable survival in the pooled patient group. Despite the limited number of 
studies included, the funnel plot for this analysis failed to demonstrate any obvious 
asymmetry (fig.4). Three studies reported use of either adjuvant chemotherapy or 
chemoradiation and a single study (Bold et al, 1999) also reported use of neoadjuvant 
chemoradiation in 43 out of the 70 patients analysed. Of the two studies excluded due to 
incomplete survival data (Friess et al, 1998; Campani et al, 2001), both failed to obseive any 
significant prognostic effect associated with bcl-2 expression.
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fig.4 - Inverted funnel plot to assess potential publication bias for bcl-2 studies.
p=0.963
Hazard Ratio
3.2.3. bax
Selection Criteria
The following search criteria were used:
• (‘bax') AND (‘pancreas’ OR ‘pancreatic’) AND (‘survival’ OR ‘prognosis’ OR
‘prognostic’)
Results
The initial search yielded 76 studies. Following review of the abstracts, a total of seven 
potentially eligible articles were identified. Two of these were excluded due to either a 
duplicated patient series (Hashimoto et al, 2005) or the inclusion of periampullary cancers of 
non-pancreatic origin in the survival analysis (Tomazic et al, 2004). Three of the five eligible 
studies investigated the individual prognostic effect of both bcl-2 and bax and were therefore 
included in both meta-analyses (Nio et al, 2001; Magistrelli et al, 2002; Dong et al, 2005).
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The five eligible studies investigating bax included a total of 274 patients with a median 
number of 60 patients per study (range = 23 to 67) - Table 6. Three of the five studies 
reported a significant survival advantage associated with bax expression. The median quality 
score was 65% (range = 55% to 85%) and the median proportion of bax positive cases was 
54% (range = 26% to 83%). fig. 5 illustrates the Forrest plot for the pooled survival data. 
There was no evidence of any significant heterogeneity in the recorded log hazard ratios (x2 = 
4.25, p = 0.37). The combined hazard ratio was recorded as 0.63 (95% Cl = 0.48 to 0.83) and 
the funnel plot for this analysis is shown in fig. 6.
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fig.6 - Inverted funnel plot to assess potential publication bias for bax studies.
p=0.817
Hazard Ratio
Discussion
Both bcl-2 and bax emerged as potentially relevant immunohistochemical prognostic factors. 
These proteins belong to the bcl-2 family and regulate apoptosis by mediating cytosolic 
release of cytochrome C from mitochondria in response to cellular stress. Cytochrome C 
binds to APAF-1 and cleaves caspase-9 into its active form, thereby initiating the activation 
of executioner caspases resulting in cytoskeletal degradation and cell death (Hamacher et al, 
2008). The bcl-2-associated X protein (bax) promotes release of cytochrome C and 
consequently exhibits pro-apoptotic properties. In contrast, bcl-2 inhibits mitochondrial 
release of cytochrome C and has anti-apoptotic effects as a result. The finding that bax 
expression is associated with more favourable survival in resected pancreatic cancer is, 
therefore, concordant with its physiological role. The observation that the same relationship is 
consistently seen for bcl-2 expression appears paradoxical. However, this finding is mirrored 
in other malignancies (Martin et al, 2003; Callagy et al, 2008) and it is believed that a 
complex interaction of competitive dimerisations between pro- and anti-apoptotic proteins 
governs the cell’s fate in response to apoptotic stimuli (Westphal et al, 2003).
175
All of the eligible bcl-2 studies used commercially available antibodies from the same 
manufacturer. Despite differences in dilutions and cut-off values used for immunostaining, 
the five studies returned broadly comparable HR estimates in the same direction. There was 
more variability in the source of primary antibodies used and the overall range of individual 
estimated hazard ratios seen in the bax studies. However, where reported, the cut-off values 
used for IHC scoring were comparable, and the direction of the survival effect of bax 
expression was consistent across the five eligible studies.
It is difficult to draw any reliable conclusions regarding the prognostic value of bcl-2 and bax 
expression for resected pancreatic cancer from the current meta-analysis due to the limited 
number of evaluable studies. Furthermore, data was unobtainable for two relevant bcl-2 
studies, both of which recorded no significant association between bcl-2 expression and 
survival. Despite this, the overall trend towards both bax and bcl-2 expression being 
associated with more favourable survival outcomes is consistent with the findings reported 
for other malignancies.
3.2.4. p!6
Selection Criteria
The following search criteria were used:
• (‘pi6’ OR ‘pi6*’ OR ‘CDKN2A’) AND (‘pancreas’ OR ‘pancreatic’) AND
(‘survival’ OR ‘prognosis’ OR ‘prognostic’)
The initial search returned 91 studies, seven of which were potentially relevant. Following 
review of these seven articles, three fulfilled all of the eligibility criteria. The remaining 
studies were rejected due to the inclusion of unresected cases (Hu et al, 1997; Biankin et al,
176
2002), no IHC used in tissue analysis (Ohtsubo et al, 2003) or only disease-free survival 
times reported (Jeong et al, 2005). A total of 229 patients were included in the pooled 
analysis.
Results
All three studies reported the survival trend to favour positive pi6 expression. However, this 
only reached significance in one (Naka et al, 1998). There was no significant heterogeneity 
across the three included studies (%2 = 2.23, p = 0.33). A combined hazard ratio of 0.64 (95% 
Cl = 0.45 to 0.91) was obtained indicating a significant association between pi 6 expression 
and more favourable survival in the pooled patient group. No analysis of the funnel plot was 
undertaken due to the limited number of eligible studies.
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Discussion
The tumour suppressor gene pi6 (CDKN2A) plays a key role in pancreatic carcinogenesis 
(Schutte et al, 1997). pi6 is a cell-cycle checkpoint protein which binds to cyclin-dependent 
kinases resulting in cell cycle arrest at the Gl/S checkpoint. The observation that positive 
immunostaining for pl6 appeal's to represent a favourable prognostic feature is, therefore, 
also consistent with its tumour suppressor function. Despite this, the three studies reported 
very disparate proportions of IHC positivity ranging from 13% to 59% and the small number 
of eligible studies included in this analysis again precludes any meaningful conclusions being 
drawn regarding the reproducibility of pi6 expression as a reliable marker of prognosis in 
resected pancreatic cancer.
3.2.5. p53
Selection Criteria
The following search criteria were used:
• CpSB’ OR ‘TP53’) AND (‘pancreas’ OR ‘pancreatic’) AND (‘survival’ OR 
‘prognosis’ OR ‘prognostic’)
The initial search returned a total of 337 studies. Following review of these abstracts, 58 
potentially relevant studies were retrieved of which 17 fulfilled all of the inclusion criteria. 
The remaining studies were rejected for the following reasons: duplicated series of patients 
(Dergham et al, 1997a; Nio et al, 1998; Dong et al, 1998; Nio et al, 1999; Dong et al, 2000; 
Nio et al, 2001; Linder et al, 2001), no dichotomised univariate survival analysis conducted 
(Sessa et al, 1998; Karademir et al, 2000; Fujioka et al, 2001; Campani et al, 2001; Evans et 
al, 2001; Gazzaniga et al, 2001; Biankin et al, 2002; Dang et al, 2002; Hashimoto et al, 2005; 
Smeenk et al, 2007; Dong et al, 2007), no IHC used in tissue analysis (Weyrer et al, 1996; Li
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et al, 1999; Yamaguchi et al, 2000; Ohshio et al, 2002; Dong et al, 2003), unresected cases 
included in survival analysis (Zhang et al, 1994; Aizawa et al, 1996; Lundin et al, 1996; 
Coppola et al, 1998; Dergham et al, 1998; Makinen et al, 1998; Ohshio et al, 1998; Hu et al, 
1999); Takikita et al, 2009), mix of different tumour types included (Sinicrope et al, 1996; 
Sato et al, 1997; Gansauge et al, 1998; Yu et al, 2004) , only disease-free survival reported 
(Jeong et al, 2005), insufficient survival data reported (Dergham et al, 1997b; Campani et al, 
1999; Stipa et al, 2002; Hermanova et al, 2009). The four corresponding authors were 
contacted for the potentially eligible studies where insufficient survival data were reported. 
Supplementary data were either unavailable (Dergham et al, 1997b) or no response was 
received (Campani et al, 1999; Stipa et al, 2002; Hennanova et al, 2009).
The 17 eligible studies included a total of 925 patients with a median number of 48 patients 
per study (range = 26 to 157) - Table 8. Nuclear staining of p53 was used for scoring in all 
cases. Five studies (29%) reported a significant adverse association between p53 expression 
and survival. The median quality score was recorded as 65% (range = 45% to 90%) and the 
median proportion of patients exhibiting positive p53 immunostaining was 47% (range = 
25% to 68%). There was no significant association between the IHC cut-off score used and 
the proportion of cases classified as p53 positive (Spearman, rho = 0.389, p = 0.206). 
Furthermore, there was no significant difference in median quality scores between significant 
and non-significant studies (Mann-Whitney, p = 0.243).
fig. 8 illustrates the Forrest plot for the survival data. There was no evidence of any significant 
publication bias (Egger’s test, p = 0.298). However, significant heterogeneity was 
demonstrated (x2 = 37.88, p = 0.002). The combined HR was recorded as 1.22 (95% Cl = 
0.96 to 1.56) indicating no significant overall association between p53 expression and
180
survival. Of the three studies excluded due to incomplete reporting of survival data, only one 
reported a significant association between p53 expression and survival (Stipa et al, 2002).
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fig.9 - Funnel plot for pooled survival data from evaluable p53 studies.
p=0.298
Hazard Ratio
Discussion
The tumour suppressor protein p53 represents the most extensively investigated 
immunohistochemical prognostic marker of those selected for analysis as part of this study. It 
was also found to exhibit the greatest degree of heterogeneity in the reported association 
between immunostaining and survival for individual studies. Although the overall trend was 
towards overexpression of p53 resulting in adverse survival for the pooled data, this did not 
reach significance and there is no obvious explanation for the contradictory results seen 
between the various studies. The majority of studies used either the monoclonal DO-7, DO-1 
or polyclonal CM-1 primary antibodies which all exhibit similar immunoreactivity with both 
wild-type and mutant forms of p53. Due to the increased stability of mutant p53, most of the 
nuclear immunostaining seen reflects the presence of the mutant rather than wild-type p53 
protein.
Despite the marked differences between studies in terms of the proportion of cases classified 
as p53 positive, the reported primary antibody dilutions used and the various cut-off values 
selected for immunohistochemical scoring, there was no clear association between any of
184
these factors and either the direction of the prognostic effect or die reported magnitude of the 
hazard ratio which might potentially explain the disparity in survival trends. These results 
indicate that p53 expression in primary tumour material fails to represent a reliable or 
reproducible prognostic factor in patients with resected pancreatic cancer.
When considering the question of publication bias for the p53 literature, only five of the 17 
evaluable studies reported a significant relationship between p53 immunostaining and 
survival. All of these five significant studies reported the direction of the effect to reflect 
adverse survival associated with positive staining. Furthermore, the funnel plot failed to 
demonstrate any evidence of marked asymmetry and Egger’s regression for this dataset 
returned a non-significant p-value. Only one of the three studies omitted due to incomplete 
reporting of survival data demonstrated a significant relationship between p53 and survival. 
These results indicate that publication bias is unlikely to represent a significant confounding 
factor in the interpretation of these results.
3.2.6. smad4
Selection Criteria
The following search criteria were used:
• (‘smadd’ OR ‘smad-4’ OR ‘smad*’ OR ‘DPC4’ OR ‘DPC-4’ OR ‘DPC*’) AND 
(‘pancreas’ OR ‘pancreatic’) AND (‘survival’ OR ‘prognosis’ OR ‘prognostic’)
The initial search returned 81 studies. Following review of these abstracts, five potentially 
relevant studies were identified which were all found to be eligible for analysis. The 
combined number of patients was 540 with a median of 88 patients per study (range = 34 to 
249) - Table 9. Three studies reported a significant relationship between smad4 expression
185
and survival. A single study (Biankin et al, 2002) reported the direction of the survival effect 
to favour loss of smad4 expression.
The median quality score was 75% (range = 60% to 95%) and the median proportion of 
patients exhibiting positive smad4 immunostaining was 45% (range = 15% to 16%). fig. 10 
illustrates the Forrest plot. Significant heterogeneity was demonstrated between the included 
studies (x2 = 9.86, p = 0.04). A combined HR of 0.88 (95% Cl - 0.61 to 1.27) was recorded 
indicating no significant overall association between smad4 expression and survival in the 
pooled patient group.
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Discussion
The smad4 (or DPC4) protein is a central component of the intracellular signalling pathway 
for transforming growth factor (3 (TGF-{3) and loss of smad4 expression represents an 
important event in the progression of PanINs to invasive malignancy (Wilentz et al, 2000). 
The results from the analysis of the five studies evaluating smad4 expression demonstrate 
unexplained heterogeneity in the reporting of the prognostic effect of this marker. Biankin et 
al reported an entirely contradictory survival trend to the other four studies with loss of 
smad4 expression being associated with significantly improved survival in their patient group 
despite use of the same primary antibody and otherwise broadly comparable study 
methodology and clinico-pathological characteristics. This survival trend appears at odds 
with the accepted tumour suppressor role of smad4 in mediating the inhibitory signalling 
associated with the TGF-|3 pathway.
Despite the fact that the patient series reported by Biankin et al only accounts for 8% of all 
patients included in the combined analysis and 14% of the weighting allocated to the pooled 
survival data, the discrepancy in the results is such that sufficient heterogeneity is introduced 
to result in a non-significant result for the overall analysis when using a random effects 
approach. These findings further underline the difficulties in making any reliable conclusions 
regarding the relative prognostic value of immunohistochemical markers when analysed in 
limited patient series.
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3.2.7. EGFR
Selection Criteria
The following search criteria were nsed:
• (‘epidermal growth factor receptor’ OR ‘EGFR’ OR ‘c-erbB*’ OR ‘erbB*’ OR 
‘HER*’) AND (‘pancreas’ OR ‘pancreatic’) AND (‘survival’ OR ‘prognosis’ OR 
‘prognostic’)
The initial search identified 324 studies. Following review of these abstracts, ten potentially 
relevant articles were retrieved. Six of these were studies were rejected for the following 
reasons: duplicated series of patients (Ueda et al, 2006; Uegaki et al, 1997), no dichotomised 
univariate survival analysis conducted (Yamanaka et al, 1993; Zhang et al, 2002), unresected 
cases included in analysis (Gansauge et al, 1998; Takikita et al, 2009).
The four eligible studies included a total of 250 patients {Table 10). Only a single study 
reported a significant relationship between EGFR expression and survival (Ueda et al, 2004). 
The median quality score was 70% (range = 65% to 10%). fig. 11 illustrates the Forrest plot 
for the pooled data. Significant heterogeneity was demonstrated on Cochran’s % test (x2 = 
7.20, p = 0.07). The combined HR was recorded as 1.35 (95% Cl = 0.80 to 2.27) indicating 
no significant overall association between EGFR expression and survival.
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Discussion
Epidermal growth factor receptor (EGFR) is the cell surface receptor for a family of 
extracellular ligands which include EGF and TGF-a and is coded for by the c-erbBl proto­
oncogene. Activation of EGFR stimulates intracellular tyrosine kinase phosphorylation with 
consequent activation of a number of signalling cascades including the MAPK (mitogen- 
activated protein kinase) and Akt (protein kinase) pathways which promote cell proliferation 
(Ciardello et al, 2008).
The analysis of the four eligible studies included in the current meta-analysis again fails to 
make a strong case for tumoral over-expression of EGFR representing a reproducible 
prognostic marker. However, the laboratory methodologies reported in the four studies 
demonstrated more marked variability (eg. use of four different EGFR primary antibodies) 
when compared with some of the other analyses.
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4. OVERALL CONCLUSIONS & FUTURE WORK
The results from Chapter 2 demonstrate the expected relationships between resected 
histological tumour characteristics and postoperative survival in the cohort of pancreatic 
cancer resections analysed. Tumour size, differentiation and nodal status emerged as the most 
important histological prognostic factors. These results provide further evidence to indicate 
that the lymph node ratio represents a more infonnative prognostic factor when compared 
with overall nodal status. The analysis of resection margin status provides the first clinical 
evidence to support previous Royal College of Pathologists recommendations regarding 
resection margin reporting in pancreatoduodenectomy cancer specimens and indicates that 
pathological reporting criteria have a major impact on R1 resection rates. These findings have 
important implications for multicentre trials when evaluating risk stratification according to 
resection margin status.
Elevated preoperative serum CA19-9 levels were shown to be a detenninant of adverse 
postoperative survival which also demonstrate a significant relationship with microscopic 
tumour burden. The platelet-lymphocyte ratio represents a newly described prognostic factor 
which exhibits a strong association with both tumour resectability, likelihood of patient 
selection for adjuvant therapy and overall survival following resection. This index has also 
been shown to have potential prognostic value in resected ampullary cancer (Smith et al, 
2008) in addition to other tumour types (Aliustaoglu et al, 2009). The potential importance of 
the preoperative inflammatory response in the study group is also evident from the prognostic 
relationships described for both C-reactive protein and albumin. These findings have 
influenced the prospective data collected as part of the ESPAC-4 trial which will allow future 
study of these prognostic indices in a much larger multicentre cohort of patients.
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The analysis of the combined preoperative score suggests that comparable prognostic 
information can be derived from routine preoperative haematological and biochemical data as 
from the histopathology report for the resected tumour specimen. If validated in larger future 
studies, these results may be of clinical utility in identifying a sub-group of patients with 
potentially resectable pancreatic malignancy who may not benefit from surgical resection.
The findings from this study have prompted further work investigating the prognostic value 
of various circulating cytokines in archived serum collected from patients undergoing 
pancreatic cancer resections. This study will also investigate the relationship between these 
inflammatory mediators and the preoperative haematological and biochemical parameters 
described in the present study.
Meta-analysis of prognostic literature is associated with a number of inherent limitations. 
One of the key limitations is the general prevalence of retrospective study design in this 
setting. None of the studies included in the current meta-analysis specified a prospective 
design and archived paraffin-embedded tumour material was utilised for IHC in all cases. 
This indicates that availability of tissue is invariably the main detenninant of study size rather 
than any specific considerations relating to adequate statistical power in order to reliably 
detect a prognostic effect for the biomarker of interest. The availability and adequacy of 
corresponding clinico-pathological data is also a significant consideration in retrospective 
studies of this type and we identified several studies reporting incomplete datasets with 
regard to histopathological details. Alongside this, an additional hindrance to meta-analysis 
of prognostic literature is the general lack of multivariable survival data. This is usually 
attributable to the fact that the number of patients included in each study is typically small, 
precluding any meaningful attempt at analysing multiple covariates.
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Additional challenges in the interpretation and comparison of immunohistochemical 
prognostic studies include variability in patient selection (ie. resected and unresected cases, 
inclusion of non-pancreatic periampullary tumours), disparate immunohistochemical criteria 
used for prognostic classification, potential bias associated with the statistical approach to 
analysis of survival data (eg. selection of data-driven cut-off values for continuous variables), 
incomplete reporting of survival data, duplicated patient series and publication bias arising as 
a result of selective reporting of ‘positive’ studies (Altman, 2001). In order to overcome some 
of these comparative difficulties, specific inclusion criteria were applied in order to select 
literature for meta-analysis. Only studies including resected pancreatic adenocarcinoma were 
included in order to avoid any confounding effects on survival associated with differing 
proportions of resected and unresected cases. Any studies including periampullary tumours of 
non-pancreatic origin were also excluded due to the disparity in survival outcomes 
characteristically associated with ampullary, duodenal and bile duct adenocarcinomas when 
compared with pancreatic adenocarcinoma (Riall et al, 2006). Furthermore, in cases where 
part or all of the same patient series was included in more than one publication, only the more 
recent or most complete study was included in the analysis in order to avoid duplicating the 
same patient data for the immunohistochemical marker of interest. For those studies where 
insufficient survival data were reported to generate indirect calculations for the logHR and 
variance, authors were contacted for additional survival data. However, in all cases the 
authors were either unable to provide any supplementary data or no response was received. 
The only supplementary raw data obtained was for two studies previously conducted at our 
own institution (Kawesha et al, 2000; Evans et al, 2001). Therefore, no subsequent attempt to 
request individual patient survival data for all eligible studies was undertaken, although this 
would have been potentially beneficial.
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When analysing the overall relationships between individual study size, reported prognostic 
significance and methodological quality scores in the present study, there was a significant 
trend towards superior methodological quality in larger studies as one might reasonably 
expect, despite the fact that study size itself was not one of the criteria used for quality 
scoring. When considering the overall effect of potential publication bias in this analysis, 
only a minority of studies (21 out of 50) actually reported a statistically significant prognostic 
result. Furthermore, the funnel plots and Egger’s tests for the individual analyses, although 
more difficult to interpret when fewer studies were included, were not generally indicative of 
any strong publication bias.
Vascular endothelial growth factor (VEGF) emerged as the most potentially informative 
prognostic factor when analysing the pooled survival data from all of the molecular markers 
included in this meta-analysis. The direction and order of magnitude for the observed 
prognostic effect of VEGF immunostaining in resected pancreatic cancer is in keeping with 
results from previously conducted meta-analyses investigating the prognostic role of VEGF 
immunostaining for other malignancies (Des Guetz et al, 2006; Delmotte et al, 2002). The 
observed association between VEGF staining and T stage when pooling the histological data 
is also in concordance with the biological role of VEGF. Analysis of the funnel plot suggests 
that publication bias is unlikely to represent a significant confounding effect when evaluating 
these results.
The results for bcl-2, bax and pi6 all indicated a significant overall prognostic effect for each 
molecular marker. However, given the smaller numbers of studies included in each analysis, 
these findings should be interpreted interpreted with caution. Despite representing the most 
widely investigated molecular prognostic marker for resected pancreatic cancer, the pooled
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survival data fails to suggest that p53 immunostaining has any prognostic significance in this 
setting. This was similarly true for smad4 and EGRF indicating that these molecular markers 
are of less prognostic value in resected pancreatic cancer.
These findings are of relevance for future research given the increasing potential for use of 
adjuvant therapies tailored to patient-specific tumour biology (Farrell et al, 2009). The results 
indicate that future studies utilising microarrayed tissue should consider inclusion of VEGF 
as a comparative molecular marker of prognosis in patients with resected pancreatic cancer. 
These results provide further evidence to suggest that in order to make reliable conclusions 
regarding immunohistochemical prognostic factors and to identify the relevance with which 
these factors can be translated into clinical use (eg. individualised patient selection for 
adjuvant therapy modalities), large collaborative studies utilising microarrayed tissue as part 
of prospective multicentre trials, with standardised approaches to both laboratory and 
statistical methodology, represent the optimal strategy to achieve these goals in the future (eg. 
Farrell et al, 2008; Manuyakorn et al, 2010). The findings of this meta-analysis have been 
published in 2011 {Appendix B).
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APPENDIX A - Supplementary figures / tables
fig.2A - Kaplan-Meier cumulative survival curves for resected pancreatic ductal adenocarcinoma patients 
according to gender.
Female
Male
Log rank - p=0.289
Time (months)
No. at risk
Male 94 47 20 10 6 4
Female 72 41 18 7 5 4
fig.4A - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients according to 
venous resection.
No venous resection 
Venous resection 
Log rank - p=0.902
No. at risk
None 156 81
Venous res. 10 7
Time (months)
35 16 11 8
3 10 0
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fig.5A - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients according to 
study period.
1997 - 2002 
2003 - 2007 
Log rank - p=0.647
Time (months)
1997-2002 62 32 19 10 8
2003-2007 104 56 19 7 3
7
1
fig. 7A - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients according to 
adjuvant chemoradiotherapy (CRT) vs. no adjuvant therapy.
Chemoradiotherapy 
No adjuvant treatment 
Log rank - p=0.754
Time (months)
CRT 6 3
No treatment 115 55
2 0
23 11
0 0
8 7
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Jig.l7A - Kaplan-Meier cumulative survival curves for pancreatic ductal adenocarcinoma patients stratified by 
lymph node 16b status (n=87).
LN16b negative 
IN 16b positive 
Log rank - p=0.261
Time (months)
No. at risk
LN16b-ve 76 44 23 11 7 5
LN16b+ve 11 6 2 1 0 0
fig.21A - Kaplan-Meier cumulative survival curves for RO cases stratified according to the presence of tumour 
involvement (direct or < 1mm) of the anterior pancreatic surface (n=35).
anteriorsurface negative 
anterior surface positive 
Log rank - p=0.220
Time (months)
anterior -ve 23 12 8 4 2 0
anterior +ve 12 7 7 5 4 3
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fig.23A - Kaplan-Meier cumulative survival curves for R1 resections stratified according to single vs. multifocal 
resection margin involvement (n=128).
1RM involved 
> 1 RM involved 
Log rank - p=0.354
Time (months)
No. at risk
1 RM 64 36 10 6 4 4
> 1 RM 64 32 12 2 1 1
fig.26A - Kaplan-Meier cumulative survival curves for resected pancreatic ductal adenocarcinoma cases 
stratified according to the presence of vascular invasion (n=138).
no vascular invasion 
vascular invasion 
Log rank - p=0.809
Time (months)
No. at risk
no vase. inv. 34 23 9 5
vase, invasion 104 50 22 9
4 2
4 3
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fig.27A - Kaplan-Meier cumulative survival curves according to preoperative biliary drainage (n=166).
stent/drain 
no stent/drain 
Log rank - p=0.946
Time (month)
No. at risk
stent/drain 141 76 31 13 7 5
none 25 12 7 4 4 3
fig.28A - Kaplan-Meier cumulative survival curves according to endoscopic vs. percutaneous drainage (n=141).
ERCP
PTC
Log rank - p=0.290
Time (months)
No. at risk
ERCP 129 70
PTC 12 6
30 13
1 0
7 5
0 0
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Table 2A - Standardised data extraction form
Survival analysis staining positive staining negative
Number of patients analysed:
Number of patients excluded from analysis:
Overall / disease-free / progression-free survival:
Observed events in group:
Number of censored cases in each group:
Survival advantage to which group:
Kaplan-Meier curves shown:
Numbers at risk quoted:
Median survival times quoted:
Univariate test statistic quoted:
Univariate hazard ratio (+/- 95% Cl) quoted:
Min. / Max. follow-up period:
Recruitment period:
Median follow-up period quoted:
Correlation with clinico-pathological data staining positive staining negative
Male / female:
Median age:
T stage:
1/2
3/4
Differentiation:
Well
Moderate
poor
Nodal status:
Positive
Negative
Margin status:
Positive
Negative
Stage:
I
il
HE
IV
Details of adjuvant therapy recorded:
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Introduction: Despite the widespread use of endoscopic biliary stenting in patients pre­
senting with potentially resectable pancreatic cancer, there is no general consensus regarding 
whether this represents a superior management approach over expeditious surgical interven­
tion. The objective of this study was to investigate the influence of preoperative biliary stenting 
and resolution of jaundice on subsequent postoperative survival following resection for 
pancreatic cancer.
Methods: 155 patients undergoing partial pancreatoduodenectomy for pancreatic ductal 
adenocarcinoma between January 1997 and August 2007 were identified from a prospectively 
maintained database.
Results: There was no survival difference when comparing patients undergoing preopera­
tive biliary drainage (n — 130) with those who did not (n = 25) (log rank, P = 0.981). When 
analysing individual prognostic factors as continuous variables in univariate Cox analysis, 
lower albumin levels (P = 0.016), elevated alkaline phosphatase levels (P = 0.011) and ele­
vated CRP levels (P = 0.021) were associated with poorer overall survival. Multivariable Cox 
regression demonstrated that both albumin (P = 0.008) and CRP (P = 0.038) remained 
significant independent predictors of overall survival alongside lymph node ratio (P = 0.018). 
Although preoperative bilirubin levels were not associated with overall survival when analysed 
as a continuous variable (Cox, P = 0.786), the presence of jaundice (i.e., bilirubin >35 pmol/I) 
at the time of surgery was a significant adverse predictor of early survival in patients under­
going preoperative biliary drainage (Breslow-Gehan-Wilcoxon, P = 0.013) and remained a 
significant predictor of early survival when included in a further Cox analysis with censoring 
of cases who survived beyond 6 months (Cox, P = 0.017).
Conclusion: These results suggest that the presence of jaundice at the time of resection has 
an adverse impact on early, but not overall, postoperative survival in pancreatic cancer pa­
tients undergoing preoperative biliary drainage.
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Pancreatic ductal adenocarcinoma represents a 
major cause of cancer mortality in developed coun­
tries1,2 and surgical resection remains the onlyPublished by Springer Science+Business Media, LLC © 200S The Society of Surgical Oncology, Inc.
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potentially curative intervention.3 Since the advent of 
partial pancreatoduodenectomy, the preoperative 
status of patients undergoing pancreatic surgery has 
been well recognised as an important factor in 
determining postoperative outcome. The rationale 
originally described for pancreatoduodenectomy 
being conceived as a two-stage procedure, comprising 
cholecystogastrostomy and gastrojejunostomy fol­
lowed by subsequent pancreatic resection, was based 
on optimising the overall physical status of the pa­
tient prior to definitive resection.4
Over 70 years later, the issue of how best to opti­
mise patients with potentially resectable pancreatic 
and periampullary malignancy prior to definitive 
surgery remains entirely relevant. Despite the wide­
spread use of endoscopic preoperative biliary stenting 
in this setting, there remains no conclusive evidence 
to prove that intervention to ameliorate obstructive 
jaundice prior to resection represents a superior 
management approach over expeditious surgery. The 
results of a previous meta-analysis suggest that pre­
operative biliary instrumentation is associated with 
an increased risk of perioperative morbidity over 
surgery alone (57% versus 42% respectively). How­
ever, this study failed to demonstrate any significant 
effect on operative mortality rates.5 Although several 
previous studies have investigated the effect of pre­
operative biliary drainage on initial postoperative 
outcomes in pancreatic and periampullary cancer 
(e.g., 30-day mortality, duration of postoperative 
admission, ITU stay, in-patient complication rates, 
relaparotomy rates, etc.),6-8 no previous published 
studies have specifically investigated the relationship 
between preoperative liver function and subsequent 
postoperative survival in patients undergoing resec­
tion for pancreatic cancer.
The objective of this study was to evaluate the 
potential relationship between preoperative biliary 
drainage, resolution of jaundice and early postoper­
ative survival in pancreatic cancer patients undergo­
ing partial pancreatoduodenectomy. The prognostic 
relevance of preoperative serum albumin and C- 
reactive protein (CRP) levels was also investigated as 
part of this analysis to determine whether these 
parameters represent potential confounding factors 
in describing the relationship between stenting, 
jaundice and survival.
METHODS
Consecutive patients undergoing partial pancreat­
oduodenectomy for histologically confirmed pancre­
atic ductal adenocarcinoma between January 1997 
and August 2007 were identified from a prospective 
database. Histopathology reporting was undertaken 
according to the Royal College of Pathologists 
guidelines.9 The lymph node ratio (i.e., number of 
tumour-involved lymph nodes as a ratio of total 
number of nodes sampled) was used in the survival 
analyses as this has been shown to be a superior 
prognostic variable when compared with overall no­
dal status (i.e., positive versus negative).10
Where patients underwent more than one procedure 
prior to successful stenting, the date of definitive bili­
ary drainage was used for analysis. All patients with 
potentially resectable pancreatic tumours and 
obstructive jaundice presenting to our institution 
during the study period routinely underwent biliary 
decompression at endoscopic retrograde cholangio­
pancreatography (ERCP) where possible. Those in 
whom endoscopic drainage was unsuccessful went on 
to undergo percutaneous transhepatic cholangiogra­
phy (PTC) or combined procedures with internal 
stenting. External drainage was required in a propor­
tion of these cases (4/12). A plastic biliary endopros­
thesis was routinely used. A metal stent was required in 
only 5 out of 126 cases undergoing internal drainage. 
Eleven of 25 unstented patients were jaundiced at the 
time of resection. Four of these 11 patients underwent 
failed endoscopic procedures and went straight to 
surgery without any additional percutaneous inter­
vention. The remaining patients either developed 
jaundice between the time of initial presentation and 
admission for surgery or went straight to laparotomy 
on the basis of logistical reasons (i.e., early availability 
of theatre session). Jaundice was defined as a serum 
bilirubin concentration of >35 pmol/l (approximately 
2 mg/dl). This level was selected as hyperbilirubina- 
emia is usually only clinically evident as jaundice when 
serum bilirubin levels exceed this value.
Statistical Analysis
Median, interquartile range (IQR) and 95% con­
fidence intervals (Cl) were used to describe continu­
ous data and the two-tailed Mann-Whiney U test was 
used for comparative analyses. Overall survival times 
were calculated from the date of resection to the date 
of death. Kaplan-Meier curves were used to illustrate 
the survival trends for the prognostic variables of 
interest. The log rank (Cox-Mantel) test was used to 
assess the effect of prognostic factors on overall and 
late survival while the Breslow-Gehan-Wilcoxon test 
was used to assess the effect on early survival.11 Cox 
proportional hazards regression was used for both
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univariate and multivariable analyses. Proportional­
ity was checked for all covariates prior to inclusion 
for Cox regression by checking the log cumulative 
hazard plots for each variable. The prognostic data 
were analysed using continuous variables for Cox 
regression where appropriate.12 Only variables 
exhibiting significance on univariate analysis were 
included in the multivariable analyses. An additional 
Cox analysis was conducted with censoring of cases 
who survived >6 months in order to identify which 
prognostic factors were specifically associated with 
early, rather than overall, postoperative survival. For 
the analysis of the prognostic significance of CRP, 
patients with preoperative values >100 mg/1 were 
excluded in order to minimise the confounding effect 
of acute cholangitis.
RESULTS
Six hundred twenty-three patients underwent sur­
gical intervention for suspected pancreatic or pe­
riampullary cancer during the study period. 
Resections were performed in 432 patients, of whom 
351 underwent pancreatoduodenectomy. One hun­
dred fifty-five patients had histologically confirmed 
pancreatic ductal adenocarcinoma. Table 1 reports 
the demographics and proportion of patients under­
going preoperative biliary drainage in this group. 
There were 33 censored cases with a median follow­
up time of 11.5 (IQR 6.2-23.1) months. The overall 
median survival was 13.3 (95% Cl 11.1-15.5) 
months. The median time interval from the date of 
preoperative liver function tests to resection was 1 
(IQR 1-2) day. The median time interval from the 
date of preoperative CRP estimation to resection was 
2 (IQR 1-11) days. Forty-one patients (26%) received 
some form of adjuvant therapy following resection, 
of whom 35 received chemotherapy.
Early Mortality
There were three postoperative deaths within 30 
days of surgery (2%) and a total of six patients (4%) 
died prior to discharge from hospital. The cause of 
death in those patients who died prior to discharge 
was pneumonia in three cases, and myocardial 
infarction, multiple organ failure following relapar­
otomy for a bile leak, and intra-abdominal sepsis in 
the remaining cases. The 90-day mortality rate was 
6% (10/155 patients). Of 149 patients followed up for 
a minimum of 6 months there were 30 recorded 
deaths within 6 months of resection (20%). Death
TABLE 1. Patient demographics and details of preoperative 
biliary drainage
No. of patients identified 155
Gender: male (%) 88 (56.8)
Age: median (IQR) 67 (61-72) years
No. (%) of cases with preoperative 151 (97.4)
LFTs recorded:
Bilirubin: median (IQR) 25 (12-56) pmol/1
Alkaline phosphatase: median (IQR) 202 (122-344) U/l
ALT: median (IQR) 49 (26-81) U/l
■yGT: median (IQR) 125 (65-352) U/l
Albumin: median (IQR) 36 (32-40) mg/1
No. of cases with preoperative 121 (78.1)
CRP recorded:
CRP: median (IQR) 11 (5-26) mg/1
Intervention for preoperative 
biliary drainage* (%):
None 25 (16.1)
ERCP + stent 118 (76.1)
PTC/combined procedure + 12 (7.7)
stent/drain
Interval from stenting to surgery: 33 (20-49) days
median (IQR)
LFTs, liver function tests; ALT, alanine aminotransferase; 7GT, 
gamma-glutamyl transferase; IQR, interquartile range; CRP, C- 
reactive protein; ERCP, endoscopic retrograde cholangiopancrea­
tography; PTC, percutaneous transhepatic cholangiopancreatog­
raphy.
* Four cases undergoing PTC required external drainage. A 
metal biliary stent was used in 5 cases out of 126 cases undergoing 
internal stenting. A plastic stent was employed in the remaining 
cases.
within 6 months of surgery was used to define “early” 
survival in the subsequent Cox analysis.
The Effect of Preoperative Biliary Drainage 
on Survival
Figure 1A demonstrates that there was no signifi­
cant difference in early or overall survival when 
comparing those patients who did or did not undergo 
biliary drainage preoperatively (log rank, 
P = 0.981). Figure IB demonstrates no significant 
difference in survival when comparing patients who 
required percutaneous intervention for biliary drain­
age with those who underwent endoscopic stenting 
(log rank, P = 0.230).
Preoperative CRP levels were found to be more 
significantly elevated in those cases requiring PTC 
[median (IQR) = 29 (22-107) mg/1] when compared 
with those stented at ERCP [median (IQR) =10 (4- 
23) mg/1] (Mann-Whitney, P = 0.022). There was no 
significant difference, however, in CRP levels at the 
time of surgery when comparing those cases who 
underwent endoscopic stenting with those cases who 
did not undergo any form of preoperative biliary 
drainage [median (IQR) = 10 (7-57) mg/1] (Mann- 
Whitney, P = 0.487).
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FIG. 1. Kaplan-Meier cumulative survival curves to demonstrate the effect of preoperative biliary stenting on survival following pancre­
atoduodenectomy for pancreatic ductal adenocarcinoma: (A) stented versus nonstented patients, and (B) patients stented at endoscopic 
retrograde cholangiopancreatography (ERCP) versus percutaneous transhepatic cholangiography (PTC).
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FIG. 2. (A) Bivariate line chart to illustrate pre- and post-stenting bilirubin levels in 12 patients requiring percutaneous intervention for 
preoperative biliary drainage. Each line signifies an individual patient's results. There was a median reduction in bilirubin levels of 73% (IQR 
49-92%) in patients undergoing PTC. However, only three patients (25%) experienced complete resolution of jaundice (i.e., <35 pmol/1). (B) 
Scattergram to demonstrate the significant inverse correlation between duration of preoperative biliary drainage (i.e., time interval between 
stenting and resection) and bilirubin levels recorded at the time of surgery.
The Effect of Biliary Drainage on Resolution 
of Jaundice
Patients requiring PTC exhibited a greater degree 
of residual jaundice at the time of surgery [median 
bilirubin level 50 (IQR 34-134) nmol/1] when com­
pared with patients stented at ERCP [median biliru­
bin level 24 (IQR 12-47) pmol/l] (Mann-Whitney, 
P = 0.041). Figure 2A illustrates the change in pre­
operative bilirubin levels before and after biliary 
decompression in patients undergoing PTC (n = 12). 
There was a median reduction in bilirubin levels of 
73% (IQR 49-92%) in patients requiring PTC or 
combined procedures. However, only 3 of 12 patients
(25%) experienced complete resolution of jaundice 
(i.e., <35 pmol/1) at the time of surgery.
When analysing patients stented endoscopically, 
there was a median reduction in preoperative biliru­
bin levels of 85% (IQR 74-93%) for these patients. In 
total, 64% (73/114) of patients undergoing stenting at 
ERCP had complete resolution of jaundice at the 
time of surgery.
Duration of Preoperative Biliary Drainage 
and Resolution of Jaundice
The median time interval between definitive biliary 
drainage and surgery was 36 (IQR 25-53) days in
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TABLE 2. Multivariable Cox proportional hazards analysis of preoperative CRP and albumin as predictors of overall survival.
Cox model to evaluate factors predictive of overall survival
Univariate analysis Multivariable analysis (ti = 107)
Hazard ratio (95% Cl) X2 P Hazard ratio (95% Cl) X2 P
Bilirubin:
(Continuous) 1.000 (0.999-1.001) 0.074 0.786
>35 gmol/1 1.338 (0.929-1.927) 2.443 0.118 - - -
Albumin 0.963 (0.935-0.993) 5.800 0.016 0.933 (0.887-0.982) 6.976 0.008
Alkaline phosphatase 1.001 (1.000-1.002) 6.538 0.011 1.000 (0.999-1.001) 0.114 0.736
CRP 1.011 (1.002-1.020) 5.323 0.021 1.012 (1.001-1.024) 4.288 0.038
Tumour size 1.022 (1.007-1.038) 8.208 0.004 1.015 (0.995-1.035) 2.227 0.136
Poor tumour differentiation* 1.615 (1.112-2.345) 6.327 0.012 1.415 (0.831-2.408) 1.636 0.201
Lymph node ratio 3.713 (1.586-8.692) 9.144 0.003 4.212 (1.281-13.856) 5.604 0.018
Resection margin positive 1.594 (1.055-2.406) 4.915 0.027 1.167 (0.636-2.144) 0.250 0.617
Adjuvant chemotherapy 0.548 (0.342-0.878) 6.260 0.012 0.666 (0.383-1.158) 2.227 0.150
* Poor tumour differentiation analysed against well/moderately differentiated tumours. Resection margin status (R1 versus RO) and 
adjuvant chemotherapy (yes versus no) were also analysed as categorical covariates. Albumin, alkaline phosphatase, CRP, tumour size and 
lymph node ratio were included as continuous covariates in the Cox model.
Note: hazard ratios for continuous prognostic data reflect increase in relative hazard with each unit increase in covariate value. 
Statistically significant P-values (i.e., those <0.050) were highlighted in bold.
patients stented endoscopically. This time interval 
was 26 (IQR 14-37) days in patients requiring PTC or 
combined procedures (Mann-Whitney, P = 0.128). 
When analysing the overall group of patients under­
going preoperative biliary drainage, there was a sig­
nificant inverse correlation between the duration of 
biliary drainage and bilirubin levels prior to resection 
(Spearman rho = -0.688, P < 0.001); i.e., a longer 
period of biliary drainage resulted in lower bilirubin 
levels at the time of surgery (Fig. 2B).
The Influence of Preoperative Liver Function and CRP 
on Overall Survival
Table 2 demonstrates the results of univariate Cox 
proportional hazards regression when modelling the 
various preoperative blood results as continuous 
prognostic variables in the overall patient group 
undergoing resection for pancreatic cancer. The 
hazard ratios quoted for each variable reflect the in­
crease in the relative hazard of death associated with 
each unit increase in the prognostic variable.
The prognostic value of preoperative CRP in the 
overall patient group for whom levels were recorded 
was not significant (« = 121; P = 0.309). However, 
this was found to be significant when excluding a 
small number {n = 8) of outlying cases with preop­
erative CRP levels >100 mg/1 {n = 113; P = 0.021). 
Figure 3A illustrates this relationship when using a 
cutoff value of 10 mg/1 (this value was selected 
according to the normal laboratory reference range 
for CRP). The eight excluded patients with CRP 
levels >100 mg/1 all underwent intervention for bili­
ary drainage; the median preoperative bilirubin level 
recorded for these patients was 140 (IQR 64-249) 
jamol/1, the median alkaline phosphatase level was 
232 (168-534) U/l and the median WBC was 13.2 
(10.3-15.3) x 109/1. The median survival for this ex­
cluded group was 13.3 months.
Univariate Cox analysis demonstrated a significant 
inverse association between preoperative albumin 
levels and postoperative survival (P = 0.016) while 
elevated alkaline phosphatase levels were also asso­
ciated with a significant trend towards poorer post­
operative survival (P = 0.011). Figure 3B and C 
show the results of the Kaplan-Meier analyses to 
illustrate these survival trends. Preoperative alanine 
aminotransferase (P = 0.807), y-glutamyl transferase 
(P = 0.233) and prothrombin time (P = 0,822) 
failed to exhibit any association with overall survival.
Table 2 also shows the results of a multivariable 
Cox proportional hazards analysis including preop­
erative CRP, albumin and alkaline phosphatase levels 
as prognostic variables alongside the resected histo­
logical tumour characteristics of significance. CRP 
(P = 0.038) and albumin (P = 0.008) were found to 
maintain significance on multivariable analysis 
alongside the lymph node ratio (P = 0.018).
The Influence of Preoperative Bilirubin Levels on Early 
Postoperative Survival in Resected Pancreatic Cancer 
Patients Undergoing Biliary Stenting
Although preoperative bilirubin levels were not 
found to exhibit a significant relationship with overall 
survival when modelled as a continuous variable
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FIG. 3. Kaplan-Meier cumulative survival curves according to preoperative C-reactive protein (A), alkaline phosphatase (B), albumin (C) 
and bilirubin (D).
(Table 2), Fig. 3D demonstrates a clear trend towards 
less favourable early survival in jaundiced patients 
(i.e., bilirubin levels >35 pmol/l) at the time of resec­
tion (Breslow-Gehan-Wilcoxon, P = 0.013). An 
additional multivariable analysis was undertaken in 
order to identify whether this observed relationship 
between resolution of jaundice and early survival was 
independent of other factors. A second Cox model 
was used to investigate which prognostic variables 
were specifically associated with 6-month survival 
(Table 3). Only patients undergoing preoperative 
biliary drainage were included in this analysis 
(n = 130). All cases who survived beyond 6 months 
(n = 100) were censored at 6 months for the purposes 
of this analysis. The results from this additional Cox 
model suggest that the association between residual 
jaundice at the time of resection and early survival was 
independent of other prognostic factors. CRP failed 
to exhibit any effect on early survival even when 
excluding cases with levels >100 mg/1 (P = 0.731). 
This trend was also evident from Fig. 2A. There were 
no clinicopathological differences between stented
patients who did or did not experience resolution of 
jaundice at the time of resection (data not shown).
DISCUSSION
There is currently no general consensus regarding 
whether preoperative biliary drainage prior to surgi­
cal intervention represents the optimal management 
approach in patients presenting with potentially 
resectable pancreatic cancer. A meta-analysis has 
suggested that preoperative intervention for biliary 
drainage is associated with an increased risk of early 
postoperative morbidity (principally relating to 
wound infection). However, no overall association 
between biliary drainage and perioperative mortality 
was identified in this study.'' This meta-analysis was 
based on level 1 evidence from five randomised trials 
comprising 302 periampullary cancers in total.13-17 
Less than half of these patients had pancreatic ade­
nocarcinoma and a similar proportion of the overall 
group actually underwent resection. These five trials
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TABLE 3. Multivariable Cox proportional hazards analysis of preoperative jaundice (i.e., bilirubin >35 nmol/1) as a predictor
of early survival in cases undergoing preoperative biliary drainage
Cox model to evaluate factors predictive of early survival
Univariate Cox analysis Multivariable Cox analysis (/i = 120)
Hazard ratio (95% Cl) *2 P Hazard ratio (95% Cl) r P
Bilirubin >35 gmol/l 5.058 (1.993-12.840) 11.635 <0.001 3.319 (1.245-8.849) 5.748 0.017
Albumin* 0.897 (0.842-0.955) 11.382 <0.001 0.913 (0.837-0.997) 4.110 0.043
Alkaline phosphatase* 1.001 (1.000-1.002) 3.161 0.075 - - -
CRP* 0.999 (0.987-1.011) 0.035 0.852 - - -
Tumour size* 1.040 (1.008-1.073) 6.083 0.014 1.037 (1.004-1.072) 4.783 0.029
Poor tumour differentiation 2.271 (1.002-5.150) 3.858 0.049 1.974 (0.814-4.790) 2.264 0.132
Lymph node ratio* 3.111 (0.416-23.273) 1.222 0.269 - - -
Resection margin positive 1.389 (0.548-3.524) 0.479 0.489 - - -
Adjuvant chemotherapy 0.124 (0.017-0.919) 4.175 0.041 0.202 (0.027-1.538) 2.385 0.123
* Albumin, alkaline phosphatase, CRP, tumour size and lymph node ratio were analysed as continuous covariates. Resection margin status 
(R1 versus RO) and adjuvant chemotherapy (yes versus no) were also analysed as categorical covariates. There were 22 deaths within 6 months 
of surgery in the 120 patients included in the multivariate Cox model. Patients who survived >6 months were right-censored in this Cox 
analysis in order to describe the relationship between prognostic covariates and early survival.
Statistically significant /’-values (i.e., those <0.050) were highlighted in bold.
encompassed a mix of both endoscopic and percu­
taneous procedures and included cases undergoing 
both internal and external drainage. The median 
bilirubin level at the time of surgery for the pooled 
patient group undergoing preoperative biliary drain­
age was recorded as 157 pmol/1. This represents a 
significantly greater value than the result recorded in 
the present study (25 jmiol/1). Given the mix of pe­
riampullary tumours and the inclusion of both re­
sected and unresected cases in the above meta­
analysis, the overall findings from this study might 
not be reliably extrapolated to the specific setting of 
resected pancreatic cancer. Nevertheless, the results 
of the present study are concordant with the above 
findings in that biliary stenting per se was not shown 
to have any adverse effect on early or late survival in 
the overall patient group undergoing partial pancre­
atoduodenectomy for pancreatic cancer. Given the 
limited number of unstented patients in this analysis, 
the negative finding from this analysis may be the 
result of inadequate sample size.
No analysis of postoperative morbidity was 
undertaken in the present study as the association 
between preoperative biliary drainage and perioper­
ative complications has been extensively evaluated 
elsewhere.5-8 The relationship between preoperative 
jaundice and cancer-specific versus operative-related 
mortality could not be analysed in this study as 
insufficient clinical information was available to 
make a reliable retrospective assessment of cause of 
death in those patients who died within 6 months of 
surgery following discharge from hospital.
The principal finding of this study was the ob­
served association between residual jaundice at the
time of surgery and less favourable early survival. A 
recent abstract has also suggested that preoperative 
liver function may represent a significant predictor of 
survival in resected pancreatic cancer.18 In the present 
study, separation of the survival curves was only 
evident within the first 12 postoperative months 
resulting in a significant P-value when using the 
Breslow-Gehan-Wilcoxon test, but not the log rank 
(Cox-Mantel) test. The Breslow-Gehan-Wilcoxon 
test is calculated according to the number of patients 
at risk along each point of the survival curve and 
provides a better discriminator of differences in early 
survival between two groups—the follow-up period 
during which the majority of patients are still alive.11 
In comparison, the log rank test, which is calculated 
according to equal weighting at each point along the 
survival curve, provides a better indication of differ­
ences in overall and late survival.
The relationship between jaundice at the time of 
surgery and early survival in patients undergoing 
preoperative biliary drainage was further investigated 
by generating a conditional Cox regression model 
where all events occurring after a specified time period 
(i.e., 6 months) were considered as censored in order 
to analyse the effect of multiple covariates on early 
survival. The process of “fixed right-censoring” is 
analogous to “end-of-study censoring” where a study 
is designed in such a way as to assess survival only 
within a specified follow-up period. Events occurring 
after this are censored at the point of the maximum 
follow-up period (as per the Cox model used in the 
present study). This type of fixed censoring is nonin- 
formative, allowing use of standard likelihood-based 
statistical approaches (i.e., log rank, Cox regression,
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etc.) for comparative analyses of survival within a 
specified follow-up period.19 The results from this 
analysis indicate that the adverse association between 
residual jaundice at the time of surgery and early 
postoperative survival was independent of hypoalbu- 
minaemia and histological parameters.
The results demonstrate that the majority of pa­
tients with resectable pancreatic cancer who present 
with obstructive jaundice can undergo successful 
preoperative biliary drainage at ERCP. The median 
bilirubin level at the time of surgery was 24 pmol/1 in 
this patient group, reflecting an 85% median reduc­
tion in bilirubin levels from presentation. Of the small 
proportion of patients who could not be stented 
endoscopically who went on to undergo percutaneous 
drainage, these patients also had a significant reduc­
tion in bilirubin levels. However, despite more inva­
sive intervention, these patients were still less likely to 
experience resolution of jaundice at the time of 
resection. The results also demonstrate that a longer 
period of preoperative biliary drainage was inversely 
correlated with bilirubin levels at the time of surgery. 
These findings suggest that a balance exists with re­
gard to the optimal timing of definitive surgery for 
this patient group, in order to allow resolution of 
jaundice where possible without compromising the 
window of opportunity for tumour resectability. This 
issue is particularly relevant for patients where bor­
derline features of resectability are present on initial 
imaging or where resolution of jaundice is protracted, 
even following percutaneous intervention. The deci­
sion-making process regarding the optimal timing of 
surgery is clearly a multifactorial one which may need 
to incorporate a number of additional logistical issues 
and should be considered on an individual patient 
basis. However, the observations from the present 
study indicate that early survival outcomes may be 
adversely influenced by inadequate resolution of 
preoperative jaundice.
Elevated CRP levels were found to be associated 
with overall but not early survival when excluding 
patients with preoperative CRP values >100 mg/1. 
Cholangitis represents the most common cause for 
acute sepsis preoperatively in patients undergoing 
biliary decompression and stenting has also been 
shown to be associated with positive bile cultures at 
laparotomy.20,21 Several studies have demonstrated 
that pre-resection CRP levels represent a potential 
prognostic factor in other gastrointestinal malignan­
cies.22-24 In the single previous study in resected 
pancreatic cancer (n = 65), an adverse association 
between elevated preoperative CRP and survival was 
shown on univariate but not multivariate analysis.25
The results from the present study demonstrate that 
the relationship between elevated preoperative CRP 
levels and poorer survival is only evident when 
excluding a small number of outlying patients with a 
significantly elevated CRP. It was not possible to 
determine which patients in this study had preopera­
tive clinical features of cholangitis on a retrospective 
basis and the selection of a CRP cutoff value of 
100 mg/1 for exclusion was a pragmatic one rather 
than being based on any predefined diagnostic crite­
ria. However, when analysing the eight excluded pa­
tients with CRP levels >100 mg/1, this subgroup of 
patients all underwent preoperative intervention for 
biliary drainage and had biochemical findings con­
sistent with biliary sepsis at the time of CRP estima­
tion. It was therefore felt to be reasonable to conclude 
that the disparity in the survival analyses outlined 
above was principally due to the confounding effect of 
cholangitis in the group of eight patients with signif­
icantly elevated CRP levels. The median survival of 
these eight excluded patients was also found to be 
comparable with the overall patient group, indicating 
that the exclusion of these patients from the Cox 
analysis would be unlikely to have a significant effect 
in skewing the overall survival results.
Although there was no significant difference be­
tween preoperative CRP levels in patients requiring 
endoscopic biliary drainage when compared with 
unstented patients, percutaneous intervention was 
associated with higher CRP levels at the time of sur­
gery. Percutaneous access to the biliary tree is clearly a 
more invasive route than that associated with ERCP. 
Furthermore, patients who required PTC or com­
bined procedures would have already undergone one 
or more unsuccessful attempts at endoscopic biliary 
stenting. Therefore, the association between elevated 
CRP levels and PTC is likely to reflect the increased 
tissue damage associated with percutaneous access in 
addition to increasing the degree of bactobilia and 
consequent likelihood of biliary sepsis due to the 
cumulative effect of previous endoscopic biliary 
instrumentation prior to successful drainage. Our re­
sults suggest that, while elevated preoperative CRP 
levels exhibit an independent association with overall 
survival, the presence of cholangitis and the require­
ment for percutaneous biliary decompression are 
likely to represent significant confounding factors 
when interpreting the prognostic value of preopera­
tive CRP levels in this patient group.
Preoperative albumin levels were found to be a 
significant predictor of both early and overall survival 
in the present study. Although previous studies have 
demonstrated that hypoalbuminaemia is associated
Atm. Smg. Oncol.
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with less favourable survival outcomes in patients 
with inoperable pancreatic cancer26 and higher mor­
bidity and mortality rates following partial pancre­
atoduodenectomy,27 no previous study has shown 
that pre-resection albumin levels are also associated 
with overall postoperative survival following resec­
tion for pancreatic cancer.25 The causative mecha­
nism for this association is unclear but impaired liver 
function and nutritional status at the time of surgery 
may be implicated. A recent study has suggested that 
the introduction of immuno-enriched nutritional 
supplements in the preoperative setting may yield 
significant improvements in early postoperative out­
comes for patients undergoing major pancreatic 
resections.
A multicentre randomised controlled trial which 
specifically aims to answer the question of whether 
preoperative biliary drainage or prompt surgical 
intervention represents the optimal management ap­
proach in potentially resectable pancreatic and pe­
riampullary cancer is currently being conducted.29 
The results of the present study suggest that the 
presence of jaundice at the time of pancreatic resec­
tion has an adverse impact on early, but not overall, 
postoperative survival in resected pancreatic cancer 
patients undergoing preoperative biliary drainage.
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bstract
udcgroum/: The aim of this study was to identify whether 
eoperative CA19-9 levels might represent an independent 
ognostic marker for overall survival in patients undergo- 
g resection for pancreatic ductal adenocarcinoma, and to 
sscribe the relationship between CA19-9 and tumour his- 
>logy. Methods: 109 patients who had a pancreatoduode- 
“ctomy for pancreatic ductal adenocarcinoma with record- 
i preoperative CA19-9 levels were identified from a 
rospectively maintained database (1997-2006). Multivari- 
:e analysis was conducted using a Cox proportional haz- 
ds model with continuous covariates where possible. Re- 
//fs:The median survival of 64 patients with a preoperative 
A19-9 level >150 kll/l was 10.4 months while in 45 patients 
ith a CA19-9 level ^150 kU/l this was 22.1 months (correct- 
d p = 0.012). Also significant on univariate analyses were 
/erall lymph node status (p = 0.011), lymph node ratio (p = 
003) and tumour diameter (p = 0.004). Preoperative CA19- 
levels >150 kU/l were associated with a larger, more poorly 
ifferentiated tumour along with an increased likelihood of 
positive resection margin status (all p<0.05). Preoperative 
A19-9 levels (p = 0.030) and lymph node ratio (p = 0.042)
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emerged as independent predictors of survival on multivar­
iate analysis. Conclusions: Preoperative CA19-9 levels and 
lymph node ratio were significant predictors of survival in 
resected pancreatic ductal adenocarcinoma.
Copyright © 2008 S. Karger AG, Basel
Introduction
The carbohydrate antigen 19-9 (CA19-9), a sialyated 
Lewis blood group antigen [1], is expressed in normal 
pancreatic ductal cells [2], and is also secreted in a mucin- 
bound form by the biliary and gallbladder mucosa and 
excreted in bile [3-5]. Obstructive jaundice will com­
monly precipitate elevated serum concentrations [6], and 
around 5% of the population are believed to lack the Lew­
is antigen glycosyltransferase enzyme required to syn­
thesize CA19-9 [7]. A cut-off level of >37 kU/l is gener­
ally used as the optimal point at which pancreato-biliary 
malignancy can be differentiated from benign disease in 
symptomatic patients [8]. Although a CA19-9 cut-off val­
ue of >300 kU/l has previously been demonstrated to be 
required in order to diagnose biliary malignancy in the 
presence of concurrent cholestasis, CA19-9 levels for di­
agnostic purposes were not shown to be significantly af­
fected by the presence of obstructive jaundice in cases of 
pancreatic malignancy [8].
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Adopting a level of >150 kU/1 targets a patient popula- 
m for whom the diagnostic yield from staging laparos- 
py is maximised in terms of detecting occult metastat- 
disease [9]. One study demonstrated marked variability 
the pattern of CA19-9 change following preoperative 
solution of obstructive jaundice in cases of pancreatic 
[enocarcinoma, with levels falling in some cases and in­
easing in others [10]. Normalisation of CA19-9 levels 
[lowing resection for pancreatic cancer has been shown 
be associated with a significant improvement in subse- 
ient survival [11-13]. However, only a small number of 
tidies have investigated the potential role of preoperative 
&19-9 levels in isolation as a prognostic index [14-16],
It was the objective of this study to investigate wheth- 
CA19-9 levels might provide meaningful prognostic 
formation prior to resection for pancreatic ductal ade- 
icarcinoma. In addition, we sought to investigate the 
lationship between preoperative CA19-9 levels and his- 
logical tumour characteristics and the extent to which 
mcurrent cholestasis might act as a confounding factor, 
le prognostic value of the lymph node ratio was spe- 
fically evaluated as this parameter has recently been 
monstrated to represent a more powerful prognostic 
arker than the overall nodal status in resected pancre- 
ic cancer [17,18]. Postoperative normalisation of CA19- 
levels was also investigated for comparative purposes.
Patients and Methods
Consecutive pancreatic cancer patients undergoing pylorus- 
eserving partial pancreatoduodenectomy or classical Kausch- 
hipple resection between January 1997 and September 2006 at 
e Royal Liverpool University Hospital were identified from a 
ospectively maintained database. Only patients with histologi- 
lly confirmed pancreatic ductal adenocarcinoma were included, 
ita collected included patient demographics, operative details, 
stological tumour characteristics including origin and classifi- 
tion of the primary tumour, nodal status, tumour size, differen- 
ition and resection margin status. A positive margin was defined 
the presence of at least one cancer cell within 1 mm of one or 
ore resection margins on microscopic examination. Pathology 
porting was undertaken using the Royal College of Pathology 
uidelines [19] according to the WHO classification [20] and 
aged using the 6th edition of the UICC TNM system [21]. Details 
'preoperative intervention for biliary drainage, adjuvant therapy 
ceived along with serum CA19-9 and bilirubin levels were also 
corded. Survival data were obtained from hospital computer re- 
irds, and date of last clinic attendance for censored cases.
Statistical Analyses
Median, interquartile range (IQR) and 95% confidence inter- 
lIs (Cl) were used to describe the data. Continuous data were 
lalysed using the two-tailed Mann-Whitney U test with x2 and
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Fishers exact for categorical data. Correlations between two con­
tinuous variables were analysed by Spearman’s rank correlation. 
Survival data were analysed using the Kaplan-Meier method with 
corrected log-rank (Cox-Mantel) testing. Multivariate analysis 
was performed for variables with or approaching univariate sig­
nificance using a Cox proportional hazards model with non-step- 
wise regression.
A corrected log-rank p value was used for a single 'optimal1 
cut-off value and parameters of interest were modelled as con­
tinuous covariates in a Cox model in order to obtain a more mean­
ingful multivariate analysis [22]. This is because dichotomizing a 
continuous prognostic covariate can produce significant bias due 
to an inflated type I error rate along with the fact that significance 
can be seen to be vary when using a number of different cut-off 
points for the parameter of interest, frequently resulting in an 
overestimated significance level on univariate analysis along with 
a disproportionate weighting on subsequent multivariate analysis 
[22-24]. Variables including preoperative CA19-9, tumour size 
and the lymph node ratio were, therefore, modelled as continuous 
covariates. CA19-9 levels were normalized for Cox modelling by 
logarithmic transformation (lnCA19-9).
All patients who died within 30 days of surgery were excluded 
from the survival analyses. Statview version 5 (SAS, Cary, N.C., 
USA) and Microsoft Excel (Microsoft Office 2002; Microsoft, 
Redmond, Wash., USA) were used to perform the various statisti­
cal functions.
Results
Relationship between P?'eoperative CA19-9 and
Bilirubin Levels
In total, 532 consecutive patients had either resection 
(n = 353) or palliative bypass (n = 179) for pancreatic or 
periampullary tumours, of whom 297 underwent pancre­
atoduodenectomy. Of these, 132 had histologically con­
firmed pancreatic ductal adenocarcinoma. Three deaths 
were excluded (2%) and in 20 patients preoperative CA19- 
9 levels were not available, leaving 109 patients for analy­
sis (table 1). Analysis of the excluded patient group due to 
missing CA19-9 data demonstrated no difference in over­
all median survival when compared with the study group 
[14.2 months (95% Cl = 8.3-24.1) vs. 13.9 months (95% 
Cl = 12.3-17.0), respectively, log-rank test, p = 0.668]. In 
cases where more than one CA19-9 level was recorded pri­
or to resection, the result taken nearest to the date of sur­
gery was used for analysis. A significant correlation be­
tween preoperative lnCA19-9 and concurrent bilirubin 
levels was demonstrated in 93 patients where both results 
were available (r - 0.265,95% Cl = 0.065-0.445, p = 0.011). 
75 patients (81%) had preoperative CA19-9 and bilirubin 
levels recorded within 24 hours of each other, 7 (8%) with­
in 2 days, 5 (5%) within 3 days and 6 (6%) within 3-7 
days.
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g. 1. Logarithmic plot of corrected p values for survival analysis 
3g-rank) using various cut-off points for preoperative CA19-9 
a prognostic marker.
Fig. 2. Kaplan-Meier cumulative survival curves for pancreatic 
ductal adenocarcinoma patients undergoing resection stratified 
by preoperative CA19-9 levels >150 kU/l.
CA19-9 and Univariate Survival
The overall median survival of the 109 patients was 
L9 months (95% Cl = 12.3-17.0). There were 80 deaths 
id a median follow-up time of 12.0 months (IQR = 8.3- 
5.1) for the 29 censored cases. Using various cut-off val­
es for CA19-9, a level approximating to 150 kU/l was 
>und to represent the transition point at which a signif- 
ant survival difference was reached (fig. 1). This ‘transi­
on point’ was recorded as the point at which the p value 
ecorded on the y-axis) fell below 0.01, not the lowest 
oint along the curve (i.e. the ‘minimum p value’). A pre- 
perative CA19-9 of >150 kU/l was therefore selected to 
ratify patients for subsequent survival analyses. A cor- 
;cted log-rank p value [22] was calculated when exclud- 
ig 5% of the smallest and largest values of CA19-9 as 
otential cut-off points using the formula pcor = -3.13p
1 + 1.65logep).
Sixty-four patients with a CA19-9 level of >150 kU/l 
ad a median survival of 10.4 months (95% Cl = 9.1-13.9) 
ampared to 22.1 months (95% Cl = 15.4-34.9) for 45 pa- 
ents with a CA19-9 level ^150 kU/l (log rank - pcor = 
.012, fig. 2). Adjuvant therapy was given to 16 of 45 cas- 
s with a preoperative CA19-9 ^150 kU/l, compared to
2 out of 64 with levels >150 kU/l. There were three pa- 
ents overall who received neo-adjuvant therapy for lo- 
ally advanced disease who were subsequently down-
Table 1. Distribution of preoperative CA19-9 and bilirubin pa­
rameters in resected pancreatic ductal adenocarcinoma
Patients 109
Male:female 65:44
Median age, years 66(60-73)
Median preoperative CA19-9, kU/l 231 (66-650)
Median interval from preoperative
CA19-9 to surgery, days 26(17-37)
Cases with normal/abnormal preoperative CA19-9
Normal (<37 kU/l) 15(14%)
Abnormal (>37 kU/l) 94 (86%)
Median preoperative bilirubin recorded
(n = 93), (xmol/l 86 (34-238)
Cases with jaundice/no jaundice when CA19-9 taken (n = 93)
No jaundice (<35 p.mol/1) 24 (26%)
Jaundice (>35 |xmol/l) 69 (74%)
Preoperative intervention for biliary drainage (n = 109)
ERCP + stent 85 (78%)
PTC + stent/external drainage 5(5%)
None 19(17%)
Timing of preoperative CA19-9 (n = 81)1
Before stenting 31 (38%)
After stenting 50 (62%)
Figures in parentheses represent the IQR or percentages.
1 Cases undergoing preoperative biliary drainage where date
of endoscopic retrograde cholangiopancreatography or percuta-
neous transhepatic cholangiography was recorded.
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blc 2. Median survival times according to preoperative CA19-9 
d histological subgroups
triable Median overall 
survival, months
P
(log-rank)
eoperative CA19-9
<150 U/ml (n = 45) 22.1 (15.4-34.9) 0.012
>150 U/ml (n = 64) 10.4 (9.1-13.9) (corrected)
)dal status
Negative (n = 21) 24.1 (14.6-63.8) 0.011
Positive (n = 88)
.„i
13.3(10.4-15.5)
Sv
<20 mm (n = 27) 22.5 (14.3-31.2) 0.053
>20 mm (n = 81) 13.3(10.4-15.4)
imour differentiation1
Well (n = 14) 22.6 (12.5-30.4) 0.066
Moderate (n = 58) 15.4(15.4-19.7)
Poor(n = 36) 12.6 (6.8-16.1)
section margin status
Negative (n = 29) 16.7 (12.5-30.4) 0.067
Positive (n = 80) 13.3(10.4-15.5)
stage
T1/T2 (n = 21) 16.6(12.5-37.1) 0.103
T3/T4 (n = 88) 13.7(10.0-16.1)
Figures in parentheses contain the IQR. Due to the small num- 
r of well-differentiated tumours, well- and moderately differ- 
tiated tumours were grouped together for analysis.
1 Histological data incomplete for one case.
staged. Table 2 demonstrates the median survival times 
associated with the various histological tumour charac­
teristics.
No significant difference was observed when compar­
ing the median bilirubin levels (79 vs. 94 (xmol/1; Mann- 
Whitney, p = 0.185) or the proportion of jaundiced pa­
tients (30 vs. 46%; x2> P = 0.290) when grouping patients 
according to preoperative CA19-9 levels <150 kU/1 or 
>150 kU/1, respectively. The median survival of 90 pa­
tients (83%) undergoing endoscopic retrograde cholan­
giopancreatography or percutaneous transhepatic chol­
angiography for stenting or external drainage prior to 
resection was 14.3 months (95% Cl = 12.5-21.3) com­
pared to 13.7 months (95% Cl = 6.9-17) for 19 patients 
(17%) who underwent no preoperative intervention for 
biliary drainage (log-rank - p = 0.698).
Relationship between CA19-9 and Tumour Histology
A CA19-9 level of >150 kU/1 was significantly associ­
ated with tumour size, resection margin status and tu­
mour grade, but not nodal status or tumour stage (ta­
ble 3). There was a significant correlation between preop­
erative lnCA19-9 and tumour size [r = 0.358 (95% Cl = 
0.166-0.525), n = 108, p < 0.001], but not lymph node ra­
tio [r = 0.019 (95% Cl = -0.187 to 0.224), n = 107, p = 
0.427]. The lymph node ratio could be calculated for 107
bl« 3. Relationship between 
eoperative CA19-9 and histological 
mour characteristics (n = 109)
Patients (stratified by Median CA19-9
preoperative CA19-9 levels) level kU/1
CA19-9 CA19-9 p (x2)
<150 kU/1 >150kU/l
Tumour size (n = 108)1
<20 mm 18 9 0.005 73 (38-258)
>20 mm 27 54 324(116-1,009)
Nodal status (n = 109)
Negative 11 10 0.251 128 (26-395)
Positive 34 54 246 (79-738)
T stage (n = 109)
T1and T2 10 11 0.512 162 (41-493)
T3and T4 35 53 233 (71-713)
Resection margin (n = 109)
Negative 17 12 0.027 90(45-476)
Positive 28 52 280 (107-947)
Differentiation (n = 108)1
Well/moderate 36 36 0.023 162 (51-610)
Poor 9 27 284(152-771)
Figures in parentheses contain the IQR.
1 Histological data incomplete for one case.
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ises. The median number of lymph nodes sampled was 
1 (IQR = 11-25) and the median lymph node ratio for 
3de positive cases was 0.24 (IQR = 0.16-0.33).
Postoperative CA19-9 and Survival
56 out of 94 patients with an elevated preoperative 
A19-9 level (>37 kU/1) had postoperative CA19-9 levels 
corded within 3 months of resection at a median inter- 
il of 47 days (IQR = 34-66). The median postoperative 
A19-9 was 47 kU/1 (IQR = 23-138). There were 25 pa- 
ents with a normal CA19-9 after resection with a me- 
lan survival of 28.4 months (95% Cl = 14.6-38.5) com- 
ired with 10.4 months (95% Cl = 9.1-14.3) for 31 patients 
ith an elevated postoperative CA19-9 (corrected log- 
ink p = 0.012; fig. 3).
Eleven out of 12 patients with a normal preoperative 
A19-9 level in whom postoperative levels were record- 
1 within 3 months of surgery had normal postoperative 
vels [median survival = 17.0 months (95% Cl = 13.8- 
).7)] compared with one patient where the postopera- 
ve CA19-9 rose to 133 kU/1 - this patient survived 7.5 
tonths. There was a significantly reduced likelihood 
:isher’s exact test, p < 0.001) of postoperative CA19-9 
Drmalisation in cases with preoperative CA19-9 levels 
150 kU/1 (9 out of 36) compared with cases who had 
reoperative CA19-9 levels of 38-150 kU/1 (16 out of 
)).
ible 4. Univariate and multivariate 
irvival analysis (Cox proportional Prognostic markers Univariate Multivariate analysis (n = 105)
izards) for CA19-9 and histological 
ognostic factors
analysis, p value Hazard ratio p value
lnCA19-9l (n = 109) 0.001 1.17(1.02-1.35) 0.030
Lymph node ratio1 (n = 107) 0.003 3.75(1.05-13.35) 0.042
Tumour size1 (n = 108)
Tumour differentiation (n = 108)
0.004 1.02(1.00-1.04) 0.071
Well/moderate
Poor
Resection margin status (n = 109)
0.066 1.24 (0.74-2.07) 0.421
Negative
Positive
0.067 1.001 (0.52-1.93) 0.998
Figures in parentheses are the 95% Cl values.
1 Modelled as continuous covariates on both univariate and multivariate analysis; 
hazard ratios for continuous data reflect an increase in relative risk of death with each 
incremental increase in the covariate value of 1 unit. Histological data was incomplete 
for a small number of patients, hence the final multivariate model included 105 cases.
Multivariate Survival Analysis 
Of the five variables selected from univariate analysis, 
only the preoperative CA19-9 (p = 0.030) and lymph node 
ratio (p = 0.042) maintained significance on multivariate 
analysis (table 4).
Number at risk:
CA19-9 ^37 kU/1 25 19 9 7 2
CA19-9 >37 kU/1 31 12 3 1 1
Fig. 3. Kaplan-Meier cumulative survival curves for pancreatic 
ductal adenocarcinoma cases according to postoperative normal­
isation of CA19-9.
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Discussion
Several histological tumour characteristics have been 
insistently demonstrated to have significant prognostic 
due in resected pancreatic adenocarcinoma [25-30]. 
lost notably, these include tumour size, nodal involve- 
lent (including lymph node 8a status), differentiation and 
section margin status. A number of molecular markers 
ave also been shown to be of prognostic value following 
:section[31-35]; however, these tumour characteristics, 
hether histological or biological in nature, are invariably 
nly amenable to assessment following surgery.
The results from the present study confirm that great- 
: preoperative CA19-9 levels are associated with a sig- 
tficantly reduced overall survival following resection 
>r pancreatic ductal adenocarcinoma. A clear statistical 
itionale is provided for the selection of a cut-off value of 
50 kU/1 in this analysis. Previous studies [14-16] that 
ave investigated the potential prognostic value of preop- 
:ative CA19-9 levels in resected pancreatic cancer di- 
aotomized the number of patients into high- and low- 
sk groups according to a single cut-off value for CA19-9 
ithout any attempt to correct for the potential bias as- 
iciated with this approach. The present study uses a 
:cognised method for correcting the quoted univariate 
•g-rank p values [22] and the multivariate analysis was 
inducted utilising continuous covariates in order to 
raid any bias associated with categorising continuous 
rognostic data [22-24].
The issue of concurrent jaundice as a confounding fac- 
>r in the interpretation of CA19-9 levels for prognostic 
arposes does not appear to be of importance in this con- 
;xt. When comparing the two patient groups stratified 
y preoperative CA19-9 levels, there was no significant 
ifference in either the median bilirubin levels recorded 
l* the overall proportion of jaundiced and non-jaundiced 
ises in each group. The strength of association between 
reoperative CA19-9 and bilirubin levels in the present 
:udy, while significant, only returned a relatively small 
defficient with a wide confidence interval, which includ- 
i values of very weak correlation. These results are con- 
stent with the findings from a previous study [8] which 
emonstrated that, in the context of diagnosing pancre- 
:ic malignancy in symptomatic patients, the presence of 
mcurrent obstructive jaundice did not significantly af- 
:ct the sensitivity or specificity of CA19-9 when using a 
:andard diagnostic cut-off value of 37 kU/1.
The deleterious survival outcome observed for cases 
ith preoperative CA19-9 levels >150 kU/1 was related to 
re association with a larger, more poorly differentiated
A19-9 Levels and Lymph Node Ratio in 
ancreatic Ductal Adenocarcinomas
tumour along with microscopic resection margin in­
volvement. These findings support the notion that preop­
erative CA19-9 levels are not only indicative of tumour 
burden, but also that CA19-9 levels may act as a marker 
of biological ‘aggressiveness’. This hypothesis is borne 
out by the finding that preoperative CA19-9 was a more 
significant variable when compared to tumour size or 
differentiation status alone. Given that the presence of lo­
cal or distant micrometastases at the time of surgery is 
believed to be the most significant factor in limiting long­
term survival for the majority of resected pancreatic can­
cer patients [36], it is a reasonable hypothesis to suppose 
that preoperative CA19-9 levels may also act as a marker 
of disseminated micrometastatic disease.
The lymph node ratio emerged as the only other sig­
nificant prognostic marker on multivariate analysis when 
analysed as a continuous covariate. This parameter has 
recently been demonstrated to reflect an important prog­
nostic index in a large series of patients undergoing resec­
tion for pancreatic ductal adenocarcinoma [17]. The 
lymph node ratio has also been shown to be a significant 
prognostic index following resection for both colorectal 
[37] and gastric malignancy [38], and is likely to be in­
creasingly used in future studies as a more representative 
reflection of overall nodal status following resection.
Analysis of postoperative changes in CA19-9 demon­
strated the expected improved survival associated with 
normalisation of levels within 3 months of surgery. The 
data also indicated that patients with a preoperative 
CA19-9 level >150 kU/1 were significantly less likely to 
experience normalisation of levels postoperatively.
These observations have two important implications. 
Firstly, the role of prognostic molecular markers [31-35] 
should be properly validated in studies that also include 
preoperative CA19-9 levels and the lymph node ratio ob­
tained by analysis of the tumour specimen. Secondly, 
stratification of patients according to both of these vari­
ables should be considered in future adjuvant trials [39, 
40].
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The platelet-lymphocyte ratio improves 
the predictive value of serum CA19-9 
levels in determining patient selection 
for staging laparoscopy in suspected 
periampullary cancer
Richard A. Smith, MRCS,a Lorraine Bosonnet, PGDip,a Paula Ghaneh, FRCS,a 
Robert Sutton, FRCS,a Johnathan Evans, FRCR,b Priya Healey, FRCR,b Connall Garvey, FRCR,b 
Mai*k Hughes, FRCR,b Michael Raraty, FRCS,“ Fiona Campbell, FRCPath,c 
John P. Neoptolemos, FRCS,a Liverpool, UK
Background. The objective of this study xuas to identify whether the preoperative platelet-lymphocyte (P/L) 
ratio might improve the predictive value of CA19-9 levels in stratifying a patient group luith suspected 
periampullary malignancy who do not require staging laparoscopy.
Methods. Patients with suspected periampidlary cancer were identified from a prospectively maintained 
10-year database. Only patients with resectable disease who undenvent staging laparoscopy and subsequent 
laparotomy zuere included. Low-risk groups zuere stratified using a CA19-9 cutoff value of^ 150 kU/l (or^ 
300kU/l in patients with a concmrentbilimbin concentration > 35 gmol/l) and a P/L ratio value of^ 150. 
Residts. From 263 patients, preoperative CA19-9 levels and P/L ratios zuere available in 216 and 225 
patients, respectively. The positive and negative predictive values for resectability, sensitivity, and specificity 
for CA19-9 levels ^ 150kU/l zuere 83%, 36%, 51%, and 73%, respectively. For P/L ratios^ 150, these 
levels zuere 81 %, 38%, 51 %, and 72%, respectively. When combining the requirement for both CA19-9 
levels and P/L ratios to be ^ 150 (n = 38 out of 183), both positive predictive value (95%) and specificity 
(96%) zuere improved (Fisher exact test, P =.065 and P < .001, respectively); 21 % of laparoscopies zuere 
avoidable zuhen using these ctiteria. IncreasingTstage (P = .005), vascular invasion (P < . 001), perineural 
invasion (P = .008), and resection margin involvement (P < .001) zuere all associated zuith greater preop­
erative P/L ratios in resected periampidlmy adenocarcinoma (n = 204).
Conclusiom. The preoperative P/L ratio reflects an index of tumor invasiveness and merits prospective 
evaluation as an adjunct to CA19-9 in determining the requirement for laparoscopic staging in patients 
zuith potentially resectable pmampullaiy malignancy. (Surgeiy 2008;143:658-66.)
Fro m the Division of Surgery and Oncology, School of Cancer Studies, University of Liverpool!1; 
and Departments of Radiology0; and Pathology0, Royal Liverpool University Hospital, UK
Operative resection remains the onlypotentially cur­
ative modality for periampullary adenocarcinoma.1 
Despite the availability of modern multidetector 
helical computed tomography (CT), a substantial 
proportion of patients with periampullary cancer 
and radiologically resectable disease will exhibit
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occult metastases or locally advanced disease at lap­
arotomy, thereby precluding the option of resec­
tion.2"4 Preoperative staging laparoscopy using 
laparoscopic ultrasonography has been investigated 
as a supplementary modality in this setting to mini­
mize the number of laparotomies conducted for un- 
resectable disease.5"7
CA19-9 is a Lewis blood group glycolipid anti­
gen that is used widely as a tumor marker in the 
preliminary diagnosis of suspected periampullary 
cancer, but it is known to lack specificity, because 
levels may be increased in the presence of pan- 
creatobiliary conditions resulting in cholestasis.8,9 
CA19-9 has been used as an additional diagnostic 
tool to select a patient group with tumors that 
appear resectable on CT, have a low risk of occult
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metastases and locally advanced disease, and who 
do not require laparoscopic staging.10"13 Use of a 
preoperative serum CA19-9 cutoff value of ^ 150 
kU/1 (or ^ 300 kU/1 in patients with concurrent 
serum bilirubin concentrations > 35 /xmol/1) are 
associated with a low incidence (5%) of advanced 
disease on subsequent laparoscopic assessment.10
Previous studies have suggested that preopera­
tive indices of systemic inflammation might pro­
vide prognosdc information in resected pancreatic 
cancer with increased levels of C-reactive protein,14 
thrombocytosis,1”’16 and lymphocytopenia,17’18 all 
having been reported to be associated with poorer 
survival outcomes in patients with pancreatic can­
cer undergoing resection. The potential value of 
preoperative markers of systemic inflammation in 
determining resectability has not been investigated 
previously. The objective of this study was to iden­
tify whether the preoperadve platelet-lymphocyte 
rado, a proposed index of systemic inflammadon, 
might be a clinically useful adjunct to CA19-9 levels 
in selecting a patient group with suspected periam­
pullary malignancy at low risk of advanced disease 
at laparotomy. An additional objective of this study 
was to define the relationship between the platelet- 
lymphocyte ratio and tumor histology in a group of 
patients undergoing resection for periampullary 
adenocarcinoma.
MATERIAL AND METHODS
Details of all referrals between January 1997 and 
September 2006 with suspected pancreatic and 
periampullary malignancy were collected prospec­
tively and maintained in a database. Patients 
undergoing contrast-enhanced computed tomog­
raphy (CT) were identified to select patients with 
radiologically resectable disease. Decision-making 
regarding tumor resectability was undertaken dur­
ing a weekly multidisciplinary team meeting. The 
principal CT criteria used to determine resectabil­
ity were based on the presence of intra- or extra­
abdominal metastatic disease and on vascular 
encasement or tumor involvement of the superior 
mesenteric-portal vein over >50% circumference 
and/or > 2 cm length. Patients with equivocal CT 
features for resectability (ie, patients with radio- 
logic features approximating the threshold values 
outlined above) who went on to undergo further 
staging and subsequent laparotomy were also in­
cluded in the analysis.
Only patients who underwent both staging lapa­
roscopy and attempted resection were included in 
the analysis. This approach was used to identify 
retrospectively what proportion of staging
laparoscopies conducted during the study period 
were potentially avoidable in the patient group 
undergoing exploration. Laparoscopic staging in­
cluded inspection of the peritoneal cavity along with 
intraoperative ultrasonographic assessment of the 
liver parenchyma and tumor relationships with local 
vasculature. Contraindications to laparoscopic stag­
ing included the presence of comorbid disease that 
would preclude consideration for further interven­
tion, gastric outlet obstruction requiring operative 
bypass, or multiple previous intra-abdominal oper­
ations. Patients with proven metastatic disease from 
intraoperative biopsy at laparoscopy were excluded 
from a laparotomy. Patients with equivocal laparo­
scopic features of resectability who went on to 
undergo laparotomy and attempted resection were 
classified as having potentially resectable disease for 
the purposes of the study. Laparoscopy and laparo­
scopic ultrasonography were in routine use at our 
institution for the entire duration of the study 
period.
The operative ciiteria for unresectable disease 
at laparotomy were based on the finding of any 
hepatic or peritoneal metastases proven on frozen 
section, vascular encasement, or tumor involve­
ment of the portal/superior mesenteric vein over
> 2 cm precluding the option of local resection. 
Venous resection was performed in 6% of all 
pancreatoduodenectomies conducted for pancre­
atic and periampullary malignancy during the 
study period. There were no significant differences 
in practice between surgeons regarding the oper­
ative criteria used to determine resectability at 
laparotomy.
Preoperative serum CA19-9 levels, concurrent 
serum bilirubin concentrations, and full blood 
count estimations were obtained. Where more 
than one result was recorded, the result taken 
nearest to the date of surgery was used for analysis. 
A CA19-9 cutoff value of ^ 150 kU/1 (or < 300 kU/1 
in patients with concurrent bilirubin concentrations
> 35 /wnol/l) was used to define a low-risk group for 
unresectable disease. This value was selected on tire 
basis of the previously published literature.8,10,12 
The platelet-lymphocyte ratio was calculated for all 
patients in whom a preoperative full blood count 
along with differential white cell count was re­
corded. Various cutoff values for the platelet-lym­
phocyte ratio were used to determine the 
optimum point at which the positive predictive value 
for resectability was maximized. A platelet-lympho­
cyte ratio of <150 was found to represent this point.
All patients with suspected periampullary cancer 
(including those with subsequently proven benign 
disease) were included in the analysis as the exact
660 Smith et al Surgery 
May 2008
Table I. Frequency of tumor type in patients with 
resectable disease according to computed
tomography assessment.
Histology
Pancreatic ductal adenocarcinoma 119
Ampullary adenocarcinoma 48
Cholangiocarcinoma 34
Other malignancy 24
Metastatic adenocarcinoma 25
(unconfirmed primary)
Presumed peripancreatic malignancy 4
Benign tumors 9
Total 263
origin and histologic nature of the primary is com­
monly unknown at the time of decision-making 
regarding operative intervention. Furthermore, the 
exact tumor origin is not established frequentiy in 
patients with locally advanced or metastatic disease 
identified at laparotomy. Therefore, this overall 
patient group reflects a more representative sample 
within which to study the predictive value of GA19-9 
and platelet-lymphocyte ratios in a clinically mean­
ingful setting.
A further group of patients was identified to 
analyze the relationship between the preoperative 
platelet-lymphocyte ratio and the histologic fea­
tures of resected periampullary tumors. Patients 
undergoing pancreatoduodenectomy for histolog­
ically confirmed periampullary adenocarcinoma 
during the same time period (with or without 
laparoscopic staging) in whom a preoperative full 
blood count result was available were recorded. 
Histopathology reporting was undertaken using 
the Royal College of Pathologists Guidelines19 
according to the 6th edition of the International 
Union Against Cancer (UICC) tumor-node-metas- 
tasis (TNM) classification20 and the 5 th edition21 
prior to 2002.
STATISTICAL ANALYSIS
Continuous data were described using the me­
dian and interquartile range (IQR) with 2-tailed 
Mann-Whitney U testing or Kruskal-Wallis testing 
for comparative analysis. Categorical data were 
analyzed using chi-squared (%2) or Fisher exact. 
Receiver operating characteristic (ROC) curves 
were used to analyse whether serum GA19-9 levels 
or platelet-lymphocyte ratios conferred superior 
predictive information with regard to tumor resect­
ability. Adjusted CA19-9 levels were calculated for 
these analyses by dividing the CA19-9 by 2 in 
patients with concurrent bilirubin concentrations
> 35 iUmol/1. The positive predictive value, negative 
predictive value, sensitivity, and specificity for 
resectability were calculated for CA19-9 levels 
< 150 kU/1 and platelet-lymphocyte ratios ^ 150 
both individually and in combination. The positive 
predictive value for tumor resectability reflects the 
likelihood of predicting correctly a resectable tu­
mor at laparotomy in the patient group analyzed.
RESULTS
A total of 1056 patients were recorded in the 
database during the study period; 675 patients 
were identified with CT resectable or borderline 
resectable pancreatic or periampullary tumors of 
whom 336 underwent staging laparoscopy. A total 
of 263 patients from this group went on to lapa­
rotomy with a resection rate of 72% (190/263). 
The median interval between laparoscopy and 
operation was 14 days (IQR, 7 to 28 days). The 
histologic diagnoses recorded in this group are 
shown in Table I. A total of 149 patients were male 
(57%), and the median age was 65 years (IQR, 58 
to 71 years).
A preoperative full blood count with differential 
white cell count was available in 225 patients; 188 
(84%) of these patients had a full blood count 
recorded within 2 days of operation, 22 (10%) 
within 2 to 7 days, and 15 (6%) within more than 7 
days prior to operation, and 216 patients had 
preoperative serum CA19-9 levels recorded. The 
median interval from the preoperative CA19-9 to 
date of operation was 26 days (IQR, 15 to 39 days). 
Concurrent serum bilirubin concentrations were 
available in 142 of these patients, 94 (66%) of 
whom had bilirubin concentrations of > 35 /rmol/ 
1. Where no concurrent serum bilirubin concen­
tration was available, the unadjusted CA19-9 was 
used for analysis.
The median adjusted CA19-9 levels and platelet- 
lymphocyte ratios recorded for patients with re­
sectable disease compared with locally advanced 
and metastatic disease at laparotomy are shown in 
Table II. The ROC curves for CA19-9 and platelet- 
lymphocyte ratios in predicting tumor resectability 
are shown in Fig 1. The area under the curve 
(AUC) recorded for the 2 prognostic indices was 
very similar: AUC = 0,67 (95% confidence interval 
[Cl], 0.58-0.76) for CA19-9 and AUC = 0.68 (95% 
Cl, 0,60-0.77) for platelet-lymphocyte ratio.
The predictive values of GA19-9 levels <150 kU/1 
in determining tumor resectability are shown in 
Table III. A positive predictive value, negative pre­
dictive value, sensitivity, and specificity of 83%, 36%, 
51%, and 73% were recorded respectively (n = 
216). The predictive values for platelet-lymphocyte
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Table II. Median platelet-lymphocyte ratio and adjusted CA19-9 levels recorded in resected and unresected 
periampullary tumors
Preoperative CA19-9 levels (kU/l) Preoperative P/L ratio
n Median CA19-9 (IQR) P n Median P/L ratio (IQR) P
Resected tumor 157 144 (27-569) .001 158 147 (113-208) <.001
Locally advanced 36 413 (106-4546) 43 202 (146-265)
Metastatic 19 1350 (232-2554) 22 176 (139-363)
P/L, Platelet-lymphocyte; IQR, interquartile range.
Quoted Pvalues for Kruskal-Wallis test. CA19-9 values are adjusted according to the presence of concurrentjaundice at the time of CA19-9 estimation. The 
reason for unresectability was not recorded in 4 patients in whom preoperative CA19-9 levels were available and 2 patients in whom platelet-lymphocyte 
ratios were available.
rados ^150 were comparable broadly with mines of 
81%, 38%, 51%, and 72%, respecdvely (n = 225). 
The predictive values of using the combined re­
quirement for both CA19-9 and platelet-lymphocyte 
ratio to be ^ 150 were 95%, 35%, 28%, and 96%, 
respectively (n = 183). These combined criteria 
resulted in an improved specificity over using 
CA19-9 in isolation (Fisher exact test, P < .001) 
and a borderline improvement in the positive pre­
dictive value for resectability (Fisher exact test, P = 
.065). If using both CA19-9 and platelet-lymphocyte 
ratio to guide decision-making regarding the re­
quirement for preoperative laparoscopic staging, 
21% (38/183) of laparoscopies would have been 
avoided with a false-positive rate for resectability at 
laparotomy of only 5% (2/38).
The median platelet-lymphocyte ratios associ­
ated with the various histologic features of 204 
resected periampullary tumors for which a preop­
erative full blood count result was available are 
shown in Table IV. This group comprised 113 pa­
tients with pancreatic ductal adenocarcinoma, 53 
with ampullary adenocarcinoma, and 38 with intra- 
pancreatic bile duct adenocarcinoma. Increasing 
platelet-lymphocyte ratios were associated strongly 
with T-stage (P = .005), perineural invasion (P = 
.008), vascular invasion (P < .001), and involve­
ment of the resection margin (P< .001). Figure 2 
illustrates the association between increasing me­
dian platelet-lymphocyte ratios and increasing T- 
stage in this group.
A separate analysis was conducted in this patient 
group to identify whether preoperative biliary’ 
stenting had any impact on the platelet-lympho­
cyte ratio recorded prior to operation. Fully 174 
patients (85%) undenvent some fonn of biliary 
drainage preoperatively (165 at endoscopic retro­
grade cholangiopancreatography and 9 at percu­
taneous transhepatic cholangiography). The 
median interval from stenting to surgery was 34 
days (IQR, 21 to 49 days). No difference in the 
median preoperative platelet-lymphocyte ratio was
Source of the Curve
° Reference Line
o P/L ratio
□ adjusted CAt 9-9
1 - Specificity
Fig 1. Receiver operating characteristic (ROC) curves to 
compare the predictive values of preoperative CA19-9 
and platelet-lymphocyte (P/L) ratio in determining dis­
ease resectability at laparotomy.
demonstrated when comparing those patients who 
underwent biliary drainage (median platelet-lym­
phocyte ratio, 157 [IQR, 113 to 219]) with those 
who did not (median platelet-lymphocyte ratio, 
156 [IQR, 120 to 327]) with the Mann-Whitney U 
test (P= .352).
DISCUSSION
Laparoscopic staging has been demonstrated to 
influence decision-making regarding operative in­
tervention in approximately 15% of patients with 
radiologically resectable periampullary malig­
nancy.5,22 Use of staging laparoscopy can minimize 
potentially unnecessary operative intervention in 
patients with locally advanced and metastatic dis­
ease missed by CT imaging and facilitate earlier 
administration of the most appropriate palliative 
therapy.23'20 Although endoscopic ultrasonogra­
phy represents a potential alternative staging mo­
dality to image tumor relationships with local 
vasculature along with regional adenopathy,2' the 
ability to inspect visually the peritoneal cavity and 
liver surface to exclude small metastatic deposits
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Table III. Contingency table for predictive values of preoperative CA19-9 and platelet-lymphocyte ratio in 
determining periampullary tumor resectability at laparotomy
Resectable cases Unresectable cases Predictive values (%)
Preoperative CA19-9 levels* < 150 kU/1 (n = 96) 80 16 PPV (83)
NPV (36)
> 150 kU/1 (n = 120) 77 43 Sensitivity (51) 
Specificity (73)
Preoperative P/L ratio < 150 (n = 100) 81 19 PPV (81)
NPV (38)
> 150 (n = 125) 77 48 Sensitivity (51) 
Specificity (72)
Combined CA19-9* and P/L ratio s 150 for both (n = 38) 36 2 PPV (95)
NPV (35)
> 150 for either (n = 145) 94 51 Sensitivity (28) 
Specificity (96)
PPV, Positive predictive value; NPV, negative predictive value; P/L, platelet-lymphocyte.
*CA19-9 cutoff value of £ 300 kU/1 used in jaundiced patients (ie, where concurrent bilirubin > 35 jumol/1).
represents the principal advantage of laparoscopy 
over other staging modalities. Staging laparoscopy 
has also been demonstrated to be as useful in influ­
encing operative decision-making for periampul­
lary tumors of nonpancreatic origin.28
Increased serum levels of CA19-9 represent a 
reliable marker of metastatic disease,12 but CA19-9 
levels are believed to be relatively less effective at 
identifying locally advanced disease.10 Low preop­
erative CA19-9 levels have been investigated previ­
ously as a potential means of reliably identifying 
patients with resectable periampullary tumors at 
laparotomy, thereby avoiding the requirement for 
supplementary staging in all patients.10'13 This 
approach presents the opportunity to make more 
judicious use of staging laparoscopy, which is par­
ticularly relevant in centers where laparoscopic 
staging is conducted routinely on separate theatre 
sessions prior to laparotomy. Previous single-center 
studies have reported favorable results associated 
with palliative gastrojejunostomy for gastric outlet 
obstruction due to inoperable malignancy in small 
patient series.29,30 No studies have been conducted 
to date, however, to suggest that routine laparo­
scopic palliative duodenal bypass represents an op­
timal management approach to prevent gastric 
outlet obstruction in patients for whom inoperable 
periampullary malignancy is identified prior to 
exploration.
Invasive cancer causes tissue damage adjacent to 
the tumor, which results in both a local and systemic 
chronic inflammatory response. Pancreatic cancer 
in particular is characterized by a marked, desmo­
plastic stromal reaction on microscopic examina­
tion that reflects an intense inflammatory and 
fibrotic host reaction to tumor.31 Inflammation re­
sults in release of both proinflammatory and
inhibitory immunologic mediators. Interleukin 
(IL)-10 and transforming growth factor-/? represent 
the most important inhibitory cytokines that can re­
sult in depressed lymphocyte function and reduced 
circulating lymphocyte counts.32 Pancreatic cancer 
cells have also been demonstrated to secrete directly 
both IL-10 and TGF-/32, thereby providing a mecha­
nism via which the tumor can evade immune surveil­
lance.33 Lymphocytopenia is associated with other 
gastrointestinal malignancies, including colorectal 
and gastric cancer.31
Megakaryocyte proliferation is promoted by a 
number of proinflammatory cytokines including 
IL-1, IL-3, and IL-6,35,36 resulting in thrombocyto­
sis. Increased platelet counts are also associated 
with several other malignancies including colorec­
tal,37 gastric,38 and esophageal cancer.39 Thrombo­
cytosis and lymphocytopenia both correlate with 
the degree of host systemic inflammation, and 
the platelet-lymphocyte ratio reflects a novel 
marker incorporating both hematologic indices. 
No previous studies to our knowledge have investi­
gated this parameter in any clinical setting.
The results of the present study suggest that the 
preoperative platelet-lymphocyte ratio correlates 
with features of local tumor invasiveness in patients 
with resected periampullary adenocarcinoma. In­
creasing T-stage, vascular invasion, and involve­
ment of die resection margin were associated with 
a trend toward greater median preoperative plate­
let-lymphocyte ratios in each of the three periam­
pullary tumor groups. Although tumors larger 
than 2 cm in diameter also resulted in a greater 
median platelet-lymphocyte ratio for ampullary 
and distal bile duct cancers, only ampullary 
cancers exhibited an association between nodal 
involvement and platelet-lymphocyte ratio,
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Fig 2. Box plots to illustrate relationship between me­
dian preoperative platelet-lymphocyte (P/L) ratios and 
T-stage in 204 resected periampullary adenocarcinomas. 
Dotted line reflects the “average” expected platelet-lym­
phocyte ratio for the normal population (ie, dividing 
the midpoint of the normal reference range for the 
platelet count [150-400 xl09/l] by the midpoint for 
the normal reference range of the lymphocyte count 
[1.0-3.5 xl09/l] - 275 ^ 2.25 = 122).
suggesting that a more marked host systemic im­
mune response is elicited according to the extent 
of local tumor invasion rather than metastatic 
spread. This observadon is also supported by the 
fact that a greater median platelet-lymphocyte 
rado was observed in padents with locally advanced 
periampullary tumors when compared with those 
with metastadc disease (Table II). This observation 
contrasts with the results for CA19-9, which dem­
onstrated greater median CA19-9 values in patients 
with metastadc disease at laparotomy, a finding 
consistent with previous studies.1-
Analysis of the ROC curves indicates that the 
overall predictive value of the preoperative plate­
let-lymphocyte rado is comparable with that seen 
for adjusted CA19-9 levels. The contingency tables 
for CA19-9 and platelet-lymphocyte ratio also 
resulted in a broadly comparable posidve predic­
tive value and specificity for both. The combined 
use of CA19-9 levels < 150 kU/1 (or < 300 kU/1 in 
jaundiced padents) and a platelet-lymphocyte rado 
^150 resulted, however, in a significant improve­
ment in the ability to idendfy a low-risk group for 
unresectable disease at laparotomy with a posidve 
predicdve value for resectability’ of 95% and a 
specificity of 96%. Use of these combined criteria 
for selecdve use of staging laparoscopy would have 
resulted in 38 of 183 laparoscopies (21%) being 
avoided, widi a false-posidve rate of only 5% (ie,
only 5% of patients going straight to laparotomy 
with unresectable disease). The poor negadve 
predicdve value and sensitivity for CA19-9 and 
platelet-lymphocyte rados indicate that neither 
parameter can predict reliably unresectable periam­
pullary’ tumors and, as such, invesdgadng the pre­
dicdve values of these parameters in the patient 
group with convincing evidence of advanced dis­
ease diagnosed at CT or laparoscopy would not 
result in any informadon that would alter deci­
sion-making regarding operative exploration.
It has been esdmated previously that less than 
5% of the overall population lack the Lewis and- 
gen glycosyi transferase enzyme required to syn­
thesize CA19-9.40 This represents a potendal 
confounding factor in interpreting the predicdve 
values associated with CA19-9; however, only 5 of 
216 padents (~2%) in the present study for 
whom a preoperative CA19-9 was recorded had un- 
recordable CA19-9 levels (< 2 kU/1). These pa­
tients were included in the analysis to avoid 
potendal bias, but this issue is unlikely to have 
any relevant impact on the validity of the CA19-9 
predicdve values recorded in this study.
Preoperadve biliary stendng represents an ad­
ditional, potendal confounding factor in interpret­
ing the predictive values of the platelet-lymphocyte 
rado. Instrumentation of the bile duct (w’hether 
endoscopic or percutaneous) is associated with a 
risk of biliary’ sepsis prior to operation, which may 
represent a potential cause for elevated preopera­
dve inflammatory markers. A previous study,11 
however, demonstrated that the incidence of post­
stenting cholangitis prior to pancreatoduodenec­
tomy is only 7%. Furthermore, although the 
majority of patients with resected periampullary 
cancer underwent preoperadve biliary drainage 
procedures in the present study, no difference in 
the median platelet-lymphocyte rado was recorded 
when comparing padents who did or did not un­
dergo biliary stendng. Given this finding, preoper­
ative intervention for biliary7 obstruction was not 
deemed to be a significant confounding factor in 
interpredng the results.
In summary7, our study suggests an association 
between preoperadve inflammadon and periam­
pullary’ cancer resectability. The preoperadve plate­
let-lymphocyte rado was associated with both 
macroscopic and microscopic features of periam­
pullary’ tumor invasiveness and appears to be a more 
effecdve marker of locally advanced disease than 
CA19-9. Use of both CA19-9 and platelet-lympho­
cyte rado in risk-stratifying padents with suspected 
periampullary malignancy for staging laparoscopy 
resulted in a significant improvement in the ability
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to identify those patients in whom supplementary 
staging can be avoided safely. The results of this 
study suggest that the preoperadve platelet-lympho­
cyte ratio merits prospecdve evaluation alongside 
CA19-9 in this setting.
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Abstract
BACKGROUND: The objective of this study was to investigate whether the preoperative platelet- 
lymphocyte (P/L) ratio represents a significant prognostic index in resected pancreatic ductal adeno­
carcinoma.
METHODS: A total of 110 patients undergoing pancreatoduodenectomy for pancreatic ductal ade­
nocarcinoma over a 10-year period were identified from a prospectively maintained database.
RESULTS: The preoperative P/L ratio was found to be a more significant prognostic marker (P < 
.001) than either the lymphocyte count (P = .007) or platelet count (P = .068) on univariate Cox 
survival analysis. The median overall survival in patients with a P/L ratio of 150 or less (n - 48) was 
19.7 months, 13.7 months in those with a P/L ratio of 151 to 300 (n = 43), and 5.8 months in patients 
with a value of greater than 300 (n = 19) (log-rank, P = .006). The preoperative P/L ratio retained 
significance on multivariate analysis (P < .001), along with tumor size (P = .010) and lymph node ratio 
(P = .013).
CONCLUSIONS: The preoperative P/L ratio represents a significant independent prognostic index in 
patients of resected pancreatic adenocarcinoma.
© 2009 Elsevier Inc. All rights reserved.
Of the 10% to 15% of patients who present with operable 
>ancreatic cancer, median survival after resection typically 
emains in the region of 12 to 18 months and less than 15% 
>f these patients can expect to live beyond 5 years.1 With
* Corresponding author. Tel.: +00-44-0151-7063898; fax: +00-44- 
1151-7065826.
E-mail address: rsmith3@liverpool.ac.uk
Manuscript received October 10, 2007; revised manuscript December 
., 2007
adjuvant chemotherapy, 5-year survival rates of more than 
20% have been achieved in recent randomized trials.2,3
Several histologic parameters of the resected pancreatic 
cancer specimen have been shown consistently to represent 
significant prognostic variables.4-10 These include tumor 
size, regional lymph node involvement (including lymph 
node 8a status7 and lymph node ratio8-10), tumor differ­
entiation, and resection margin status. An increasing 
number of molecular markers also have been identified as 
having potential prognostic value in resected pancreatic
>002-9610/$ - see front matter © 2009 Elsevier Inc. All rights reserved, 
loi: 10.1016/j.amjsurg.2007.12.057
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ancer.11,12 Whether histologic or biological in nature, 
icse parameters are invariably only amenable to assess- 
icnt after surgery.
Several studies have investigated potential prognostic 
idices that might be amenable to assessment preopera- 
ively. The preoperative neutrophil-lymphocyte ratio has 
een shown to be a significant prognostic index in resected 
olorectal cancer.13 Only 2 previous articles have investi- 
ated the potential prognostic value of decreased preopera- 
ive lymphocyte counts in resected pancreatic cancer,14,15 
owever, both of these studies were based on limited patient 
umbers (14 and 23 patients, respectively) and included 
atients with mixed pancreatic pathology.
An association between the preoperative platelet count 
nd survival also has been described in resected pancreatic 
denocarcinoma. Conflicting evidence exists as to whether a 
reater platelet count contributes to a poorer or more favor- 
ble survival outcome,16-18 however, increased platelet 
ounts have been shown to be associated with poorer sur- 
ival in other gastrointestinal malignancies.19,20
It was the objective of this study to identify whether the 
ireoperative lymphocyte and platelet counts can provide 
neaningful prognostic information in resected pancreatic 
wctal adenocarcinoma by analyzing each parameter as a 
ontinuous covariate and identifying whether a combination 
if these 2 parameters, the platelet-lymphocyte (P/L) ratio, 
night represent a more useful prognostic index.
Methods
Patients who had a partial pylorus-preserving pancre- 
toduodenectomy or classic Kausch-Whipple resection 
rom January 1997 to September 2006 were identified from 
. prospectively maintained database. Only histologically 
onfirmed patients of pancreatic ductal adenocarcinoma 
vere included in the analysis. Data collected included pa- 
ient demographics, surgical details, preoperative full blood 
ount, details of intervention for preoperative biliary drain- 
ige, and standard histologic tumor characteristics. Histo- 
>athology reporting was undertaken according to the 
toyal College of Pathologist’s minimum data set for 
lancreatoduodenectomy reporting.21 These guidelines 
stipulate that a positive margin is defined as the presence 
>f at least one cancer cell within 1 mm of any 1 of 7 
esection margins on microscopic examination (transec- 
ion, posterior, medial [superior mesenteric vein], ante- 
ior capsule, distal duodenal, proximal duodenal [or gas- 
ric], and bile duct). These histopathology reporting 
;tandards were in place at our institution for the entire 
luration of the study period. Hospital computer records 
vere used to identify dates of death along with dates of 
ast clinic attendance for censored patients (ie, patients 
dill alive as of September 2006).
Statistical analysis
Continuous data were analyzed using median, interquartile 
range, and 95% confidence intervals with 2-tailed Mann-Whit­
ney V testing for comparative analysis. The chi-square and the 
Fisher exact tests were used to analyze categoric data and 
correlation between 2 continuous data sets was analyzed using 
the Spearman rank correlation. A preliminary univariate sur­
vival analysis was undertaken using Cox proportional hazards 
regression for each of the hematologic parameters of interest. 
These were modeled as continuous covariates on both univar­
iate and multivariate analysis to more reliably describe their 
prognostic value. Kaplan-Meier curves were generated to il­
lustrate survival trends according to P/L ratios. Patients who 
died within 30 days of surgery (3 of 132 resections) were 
excluded from survival analyses. Statview version 5 (SAS 
Institute, Cary, NC) and Microsoft Excel (Microsoft Office 
2002; Microsoft Inc., Redmond, WA USA) were used to 
perform the various statistical functions.
Results
There were 532 patients who had surgical intervention 
for periampullary tumors during the study period. Of the 
297 patients who had partial pancreaticoduodenectomy, 132 
patients were identified with histologically confirmed pan­
creatic ductal adenocarcinoma. Of these, the preoperative 
full blood count was available in 110 and the results ob-
Table 1 Demographics and preoperative hematology 
results from resected pancreatic ductal adenocarcinoma
patients
No. of patients analyzed 110
Male:female ratio 65:45
Median age, y (interquartile range) 67 (61-73)
Mean interval from FBC to surgery, d (±SEM) 2.4 (.4)
Timing of preoperative FBC
Number of patients within 24 hours of surgery 75
Within 1-2 days of surgery 17
Within 3-7 days of surgery 12
>7 days of surgery 6
Neutrophilia present (>7.5 x 106/mL)
No 87 (79%)
Yes 23 (21%)
Lymphocytopenia present (<1.0 X 106/mL)
No 102 (93%)
Yes 8 (7%)
Thrombocytosis present (>400 x 106/tnL)
No 85 (77%)
Yes 25 (23%)
Intervention for preoperative biliary drainage
No 18 (16%)
ERCP 4- stent 85 (77%)
PTC ± stenting 7 (7%)
ERCP = endoscopic retrograde cholangiopancreatography; FBC = 
full blood count; PTC = percutaneous transhepatic cholangiography; 
SEM = standard error.
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Table 2 Univariate survival analysis of preoperative hematologic parameters as prognostic covariates in resected pancreatic ductal
adenocarcinoma (Cox proportional hazards)
Median value (interquartile range) Hazard ratio (95% Cl) P
Lymphocyte count, X106/mL 1.9 (1.3-2.4) .677 (.511-.897) .007
Neutrophil count, xi06/mL 5.5 (4.0-7.1) 1.038 (.956-1.127) .373
Platelet count, xi06/mL 303 (258-375) 1.002 (1.000-1.004) .068
N/L ratio 2.9 (1.9-4.8) 1.047 (.985-1.113) .140
P/L ratio 159 (116-230) 1.004 (1.002-1.006) .0001
Hazard ratios for continuous data reflect an increase in the relative risk of death with each incremental increase in a covariate value of 1 unit. 
N/L ratio = neutrophil-lymphocyte ratio.
lined nearest to the date of surgery were used for analysis. 
)emographic and hematologic data are shown in Table 1.
There was a significant inverse relationship between the 
ireoperative neutrophil and lymphocyte counts (rho, — .191; 
>5% confidence interval [Cl], —.345 to .020; P = .040). A 
ignificant association between platelets and neutrophils 
Iso was observed (rho, .287; 95% Cl, .105-450; P = 
303).
The median overall survival recorded in the group of 110 
latients analyzed was 13.9 months (95% Cl, 12.3-17.0 mo), 
'here were 31 censored patients with a median follow-up 
ime of 12.0 months (interquartile range, 7.8-25.5 mo). The 
esults of univariate survival for each of the hematologic 
larameters are shown in Table 2. Kaplan-Meier cumulative 
urvival curves for patients stratified into 3 groups accord- 
ng to the preoperative P/L ratio are shown in Fig. 1. 
’atients with a P/L ratio of greater than 300 had a signifi- 
antly poorer median survival (5.8 mo; 95% Cl, 5.2-10.0) 
vhen compared with patients with a P/L ratio of 151 to 300 
13.7 mo; 95% Cl, 10.4-16.7) or 150 or less (19.7 mo; 95% 
II, 13.3-26.5) (P = .006). Median survival times associ- 
ited with histologic subgroups are shown in Table 3.
Patients with greater P/L ratios showed an increased 
ikelihood of poorly differentiated tumors (P = .016), how-
PA. ratio * 151-300
Log rank - p * 0.006
P/L ratios ISO 46 28 14 6 2
P/L ratio* 151-300 43 23 8 2 1
P/L ratio >300 19 4 1 1 1
Figure 1 Kaplan-Meier cumulative survival curves for pancre- 
»tic ductal adenocarcinoma patients according to the preoperative 
P/L ratio. Purple line, P/L ratio <150; blue line, P/L ratio = 
151-300; red line, P/L ratio >300. Log-rank P — .006.
ever, there was no significant association with any other 
histologic tumor characteristics (Table 4). The patient group 
with a P/L ratio greater than 300 had a significantly lower 
proportion of patients that underwent intervention for pre­
operative biliary drainage than the other 2 patient groups. A 
separate survival analysis was undertaken to identify 
whether preoperative intervention for biliary drainage con­
ferred any survival advantage or disadvantage in the overall 
patient group. The median survival of 92 patients who 
underwent biliary drainage in the preoperative period was 
13.9 months (95% Cl, 12.3-19.7 mo) whereas the median 
survival of 18 patients who did not undergo biliary drainage 
was 13.7 months (95% Cl, 5.7-24.1 mo) (log rank, P = 
.873).
The results of univariate and multivariate survival anal­
yses modeling the preoperative P/L ratio as a continuous 
covariate alongside established histologic prognostic pa­
rameters are shown in Table 5. The results showed that the
Table 3 Median survival times according to P/L ratio and 
histologic subgroups
Variable
Median overall 
survival, mo 
(95% Cl) P (log-rank)
P/L ratio
<150 (n = 48) 19.7 (13.3-26.5) .006
151-300 (n = 43) 13.7 (10.4-16.7)
>300 (n = 19) 5.8 (5.2-10.0)
Size*
<20 mm (n = 27) 22.5 (12.1-34.9) .041
>20 mm (n = 81) 13.3 (10.4-16.6)
Nodal involvement
Negative (n = 21) 16.7 (13.2-NR) .042
Positive (n = 89) 13.7 (10.4-17.0)
Resection margin status
Negative (n = 32) 22.5 (10.8-34.2) .059
Positive (n = 77) 13.3 (11.4-15.2)
Tumor differentiation*
Well (n = 16) 22.6 (12.5-NR) .129
Moderate (n = 56) 14.3 (12.3-19.7)
Poor(n = 37) 12.6 (5.7-16.6)
NR = not reached.
•Histologic data were incomplete for one patient. Because of the 
smalt number of well-differentiated tumors, well and moderately dif­
ferentiated tumors were grouped together for analysis.
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Table 4 Distribution of histologic tumor characteristics stratified by the preoperative P/L ratio
Number of patients stratified by P/L ratio
<150 151-300 >300 P value (interquartile range)
Tumor size
<20 mm 13 11 3 .614 151 (110-189)
>20 mm 34 31 16 162 (116-252)
Nodal status
Negative 7 11 3 .401 179 (140-275)
Positive 41 32 16 155 (114-229)
Resection margin
Negative 16 14 2 .143 150 (110-193)
Positive 31 29 17 173 (124-291)
Differentiation*
Well 10 6 0 .016 137 (109-173)
Moderate 24 21 11 156 (116-235)
Poor 13 16 18 187 (139-295)
Adjuvant therapy
No 34 32 1 .081 177 (116-259)
Yes 14 11 18 149 (107-203)
Preoperative biliary drainage
No 7 4 7 .035 159 (113-361)
Yes 41 39 12 159 (116-220)
P values for the Fisher exact test calculated were for 3 X 2 contingency tables (ie, Freeman-Halton test). 
*X* for 3 x 3 table with Yates correction.
7L ratio remains a significant independent prognostic 
narker along with the tumor size and lymph node ratio, 
lazard ratios for continuous variables included in a Cox 
nodel refiect the proportional increase in relative risk of 
leath with each incremental increase in the continuous 
irognostic variable of 1 unit. The hazard ratio of 1.004 
[noted for the preoperative P/L ratio reflects a regression 
©efficient of .004 (ie. c 004 = 1.004). Therefore, the relative 
lazard associated with an increase in the P/L ratio by 200 
mits would be e^200 x 004) = 2.226. The chi-square statistic 
;ives a further indication of the strength of the relationship 
>etween the prognostic variable and survival.
Comments
Systemic inflammation is associated with the release of a 
number of inhibitory immunologic mediators, most notably 
interleukin-10 (IL-10) and transforming growth factor-/3, 
which can result in a significant immunosuppressive effect 
with consequent impaired lymphocyte function.22 Pancre­
atic cancer cells directly secrete these 2 inhibitory cyto­
kines23 and decreased serum levels of transforming growth 
factor-/32 have been shown to be associated with a more 
favorable survival outcome in pancreatic ductal adenocar­
cinoma.24 Lymphocytopenia has been shown previously to
Table 5 Univariate and multivariate (Cox proportional hazards) survival analysis for prognostic factors in pancreatic ductal 
adenocarcinoma
Univariate analysis Multivariate analysis (n = 104)
Prognostic factors P value Hazard ratio (95% Cl) Chi-square P value
Continuous covariates
Platelet-lymphocyte ratio (n = 110)* .0001 1.004 (1.002-1.006) 14.092 .0003
Tumor size (n = 108)* .003 1.025 (1.006-1.044) 6.214 .010
Lymph node ratio (n = 107)*
Categoric covariates
Resection margin status
.004 6.109 (1.465-25.478) 6.508 .013
Negative (n = 32)
Positive (n = 77)
Tumor differentiation
.062 1.158 (.601-2.233) .071 .661
Well/moderate (n = 72)
Poor (n = 37)
.141 1.186 (.706-1.990) 1.209 .520
Histologic data were incomplete for some patients, hence the overall number of patients included in the final Cox model was 104.
•Modeled as continuous covariates on both univariate and multivariate analyses— hazard ratios for continuous data reflect an increase in the relative 
risk of death with each incremental increase in a covariate value of 1 unit.
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e associated more strongly with pancreatic adenocarci- 
oma when compared with gastric and colorectal cancer,25 
.iggesting that pancreatic malignancy is associated with a 
lore marked host inflammatory response than other gastro- 
itestinal cancers. In addition to pancreatic cancer com- 
lonly showing reduced circulating lymphocyte popula- 
ons, a reduced number of tumor-infiltrating lymphocytes 
i resected pancreatic adenocarcinoma specimens also have 
een found to be associated with poorer survival rates after 
jrgery.26 Lymphocyte trapping within peritumoral fibrous 
ssue is believed to be an additional factor by which pan- 
reatic cancer cells evade immune surveillance.27
Pancreatic cancer commonly causes a hypercoagulable 
:ate resulting in a predisposition to thromboembolic 
vents.28 This is largely attributable to tumor expression of 
ssue factor that binds to factor Vila, thereby activating the 
lotting cascade and promoting thrombin production.29 Pan- 
reatic cancer shows significant overexpression of tissue 
ictor when compared with normal pancreatic tissue along 
dth up-regulation of vascular endothelial growth factor 
xpression, thereby potentiating tumor angiogenesis.30 Tis- 
ue factor expression also has been linked with an adverse 
rognosis in pancreatic ductal adenocarcinoma.31
The significance of tumor-platelet interactions within 
lis context is incompletely understood. A number of proin- 
ammatory mediators (notably IL-1, IL-3, and IL-6) are 
nown to stimulate megakaryocyte proliferation,32,33 there- 
Dre, the association between a relative thrombocytosis and 
dverse overall survival in pancreatic cancer might be ex- 
lained on the basis that the platelet count reflects an addi- 
onal index of systemic inflammation elicited by the tumor, 
'latelet aggregation and degranulation along with the con- 
equent release of platelet-derived proangiogenic mediators 
/ithin the microvasculature of the tumor also could be an 
nportant determinant of tumor growth.34 It has been sug- 
ested previously that antiplatelet agents might have an 
ihibitory effect on the invasive potential of pancreatic 
ancer cells in vitro by down-regulating tumor secretion of 
ratrix metalloproteinase-9.35
The preoperative systemic host immune response as a 
irognostic factor in resected pancreatic cancer previously 
las not been evaluated extensively. It has been reported that 
. more marked preoperative and postoperative systemic 
nflammatory response (as evidenced by an increased serum 
Lreactive protein [CRP] level >10 mg/L) is associated 
vith a poorer survival after resection for pancreatic ductal 
denocarcinoma.36 Increased preoperative CRP levels also 
lave been shown to be associated with poorer survival after 
urgery in other gastrointestinal malignancies.37,38 In addi- 
ion to an increased CRP level, the presence of a neutro- 
>hilia and relative lymphocytopenia are recognized features 
>f the systemic inflammatory response. Only 2 small studies 
o date have investigated the potential prognostic role of 
aeoperative lymphocytopenia in resected pancreatic can- 
:er.14,15 A similarly small number of studies have investi­
gated the potential utility of the preoperative platelet count
as a prognostic marker in resected pancreatic cancer and the 
results from these studies have been conflicting.16-15
The present study provides further evidence to support 
the assertion that the preoperative lymphocyte and platelet 
counts appear to confer significant prognostic information 
in resected pancreatic ductal adenocarcinoma. The expected 
inverse correlation between neutrophil and lymphocyte 
counts was observed, suggesting that a significant propor­
tion of patients with pancreatic ductal adenocarcinoma 
show some degree of systemic inflammation before sur­
gery.36 Furthermore, the positive correlation between neu­
trophil and platelet count suggests that the preoperative 
platelet count does reflect an additional index of systemic 
inflammation. This is perhaps also evidenced by the fact that 
a preoperative neutrophilia and thrombocytosis were re­
corded in a similar proportion of the overall patient group.
The results of the preliminary univariate survival analy­
sis indicated that the preoperative lymphocyte count carried 
the most significant prognostic information of the 3 re­
corded hematologic parameters when modeled as a contin­
uous covariate, with the platelet count displaying only bor­
derline significance. The P/L ratio was a superior prognostic 
marker when compared with either individual parameter or 
the neutrophil-lymphocyte ratio. When categorizing the overall 
number of patients into 3 groups according to the preoperative 
P/L ratio, Kaplan-Meier analysis also showed a consistent 
pattern of progressively poorer survival associated with larger 
P/L ratios. The median survival associated with a value of 
greater than 300 appeared to be comparable with what would 
be expected for locally advanced disease.39
Eighty-four percent of patients underwent biliary drain­
age procedures during the preoperative period, which may 
represent a potential confounding factor in interpreting the 
prognostic value of preoperative inflammatory markers. 
However, a previous meta-analysis has shown that although 
preoperative biliary stenting increases the risk of early post­
operative morbidity such as wound infection,40 biliary 
drainage before surgery was shown to have no influence on 
surgical mortality rates and no literature exists to suggest 
that stenting has any impact on intermediate or late survival 
in resected pancreatic cancer. The group with a P/L ratio 
greater than 300 actually had a significantly smaller propor­
tion of patients undergoing biliary drainage in the preoper­
ative period, with no difference in survival between patients 
who did or did not require biliary drainage in the overall 
group. Given these findings (along with the existing litera­
ture), it is unlikely that the issue of preoperative biliary 
drainage is a significant factor in explaining the strong 
association between the preoperative host inflammatory re­
sponse (as measured by the P/L ratio) and overall postop­
erative survival shown in the present article.
Similarly, there was no significant difference in the pro­
portion of patients who went on to receive adjuvant therapy 
in each of the 3 groups stratified by the P/L ratio. The results 
are consistent with the hypothesis that greater preoperative 
P/L ratios reflect an enhanced host inflammatory response to
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lore aggressive tumor biology. When stratifying patients 
^cording to histologic characteristics (Table 3), a clear 
end towards poorly differentiated tumors showing greater 
/L ratios was observed.
Rather than analyze the P/L ratio as a categorized co- 
ariate, the multivariate analysis was conducted using con- 
nuous covariates where possible to maximize the statistical 
alidity of the analysis. This approach avoids the potential 
ignificant bias associated with categorizing continuous data 
3r prognostic purposes.41 The P/L ratio emerged as the 
lost significant determinant of survival whereas tumor size 
nd the lymph node ratio also retained significance. Con- 
ucting the multivariate analysis in this way also allows for
more meaningful comparison of individual prognostic 
idices to be made when comparing results between differ- 
nt studies.
The powerful preoperative prediction of survival by the P/L 
itio merits validation in a larger patient cohort and requires 
ompadson with other potential prognostic markers such as a 
arbohydrate antigen (CA19-9)42 and CRP.36 This may have 
articular implications for developing criteria for more selec- 
ve use of laparoscopic staging along with stratification of 
atients in future trials for neoadjuvant and adjuvant therapy.
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Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour 
nvolvement within 1 mm of a resection margin
tims: The current Royal College of Pathologists guide- 
ines for pancreatoduodenectomy specimen reporting 
ecommend that microscopic evidence of tumour 
vithin 1 mm of a resection margin (RM) should be 
dassified as Rl. No clinical evidence exists to justify 
his classification. The aim of this study was to identify 
he proportion of pancreatoduodenectomy specimens 
n which ‘equivocal’ RMs are present (tumour involve- 
nent within 1 mm of, but not directly reaching, one or 
nore resection margins) and whether the survival of 
hese patients was similar to that of patients with 
unequivocal’ RM involvement.
Vlethods and results: Patients with histologically con- 
irmed pancreatic ductal adenocarcinoma undergoing
keywords: pancreatic cancer, prognosis, resection margin
Abbreviation: Cl, confidence interval
pancreatoduodenectomy between 1997 and 2007 
(n = 163) were identified from a prospective database. 
One hundred and twenty-eight cases (79%) were 
classified as Rl. Of these, 57 (45% of all Rl cases) 
were based on ‘equivocal’ margin involvement. There 
was no significant difference in overall survival 
between equivocal and unequivocal Rl resections 
(log rank, P = 0.102), All Rl resections had a poorer 
survival on univariate (log rank, P = 0.013), but not 
multivariate, analysis (Cox, P = 0.132).
Conclusions: Our results indicate that cases with micro­
scopic tumour involvement within 1 mm of a resection 
margin should be considered synonymous with incom­
plete excision for resected pancreatic cancer.
ntroduction
Pancreatic ductal adenocarcinoma has a poor prog- 
losis and surgical resection remains the only poten- 
ially curative intervention. Due to its late 
jresentation and aggressive tumour biology, only 
10-15% of cases are resectable.1 Patients who 
.mdergo resection for pancreatic cancer typically have
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5-year survival rates of <10%. However, adjuvant 
chemotherapy has been demonstrated to improve 
long-term survival outcomes significantly in recent 
randomized trials.2,3 Microscopic tumour involvement 
of the surgical resection margin (Rl) represents one of 
a number of histological features of the resected 
pancreatic specimen (including tumour size, differen­
tiation and nodal involvement) that have been 
reported to confer significant prognostic informa­
tion.4-9 Quoted Rl resection rates can vary signifi­
cantly between individual specialist centres 
(14-85%),7-10 and it is not known to what extent 
these differences reflect different pathological practices.
D 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Limited.
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The Royal College of Pathologists minimum dataset 
for histological reporting of pancreatoduodenectomy 
specimens11 recommends that cases with microscopic 
evidence of tumour extension to within 1 mm of one or 
more resection margins should be classified as Rl. 
However, this changes the current definition of Rl, 
which is defined by the International Union Against 
Cancer as tumour at the resection margin(s). No 
previous clinical studies have been conducted to 
demonstrate whether cases with tumour within 
1 mm of, but not directly reaching, one or more 
resection margins (i.e. an ‘equivocal’ Rl status), have 
comparable survival outcomes when compared with 
cases with ‘unequivocal’ margin involvement (i.e. 
cancer reaching the resection margin on microscopy). 
The principal objectives of this study were to identify 
the proportion of patients undergoing pancreatoduo­
denectomy for pancreatic ductal adenocarcinoma in 
whom an Rl classification was based on one or more 
‘equivocal’ resection margins, and to establish whether 
this distinction conferred any prognostic relevance.
Materials and methods
Consecutive patients with histologically confirmed
pancreatic ductal adenocarcinoma undergoing pancre­
atoduodenectomy at the Royal Liverpool University 
Hospital between January 1997 and December 2007 
were identified from a prospective database. All the 
histology reports were read to identify cases where 
margin involvement was documented by the reporting 
pathologist. In all cases reported as R0, the histo- 
pathology slides were retrieved and reviewed by a 
single consultant pathologist (F.C.) in order to confirm 
an R0 classification. Figure IB illustrates an example of 
an ‘equivocal’ resection margin where tumour can be 
seen to extend to within 1 mm, without directly 
reaching the margin itself. Figure 1C shows an exam­
ple of direct tumour involvement at a painted resection 
margin.
Specimens were serially sliced axially1'10 and histo- 
pathology reporting was conducted according to the 
Royal College of Pathologists minimum dataset for 
pancreatic and periampullary adenocarcinoma.11 The 
reporting criteria in the dataset were routinely used at 
our institution both before and after their publication 
in 2002. These guidelines recommend that the status 
of six discrete resection margins be documented by the 
reporting pathologist: the pancreatic transection mar­
gin, the medial (or superior mesenteric vessel) margin, 
the posterior margin, the proximal duodenal (or 
gastric) margin, the distal duodenal margin and the 
common bile duct margin. Microscopic evidence of
Figure 1. A, Macroscopic photograph shows an axial slice through 
the head of the pancreas with adenocarcinoma close to the posterior 
(green) resection margin and clear of the medial (orange) resection 
margin. A lymph node is seen within the anterior pancreatoduodenal 
groove (yellow paint). Light micrographs showing an 'equivocal' 
resection margin (B) with adenocarcinoma extending to within 
<1 mm of a painted resection margin, and 'unequivocal' resection 
margin involvement (C).
tumour involvement at any one of these six margins 
results in an Rl classification. Isolated tumour involve­
ment of the anterior surface of the pancreatic specimen
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yas not considered as an R1 resection in our patient 
ohort. Similarly, the presence of pancreatic intraepi- 
helial neoplasia-3 at an otherwise negative transection 
aargin was not considered an R1 resection. No cases 
rere classified as R1 exclusively on the basis of 
lerineural invasion at a resection margin. Similarly, 
lodal involvement at a resection margin did not 
onstitute an R1 classification in the absence of direct 
umour involvement. No R2 resections were included 
a this series of patients. Survival data were obtained 
com hospital computer records. Data regarding adju- 
rant therapy were also collected. Patient selection for 
idjuvant therapy was not based on resection margin 
tatus.
TATISTICS
Continuous data were described using median, inter- 
[uartile range and 95% confidence intervals (Cl). 
)verall survival was calculated from the date of 
esection to the date of death. Univariate survival for 
:ategorical data was investigated using Kaplan-Meier 
malysis with significance assessed by log rank (Man- 
el-Cox) testing. Univariate survival for continuous 
lata was assessed using Cox proportional hazards 
egression. Multivariate survival analysis was con- 
lucted using Cox regression with inclusion of clinico- 
>athological factors of univariate significance, 
tesection margin status was analysed alongside 
umour size, lymph node ratio, differentiation and 
idjuvant chemotherapy. The relationship between 
listological factors and likelihood of resection margin 
nvolvement was assessed using logistic regression. 
Significance was set at P < 0.05. Statistical analyses 
vere conducted using statview version 5 (SAS Insti- 
;ute, Cary, NC, USA).
Results
One hundred and sixty-three patients were identified 
'or whom a pancreatoduodenectomy was performed for 
pancreatic ductal adenocarcinoma during the study 
period. Table 1 summarizes the demographic and 
dinicopathological data for this patient group. Of the 
128 cases (79%) classified as Rl, 57 (45%) were based 
m tumour involvement within 1 mm of one or more 
nargins, without direct involvement of the margin 
tself (i.e. an ‘equivocal’ margin). Table 2 demonstrates 
a breakdown of resection margin involvement accord­
ing to the number of involved margins per specimen 
and to the distribution of margin involvement. These 
results indicate that 35% of Rl resections exhibited 
amltifocal margin involvement (i.e. more than one
Table 1. Demographic and clinicopathological data
Total number of patients 163
Maledemale 91:72
Median age (IQR) 66.4 (60.8-73.0) years
30-day mortalities 4 (2%)
Median overall 
survival (95% Cl)
13.9 months (12.4, 16.1)
Adjuvant chemotherapy given 44 (27%)
Type of pancreatoduodenectomy 
Pylorus-preserving 147 (90%)
Classical 16 (10%)
Median tumour size (IQR) 30 (23-38) mm
Tumour differentiation
Well 25 (15%)
Moderate 84 (52%)
Poor 53 (33%)
Lymph node status
Positive 25 (15%)
Negative 138 (85%)
Median lymph 
node yield (IQR)
18 (12-25)
Median lymph node ratio for 
node-positive cases (IQR)
0.23 (0.14-0.37)
T stage
T1 7 (4%)
T2 17 (10%)
T3 135 (83%)
T4 4 (3%)
Resection margin status
Negative 35 (21 %)
Positive 128 (79%)
Direct involvement 71
<1 mm 57
IQR, interquartile range.
margin involved in a single specimen), while the 
posterior and medial margins were the most commonly 
involved margin locations.
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Table 2. Distribution of resection margin involvement
All R1 resections 128 (79%)
Number of involved resection margins per specimen
1 83 (65%)
2 37 (29%)
3 7 (5%)
4 1 (1%)
Distribution of resection margin involvement
Posterior 69 (54%)
Medial 64 (50%)
Transection 38 (30%)
Proximal duodenal/gastric 6 (5%)
Common bile duct 4 (3%)
Distal duodenal -
THE PROGNOSTIC RELEVANCE OF ‘EQUIVOCAL’ 
RESECTION MARGINS
Figure 2A illustrates the Kaplan-Meier survival curves 
according to the three margin classifications—equivo­
cal R1 (<1 mm), unequivocal R1 (direct) and R0. 
Equivocal R1 cases had a median survival of 
15.4 months (95% Cl 11.3, 18.2) compared with 
12.6 months (95% Cl 9.2, 14.3) for unequivocal R1 
cases and 25.4 months (95% Cl 10.5, 40.8) for R0 
cases. When comparing the overall R1 group with R0 
cases (Figure 2B), a significant difference in survival 
was recorded (log rank, P = 0.013). When comparing 
equivocal with unequivocal R1 cases (Figure 2C), no 
significant difference in survival was recorded (log 
rank, P = 0.102). This was similarly true when com­
paring the equivocal R1 group with the R0 group (log 
rank, P = 0.114), Table 3 demonstrates the results of 
both univariate and multivariate survival analysis 
using Cox proportional hazards regression. These 
results indicate that resection margin status failed to 
maintain significance when analysed alongside the 
other important histopathological factors (lymph node 
ratio, tumour size, differentiation) and adjuvant 
chemotherapy.
PROGNOSTIC RELEVANCE OF MARGIN LOCATION
When analysing only R1 resections, involvement of the 
transection margin was found to exhibit a marginal 
trend towards poorer survival. However, this failed to 
reach significance (log rank, P = 0.085). Neither
R0
<1 mm R1 
Direct R1
re 0.8 -
Log rank
3 0.6- P= 0.010
O 0.2-
24 36
Time (months)
No. at risk
<1mmR1 57 33 11 5 4 4
Direct R1 71 35 11 3 1 1
R0 35 19 15 9 6 3
All R1
to 0.8 - Log rank
P = 0.013
« 0.6-
1 0.4-
O 0.2-
Time (months)
No. at risk
All R1 128 68 22 8 5 5
R0 35 19 15 9 6 3
<1 mm R1 
Direct R1
co 0.8 -
Log rank
P= 0.102
^ 0.4-
O 0.2-
Time (months)
No. at risk
Direct R1 71 35 11 3 1 1
<1mmR1 57 33 11 5 4 4
Figure 2. Kaplan-Meier cumulative survival curves according to 
resection margin status. Crosses on survival curves indicate censored 
cases. Numbers at risk recorded beneath each x-axis.
posterior (P = 0.217) nor medial margin involvement 
(P = 0.257) was associated with poorer outcomes 
within the R1 group of patients. When analysing the
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able 3. Univariate and multivariate survival analysis for histopathological prognostic variables
Univariate analysis Multivariate analysis (n = 155)
Hazard ratio (95% Cl) x2 P Hazard ratio (95% Cl) x2 P
‘umour sizet 1.020 (1.005, 1.036) 6.629 0.010 1.016 (1.000, 1.033) 3.887 0.049
'oor tumour differentiation* 1.660 (1.152, 2.392) 7.387 0.007 1.428 (0.965, 2.112) 1.783 0.075
.ymph node ratiot 4.679 (2.003, 10.930) 12.713 <0.001 3.116 (1.304, 7.444) 6.544 0.011
(esection margin-positive 1.747 (1.117, 2.734) 5.978 0.015 1.443 (0.896, 2.324) 2.272 0.132
Adjuvant chemotherapy 0.583 (0.384, 0.887) 6.363 0.012 0.605 (0.394, 0.930) 5.242 0.022
'Poor tumour differentiation analysed against well/moderately differentiated tumours. Resection margin status (R1 versus RO) 
tnd adjuvant chemotherapy (yes versus no) were also analysed as categorical covariates.
•Tumour size and lymph node ratio were included as continuous covariates in the Cox model (NB. hazard ratios for continuous
>rognostic data reflect increase in relative hazard with each unit increase in covariate value). Histological data were incomplete 
or a small number of cases. Hence, the final multivariate model included 155 cases.
> < 0.05 highlighted in bold.
jroup of 35 RO resections. 12 cases exhibited isolated 
umour involvement (either direct or <1 mm) of the 
interior pancreatic surface. There was no significant
lifference in survival between this group of patients 
ind the remaining 23 RO resections (log rank, 
3 = 0.220).
(ELATIONSHIP BETWEEN R1 STATUS AND OTHER 
11STOLOGICAL TUMOUR CHARACTERISTICS
\ logistic regression analysis was conducted to identify 
vhether any of the other histological tumour charac- 
eristics were associated with an increased likelihood of 
nicroscopic margin involvement. R1 likelihood was 
ncluded as the dependent variable in this analysis, 
increasing tumour size (recorded in mm) was associ­
ated with a significantly increased likelihood of an R1 
•esection when included as a continuous independent 
/ariable (odds ratio 1.049; 95% Cl 1.010, 1.088; 
P = 0.013). Neither poor tumour differentiation 
P = 0.095) nor nodal status (F = 0.738) exhibited a 
significant relationship with R1 likelihood in this 
patient cohort.
Discussion
The relative prognostic significance of resection margin
status is variably reported for pancreatic cancer. 
Although several studies have suggested that resection 
margin involvement has significant prognostic value 
on multivariate analysis alongside other histological 
tumour characteristics,4-6 studies including larger 
patient series typically demonstrate that R1 status
either fails to maintain significance on multivariate 
analysis'12 or that R1 status fails to emerge as a 
significant univariate predictor of survival.1514 These 
results have also been mirrored in a recent meta­
analysis of four adjuvant therapy trials, which failed to 
demonstrate a significant overall survival diflerence 
according to resection margin status in a pooled group 
of 869 pancreatic adenocarcinoma resections.1^
Highly variable R1 resection rates for pancreatic 
cancer are commonly quoted in different studies. 
Sizeable multicentre adjuvant therapy trials2 1 have 
previously reported R1 resection rates of 17-19%. 
However, these studies do not report potential differ­
ences in R1 rates between individual surgical centres. 
Studies reporting results from single-centre cohorts 
have demonstrated marked variability in R1 rates (17- 
85%).'-10 It is unknown to what extent this hetero­
geneity in quoted R1 rates may be explained by 
differences in pathological practice rather than opera­
tive expertise. Meaningful comparison of R1 rates 
between individual centres is further complicated by 
the lack of standardized terminology for margins, and 
the lack of any internationally recognized protocol for 
pathological examination and reporting. However, 
increasing evidence exists to suggest that the standard 
of histopathological processing and reporting has a 
significant impact on R1 resection rates.910
A previous study by Verbeke et al.10 demonstrated 
that utilization of a standardized protocol for histolog­
ical processing and examination of pancreatoduoden­
ectomy specimens for pancreatic cancer, based on the 
Royal College of Pathologists guidelines, was associated 
with an R1 resection rate of 85%. This study also
S 2009 The Authors. Journal compilation © 2009 Blackwell Publishing Ltd, Histopathology. 55, 277-283.
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demonstrated a significant correlation between an 
increasing number of tissue blocks taken and an 
increasing likelihood of an R1 classification. A more 
recent study by Esposito et al.? using a similar stan­
dardized histopathology protocol, reported an R1 rate 
of 76%. These findings are consistent with the hypo­
thesis that a negative resection margin status may be 
commonly incorrectly assigned to cases with suboptimal 
pathological processing. The assertion that R1 resec­
tions are commonly under-reported is also supported 
by the observation that 60-80% of cases with resected 
pancreatic cancer develop local recurrence,16-18 a 
finding that seems inconsistent with quoted R1 resec­
tion rates of <20%. Differences in histological R1 
classification between individual centres may also in 
part explain the variable reporting of resection margin 
status as a prognostic index for pancreatic cancer.
The present study represents the first attempt to 
quantify the impact of the ‘<1 mm rule' in defining 
R1 classification for resected pancreatic cancer and 
provides further evidence to suggest that R1 resections 
may be commonly under-reported. Our R1 resection 
rate of 79% is comparable to the rates quoted by 
Esposito et al (76%) and Verbeke et al (85%) 9,10 using 
standardized pathology protocols based on the Royal 
College of Pathologists guidelines. Our results also 
suggest a similar proportion of multifocal R1 resections 
(35%) when compared with these two studies (32% 
and 45%, respectively). There is currently no evidence 
to indicate that nodal involvement or perineural/ 
intravascular invasion at a resection margin should 
constitute an R1 classification. These features reflect 
distinct infiltrative tumour characteristics that are 
reported separately and represent discrete prognostic 
factors. Therefore, incorporating these additional 
features into a system of resection margin classifica­
tion potentially duplicates prognostic information. 
The presence of nodal involvement or perineural/ 
intravascular invasion at a resection margin did not 
constitute an R1 case in this study. It has also 
previously been demonstrated that this issue is relevant 
for only a small proportion of cases.9
Our findings indicate that the ‘<1 mm rule’ has a 
significant impact on the quoted R1 resection rate. In 
total, 45% of all R1 resections in this cohort of patients 
were based on 'equivocal' margin involvement (i.e. 
tumour within 1 mm of one or more margins, in the 
absence of direct involvement). If these cases had been 
classified as R0, the R1 resection rate would have fallen 
significantly from 79 to 44%. Analysis of the survival 
curves supports the recommendation made in the 
Royal College of Pathologists guidelines that tumour 
involvement within 1 mm of a resection margin should
be considered synonymous with incomplete excision. 
Although the differenice between equivocal R1 cases 
and R0 cases did not reach significance, the median 
survival of the equivocal R1 group (15.4 months) was 
clearly more comparable to the unequivocal R1 group 
(12.6 months), when compared with the R0 group 
(25.4 months). Kaplan-Meier analyses also demon­
strate that the survival distribution for equivocal R1 
cases exhibits much closer overall concordance with 
the unequivocal R1 group. The overall survival pattern 
raises the possibility that a larger study may result in 
the equivocal R1 cases representing an intermediate 
prognostic group. However, a case for pathological sub­
categorization of R1 resections could be supported only 
if a clear distinction between the two R1 groups was 
evident, which was not demonstrated from the present 
data. Larger studies are required to address this issue 
definitively.
When analysing the distribution of margin involve­
ment in R1 resections for pancreatic cancer, the finding 
that the posterior and medial margins represent the 
most frequently involved margin locations is also 
consistent with the existing literature.91019 The pro­
portion of cases with microscopic tumour involvement 
of the transection margin in the present study is greater 
than quoted elsewhere.9,10 However, the majority of 
these cases typically exhibited very focal involvement, 
and only nine cases exhibited isolated transection 
margin involvement. The anterior surface of the 
pancreas is not considered to be a surgical margin 
and was therefore not considered as an R1 resection in 
this study. However, involvement of this surface could 
potentially affect survival. When analysing the small 
subgroup of patients with isolated tumour involvement 
of the anterior surface (whether direct or <1 mm), 
there was no significant difference in survival com­
pared with R0 cases.
Previous studies have suggested that the presence of 
poor tumour differentiation20 and increasing tumour 
size7 may be associated with an increased likelihood of 
resection margin involvement in pancreatic cancer. 
The results from the present study are consistent with 
these findings. However, this observation reached 
significance only for tumour size. The association 
between these histological tumour characteristics and 
R1 likelihood may also, in part, explain why resection 
margin status commonly fails to emerge as a significant 
independent prognostic index when analysed in a 
multivariate context, as in the present study.
In summary; this study has provided the first clinical 
evidence to support the Royal College of Pathologists 
guidelines regarding R1 classification in pancreatoduo­
denectomy specimens for pancreatic cancer. The find-
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ngs highlight the importance of standardized histo- 
)athologicaI reporting and provide a potential expla- 
ratioii for the significant heterogeneity in reported R1 
■ates quoted by different specialist cancer centres. The 
lata also provide further evidence to indicate’ that 
■obust pathological practice is a more important 
leterminant of R1 classification in pancreatic cancer 
ban operative expertise. These findings have consid- 
rable implications for stratification of patients as part 
)f future adjuvant therapy trials, including the pending 
iSPAC-3 results.21
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Meta-analysis of immunohistochemical prognostic markers in 
resected pancreatic cancer
RA Smith1, J Tang1, C Tudur-Smith1,2, JR Neoptolemos1 and P Ghaneh*’1
'Division of Surgery and Oncology. School of Cancer Studies, University of Liverpool, Royal Liverpool University Hospital, 5th Floor Duncan Building, 
Daulby Street Liverpool L69 3GA, UK
background: The potential prognostic value of several commonly investigated immunohistochemical markers in resected pancreatic 
cancer is variably reported. The objective of this study was to conduct a systematic review of literature evaluating p53. pi 6, smad4. 
bcl-2, bax, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression as prognostic factors 
in resected pancreatic adenocarcinoma and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. 
methods: Relevant literature was identified using Medline, EMBASE and ISI Web of Science. The primary end point was overall 
survival assessed on univariate analysis. Only studies analysing resected pancreatic adenocarcinoma were eligible for inclusion and the 
summary loge hazard ratio (logHR) and variance were pooled using an inverse variance approach. Evidence of heterogeneity was 
evaluated using the y2 test for heterogeneity and its impact on the meta-analysis was assessed by the I2 statisic. Hazard ratios greater 
than one reflect adverse survival associated with positive immunostaining.
RESULTS: Vascular endothelial growth factor emerged as the most potentially infomative prognostic marker (I I eligible studies, 
n = 767, HR =1.51 (95% confidence interval, 0=1.18-1.92)) with no evidence of any significant publication bias (Egger’s 
test, P = 0.269). Bcl-2 (5 eligible studies, n = 3l4, HR = 0.51 (95% 0 = 0.38-0.68)), bax (5 studies, n = 274, HR = 0.63 
(95% 0 = 0.48-0.83)) and pi6 (3 studies, n = 229, HR = 0.63 (95% 0 = 0.43-0.92)) also returned significant overall survival 
differences, but in smaller patient series due to a lack of evaluable literature. Neither p53 (17 studies, n = 925, HR = 1.22 
(95% 0 = 0.96-1.56)), smad4 (5 studies. n = 540, HR = 0.88 (95% 0 = 0.61-1.27)) nor EGFR (4 studies, n = 250, HR= 1.35 
(95% 0 = 0.80-2.27)) was found to represent significant prognostic factors when analysing the pooled patient data. There was 
evidence of significant heterogeneity in four of the seven study groups.
conclusion: These results support the case for immunohistochemical expression of VEGF representing a significant and reproducible 
marker of adverse prognosis in resected pancreatic cancer.
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Pancreatic ductal adenocarcinoma is characterised by its singularly 
aggressive tumour biology and unfavourable patient outcomes. 
Despite overall 5-year survival rates of <5%, previous randomised 
trials have demonstrated that for patients presenting with localised 
disease, resection with administration of adjuvant chemotherapy is 
associated with 5-year survival rates of over 20% (Neoptolemos 
et al, 2004; Oettle et al, 2007).
Reliable identification of molecular prognostic markers is 
important in order to facilitate the rational selection of potential 
therapeutic targets in the development of novel cancer therapies 
and to allow meaningful and reproducible risk stratification as part 
of clinical trials. There is marked disparity in the literature 
between individual studies as to the relative prognostic impact of
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several immunohistochemical tissue markers in pancreatic cancer. 
This may, in part, be explained by heterogeneity in patient 
selection due to inclusion of resected and unresected patients 
in survival analyses or inclusion of mixed tumour types and 
laboratory methodology when comparing different studies. 
The objective of the present study was to conduct a systematic 
review and meta-analysis of published literature investigating the 
commonly reported immunohistochemical prognostic markers in 
resected primary tumour material from patients with pancreatic 
adenocarcinoma and to identify potential sources of heterogeneity 
when comparing the results of individual studies.
MATERIALS AND METHODS 
Search strategy
Medline, EMBASE and ISI Web of Science were searched to 
identify potentially relevant published literature. No chronological 
search criteria were applied. Existing systematic reviews and 
reference lists were also checked for any potentially relevant
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additional studies. The most widely investigated and biologically 
relevant immunohistochemical tissue markers for pancreatic 
cancer were selected for meta-analysis. These comprised p53, 
smad4, pi6, bcl-2, bax, vascular endothelial growth factor (VEGF) 
and epidermal growth factor receptor (EGFR).
Selection criteria
The following criteria were used to search English language articles 
and abstracts: ‘(marker)' AND (‘pancreas’ OR ‘pancreatic’) AND 
(‘survival’ OR ‘prognosis’ OR ‘prognostic’). Each search was 
repeated for individual markers by substituting the name 
of marker of interest along with relevant synonyms: ‘p53’ OR 
‘TP53’; ‘pi6’ OR ‘pl6*’ OR ‘CDKN2A’; ‘smad4’ OR ‘smad-4’ OR 
‘smad*’; ‘DPC4’ OR ‘DPC-4’ OR ‘DPC*’; ‘bcl-2’ OR ‘bdT OR ‘bcl’ 
OR ‘bcl*’; Tjax’; ‘vascular endothelial growth factor’ OR ‘VEGF’ 
OR ‘VEGF*’; ‘epidermal growth factor receptor’ OR ‘EGFR’ OR 
‘c-erbB*’ OR ‘erbB*’ OR ‘HER*’. The search was performed in 
November 2009. Abstracts were initially checked for relevance and 
the full article was retrieved for all potentially eligible studies. 
Where part or all of the same patient series was included in more 
than one publication, only the more recent or most complete study 
was included in the analysis in order to avoid duplication of the 
same survival data.
The following inclusion criteria were used to select literature: 
only cases of resected pancreatic adenocarcinoma analysed, 
immunohistochemical expression assessed in resected primary 
tumour material, dichotomised univariate survival analysis 
reported (i.e. positive vs negative staining) and overall survival 
times used in analysis. For the analysis of VEGF, only studies 
investigating the prognostic value of VEGF-A expression were 
included. Authors were contacted for unpublished results in cases 
where insufficient survival data were reported to estimate the log,, 
hazard ratio (logHR) and variance. Due to the minority of studies 
reporting multivariable analyses, no attempt was made to use 
any adjusted survival data as part of this meta-analysis (i.e. only 
univariate survival data were extracted).
End points
The primary outcome measure was overall survival (i.e. date of 
resection to date of death). Additional details were also collected in 
order to identify potential sources of heterogeneity. These included 
the specific primary antibody (and dilution) used for immuno- 
histochemistry, the scoring criteria used to define positive staining 
and relevant clinico-pathological data. An assessment of study 
methodology was made according to previously defined criteria 
(Hayden et al, 2006; McShane et al, 2006). These principles were 
used to define 20 individual study characteristics, which were 
deemed to be key factors to report in an immunohistochemical 
prognostic study (Table 1). For any criterion not fulfilled 
according to the information outlined in the article, one point 
was deducted from a maximum of 20 and the final score 
was recorded as a percentage. The eligibility criteria and quality 
scoring were assessed by two independent investigators. Any 
disagreement was resolved by discussion.
Statistical analysis
Previously reported indirect methods were utilised for extracting 
the logHR and variance due to the paucity of prognostic literature, 
which report these values directly (Parmar et al, 1998; Williamson 
et al, 2002; Tierney ef al, 2007). These values were either calculated 
from the HR and 95% confidence interval (Cl) where quoted, the 
log rank P-value, or from the Kaplan-Meier survival curves 
directly. The software used for these indirect calculations 
was designed by Matthew Sydes and Jayne Tierney of the 
Medical Research Council Clinical Trials Unit, London, UK
Table I Methodological scoring criteria used
Study group
Study population adequately described
Gender/age I Point
Histology I Point
Period of recruitment I Point
Inclusion/exclusion criteria used I Point
Study attrition
>90% of cases identified included in final analysis I Point
Reasons for attrition/loss to follow-up given I Point
Peri-operative mortality details I Point
Scientific methodology
IHC methodology outlined
Details of I °/20 Abs used I Point
Concentration of I ° Abs used I Point
Positive/negative controls outlined I Point
Description of scoring technique
> I independent scorer I Point
Scorers blinded to dinical data I Point
Criteria for positivity clearly outlined
Distribution (cytoplasm vs membranous vs nuclear) I Point
% positive cells for immunostaining classification I Point
Confounding factors considered
Adjuvant therapy details provided I Point
Histological breakdown according to IHC staining I Point
Statistical analysis
HR (confidence interval) provided I Point
Exact P-value quoted I Point
Numbers at risk for Kaplan-Meier curves I Point
Number of censored cases recorded I Point
Abbreviations: HR = hazard ratio; IHC = immunohistochemical.
(Tierney et al, 2007). The logHR and variance for individual 
studies were entered into RevMan 4.2 (Cochrane collaboration, 
Oxford, UK) and pooled using a random effects inverse variance 
approach. The overall prognostic effect of positive immunostain­
ing was recorded as an HR and 95% Cl (i.e. an HR> 1 reflecting 
adverse survival associated with positive immunostaining). 
Heterogeneity was assessed using a y2 test for heterogeneity with 
a P-value of <0.10 taken to reflect the presence of significant 
heterogeneity. The I2 statistic was calculated to quantify the degree 
of heterogeneity (Higgins and Thompson, 2002). A P-value of 
<0.050 was taken to reflect significance for all other analyses. 
Publication bias was assessed by inspection of the funnel plot with 
Egger’s regression. Continuous data were compared using Spear­
man’s rank correlation and two-sided Mann-Whitney testing 
for categorical data.
RESULTS
VEGF
The initial search returned a total of 255 studies. Following review 
of these abstracts, 20 potentially relevant studies were identified as 
eligible of which nine were excluded for the following reasons: 
duplicated series of patients (Ikeda et al, 1999; Niedergethmann 
et al, 2000; Tang et al, 2001), only VEGF-C and/or VEGF-D 
analysed (Kurahara et al, 2004; Zhang et al, 2007), no dichot­
omised univariate survival analysis reported (Ellis et al, 1998; 
Fujioka et al, 2001), mix of resected and unresected cases included 
in survival analysis (Chung et al, 2006) and only VEGF receptor 
status analysed (Biichler et al, 2002).
The 11 eligible studies (all retrospective) included a total 
of 767 patients with a median number of 62 patients per 
study (range = 19-142). Table 2 outlines the demographic.
© 2011 Cancer Research UK British Journal of Cancer (2011) 104(9), 1440 - 1451
M
ol
ec
ul
ar
 D
ia
gn
os
tic
s
Meta-analysis of IHC prognostic markers
RA Smith et al
12
Table 2 Methodological and clinico-pathological data for eligible prognostic studies evaluating VEGF, bcl-2, bax and pl6
HR Signi- 1 Ab IHC IHC Adjuvant
Reference n (95% Cl) ficant (♦dilution) +ve cutoff (%) Male Age N1 T3/T4 Well Mod. Poor therapy
VEGF
Itakura et o/ (1997) 75 1.12 (0.69-1.82) No NC (30/tgmr') 48 (64) > 10 46 (61) 62 47 (63) 43 (57) 13(17) 44 (59) 18 (24) NS
Fujimoto et al (1998) 50 0.78 (0.44-1.40) No Santa Cruz A20 (1:200) 28 (40) NS 28 (56) 62 29 (58) 34 (68) 9(18) 31 (62) 10 (20) NS
Seo et al (2000) 142 1.46 (1.02 -2.09) Yes Santa Cruz (NS) 94 (66) >30 79 (56) 64 95 (67) NS NS NS NS NS
Ikeda et al (2001) 48 2.74 (1.44 - 5.20) Yes Santa Cruz (1:200) 31 (65) >10 37 (77) 64 24 (50) 40 (83) 15(31) 28 (58) 5(11) 48 (100)
Knoll et al (2001) 19 2.37 (0.88-6.40) No R&D Ab293NA (1:200) 13 (68) >5 11 (58) 58 18 (95) 1 (5) 1 (5) 12(63) 6(32) 0(0)
Niedergethmann et al 
(2002)
70 2.48 (1.22-5.05) Yes Santa Cruz (1:200) 28 (40) > 10 42 (60) 63 41 (59) NS 25 (36) 45 (64) 22(31)
Kuwahara et al (2003) 55 2.08 (1.12-3.88) Yes Santa Cruz scl52 (1 :200) 39 (71) >50 34 (62) 64 30 (55) 40 (73) 13(24) 33 (60) 9(16) NS
Lim et al (2004) 72 0.82 (0.49- 1.37) No Santa Cruz (1:2000) 23 (32) > 10 43 (60) 60 38 (53) 59 (82) 14 (19) 44 (61) 14 (19) 26 (36)
Khorana et al (2005) 124 1.30 (0.87-1.95) No Zymed (1:50) 70 (56) >5 69 (56) 67 56 (45) 69 (58) 23 (19) 52 (43) 45 (38) 88 (79)
Tang et al (2006) 50 1 46 (0.84-2.54) No NS (2 fig ml ~ ) 25 (50) >10 25 (50) 63 39 (78) 25 (50) 15 (30) 31 (62) 4(8) NS
Ai et al (2008) 62 2.34 (1.41-3.89) Yes Neomarkers (NS) 37 (60) > 10 36 (58) 65 49 (79) 32 (52) 17(27) 15(24) 30 (48) 0(0)
bd-2
Bold etal (1999) 70 0.64 (0.35-1.18) No DAKO (NS) 23 (33) >25% 36(51) 64 32 (46) NS 15(22) 37 (55) 15(22) 19(27)
Nio et al (2001b) 66 0.45 (0.25 - 0.82) Yes DAKO M0887 (1:100) 16 (24) >5% 31 (47) 66 54 (82) NS 33 (50) 29 (44) 4(6) 36 (55)
Magistrelli et al (2006) 67 0.56 (0.33-0.96) Yes DAKO cl24 (1:40) 45 (67) >5% 45 (67) 63 34(51) 40 (62) 14(21) 28 (42) 15(22) 30 (45)
Sarela et al (2002) 52 0.50 (0.08-3.33) No DAKO (1:40) 6(12) > 10% 27 (52) 64 40 (78) 49 (94) II (22) 24 (47) 16(31) NS
Dong et al (2005b) 59 0.43 (0.25 - 0.74) Yes DAKO M 124(1:100) 21 (36) >5% 19 (32) 55 54 (82) NS 19 (32) 21 (36) 19 (32) NS
bax
Press eta/(1998) 60 0.47 (0.23-0.97) Yes Santa Cruz (NS) 50 (83) NS 32 (53) 63 38 (63) NS NS NS NS NS
Evans et al (2001) 23 0.80 (0.28-2.29) No Santa Cruz (1:1600) 6(26) >5% 15 (65) 59 38 (63) NS 5(22) 13(54) 5(22) 0(0)
Nio eta/(2001b) 65 0.49 (0.28-0.85) Yes DAKO A3533 (1:100) 42 (65) >10% 31 (47) 66 54 (82) NS 33 (50) 29 (44) 4(6) 36 (55)
Magistrelli et al (2006) 67 0.56 (0.33-0.95) Yes Zymed c2D2 (1:80) 36 (54) >10% 45 (67) 63 34(51) 40 (62) 14(21) 28 (42) 15(22) 30 (45)
Dong et al (2005b) 59 0.93 (0.57-1.52) No DAKO A3533 (1:100) 29 (49) >10% 19 (32) 55 54 (82) NS 19(32) 21 (36) 19 (32) NS
p/6
Naka eta/(1998) 32 0.45 (0.21 -0.96) Yes Santa Guz C20 (1 :500) 19 (59) NS 20 (63) 65 23 (72) 13(41) NS NS NS NS
Kawesha et al (2000) 157 0.82 (0.50-1.33) No Santa Cruz (1: KXI) 21 (13) >5% 100 (64) 60 71 (46) NS 21 (13) 77 (49) 59 (38) 13(8)
Gerdes et al (2002) 40 0.51 (0.25-1.04) No Ftiarmmgen G175-405 
(1:50)
13(33) >5% 22 (55) NS 16 (40) NS NS NS NS 0(0)
Abbreviations; Cl = confidence interval; HR = hazard ratio; IHC = immunohistochemical; NC = non-commercial; NS = not specified; VEGF = vascular endothelial growth factor. 
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod/Poor refers to tumour differentiation.
clinico-pathological, methodological and outcome characteristics 
of these studies. The median quahty score was recorded as 70% 
(range = 60-95%). There was no significant difference in median 
quality scores between significant and non-significant studies 
(Mann-Whitney, P = 0.516). Similarly, there was no significant 
correlation between study size and quality scores (Spearman’s 
p = 0.139, P = 0.698). Figure 1 illustrates the Forrest plot for the 
survival data. Significant heterogeneity was demonstrated accord­
ing to Cochran’s y2 test (y2 = 22.08, P = 0.01; f2 = 54.7%). The 
combined HR was recorded as 1.51 (95% €1 = 1.18-1.92), 
indicating that positive immunostaining for VEGF was signifi­
cantly associated with adverse survival in the pooled patient group. 
When assessing the funnel plot for this analysis (Figure 2), the data 
points approximated a symmetrical distribution (Egger’s test, 
P = 0.269), indicating that publication bias is unlikely to be a 
significant confounding factor in describing this relationship.
The median proportion of patients classified as VEGF positive in 
the included studies was recorded as 60% (range = 32-71%). The 
proportion of VEGF positive cases reported in each study failed to 
exhibit any correlation with the assessment of methodological 
quality (Spearman’s P = 0.491) or the % cutoff used to define 
positive immunostaining (Spearman’s P = 0.388). Only six studies 
reported the proportion of patients who received any form of 
adjuvant therapy (Table 2) and administered treatment modalities 
included a mix of both chemotherapy and chemoradiation. No 
studies reported use of any neoadjuvant therapy and only a single 
study reported use of intra-operative radiotherapy (Ikeda et al, 
2001). Of the five studies that reported positive VEGF expression 
as a significant adverse prognostic variable, only three conducted 
some form of multivariate analysis. These three analyses included 
a variety of disparate covariates alongside VEGF. However, each 
reported that VEGF expression retained statistical significance.
bcl-2
The initial search returned a total of 232 abstracts of which 16 
potentially eligible articles were retrieved. A total of 11 were 
excluded for the following reasons: duplicated series of patients 
(Nio et al, 2001a), mix of resected and unresected cases included 
(Gansauge et al, 1998; Makinen et al, 1998; Ohshio et al, 1998; Hu 
et al, 1999), inclusion of ampullary tumours (Sinicrope et al, 1996), 
no dichotomised univariate survival analysis conducted (Evans 
et al, 2001; Stipa et al, 2002; Sun et al, 2002) and insufficient 
survival data reported for indirect estimation of logHR and 
variance (Friess et al, 1998; Campani et al, 2001).
The five eligible studies included a total of 314 patients with a 
median number of 63 patients per study (range = 52-70) (Table 2). 
The median quality score was recorded as 75% (range = 65-85%) 
and the median proportion of bcl-2 positive cases was 33% 
(range = 12-67%). Figure 2 illustrates the Forrest plot for the 
pooled survival data. There was no evidence of any significant 
heterogeneity (x2 = 1.19, P = 0.88). The combined HR was 
recorded as 0.51 (95% Cl = 0.38-0.68), indicating a significant 
association between positive bcl-2 immunostaining and more 
favourable survival in the pooled patient group. Despite the limited 
number of studies included, the funnel plot for this analysis 
failed to demonstrate any obvious asymmetry (Figure 3). Three 
studies reported use of either adjuvant chemotherapy or chemor­
adiation and a single study (Bold et al, 1999) also reported use 
of neoadjuvant chemoradiation in 43 out of the 70 patients 
analysed. Of the two studies rejected due to incomplete 
survival data (Friess et al, 1998; Campani et al, 2001), both failed 
to observe any significant prognostic effect associated with 
bcl-2 expression. Neither study reported the direction of the 
prognostic effect.
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VEGF LogHR (SE) HR (95% Cl) Weight (%) HR (95% Cl)
8.74 0.78 [0.44, 1.40)
9.83 0.82 [0.49, 1.37]
10.29 1.12 [0.69, 1.82)
11.78 1.30 [0.87, 1.95]
9.17 1.46 [0.84, 2.54]
12.66 1.46 [1.02, 2.09]
8.16 2.08 [1.12, 3.88]
9.94 2.34 [1.41, 3.89]
4.48 2.37 [0.88, 6.40]
7.03 2.48 [1.22, 5.05]
7.92 2.74 [1.44, 5.20]
100.00 1.51 [1.18, 1.92]
Fujimoto et al 
Lim et al 
Itakura et al 
Khorana et al 
Tang eta!
Seo et al 
Kuwahara et al 
Al eta!
Knoll eta!
Niedergethmann et I 
Ikeda et al
-0.2485
-0.1985
0.1133
0.2624
0.3784
0.3784
0.7324
0.8502
0.8629
0.9083
1.0080
(0.2971)
(0.2620)
(0.2483)
(0.2065)
(0.2828)
(0.1830)
(0.3178)
(0.2589)
(0.5070)
(0.3627)
(0.3265)
Total (95% Cl)
Test for heterogeneity: /2 = 22.08, df = 10 (P= 0.01), I2 = 54.7% 
Test for overall effect: Zb 3.30 (P= 0.0010)
bcl-2
Dong etal 
Nio etal 
Sarela etal 
Magistrelli et al 
Bold et al
Total (95% Cl)
Test for heterogeneity: / 
Test for overall effect: Z
bax
Friess etal 
Nio et al 
Magistrelli et al 
Evans etal 
Dong etal
-0.8440 (0.2766) 
-0.7985 (0.3090) 
-0.6932 (0.9667) 
-0.5798 (0.2772) 
-0.4463 (0.3105)
2 = 1.19, df = 4 (P= 0.88), /2 = 0% 
4.66 (P< 0.00001)
-0.7550
-0.7134
-0.5798
-0.2231
-0.0726
(0.3722)
(0.2795)
(0.2680)
(0.5361)
(0.2498)
Total (95% Cl)
Test for heterogeneity: y2 = 4.25, df = 4 (P= 0.37), I2 = 5.9% 
Test for overall effect: Z= 3.36 (P= 0.0008)
p16
Naka et al 
Gerdes et al 
Kawesha ef al
-0.7985 (0.3849) 
-0.6733 (0.3611) 
-0.1985 (0.2475)
Total (95% Cl)
Test for heterogeneity: /2 = 2.23, df = 2 (P= 0.33), I 
Test for overall effect: Z= 2.39 (P= 0.02)
2 _ 10.5%
27.23 0.43 [0.25, 0.74]
21.82 0.45 [0.25, 0.82]
2.23 0.50 [0.08, 3.33]
27.11 0.56 [0.33, 0.96]
21.61 0.64 [0.35, 1.18]
100.00 0.51 [0.36, 0.68]
13.51 0.47 [0.23, 0.97]
23.95 0.49 [0.28, 0.85]
26.05 0.56 [0.33, 0.95]
6.51 0.80 [0.28, 2.29]
29.98 0.93 [0.57, 1.52]
100.00 0.63 [0.48, 0.83]
23.25 0.45 [0.21, 0.96]
26.14 0.51 [0.25, 1.04]
50.61 0.82 [0.50, 1.33]
100.00 0.63 [0.43, 0.92]
0.1 0.2 0.5 1 2 5 10
Favours positive Favours negative
Figure I Forrest plot to assess overall effect of VEGF, bcl-2, bax and pi 6 expression on survival.
bax
The initial search yielded 76 studies. Following review of the 
abstracts, a total of seven potentially eligible articles were 
identified. Two of these were excluded due to either a duplicated 
patient series (Hashimoto et al, 2005) or the inclusion of 
periampullary cancers of non-pancreatic origin in the survival 
analysis (Tomazic et al, 2004). Three of the five eligible studies 
investigated the prognostic effect of both bcl-2 and bax and were, 
therefore, included in both meta-analyses (Magistrelli et al, 2006; 
Nio et al, 2001b; Dong et al, 2005b).
The five eligible studies investigating bax included a total of 274 
patients with a median number of 60 patients per study 
(range = 23-67) (Table 2). The median quality score was 65% 
(range = 55-85%) and the median proportion of bax positive cases 
was 54% (range = 26-83%). Figure 2 illustrates the Forrest plot for 
the pooled survival data. There was no evidence of any significant 
heterogeneity (^2 = 4.25, P = 0.37; I2 = 5.9%). The combined HR 
was recorded as 0.63 (95% Cl = 0.48-0.83) and the funnel plot for 
this analysis is shown in Figure 3.
pl6
The initial search returned 91 studies, seven of which were 
potentially relevant. Following review of these seven articles, three 
fulfilled all of the eligibility criteria. The remaining studies were 
rejected due to the inclusion of unresected cases (Hu et al, 1997; 
Biankin et al, 2002), no IHC used in tissue analysis (Ohtsubo et al, 
2003) or only disease-free survival times reported (Jeong et al, 
2005). A total of 229 patients were included in the pooled analysis. 
There was no evidence of any significant heterogeneity across the 
three included studies (xz = 2.23, P = 0.33; /2 = 10.5%). A com­
bined HR of 0.63 (95% Cl = 0.43-0.92) was obtained, indicating a 
significant association between pl6 expression and more favour­
able survival.
p53
The initial search returned a total of 337 studies. Following review 
of these abstracts, 58 potentially relevant studies were retrieved of 
which 17 fulfilled all of the inclusion criteria. The remaining
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p53 LogHR (SE) HR (95% Cl)
Sarela et al -0.6350 (0.7980)
Bold et al -0.4780 (0.3021)
Magistrelli et al -0.3857 (0.2725)
Ahrendt et al -0.2614 (0.3457)
Naka et al -0.1744 (0.4678)
Kawesha et al -0.1054 (0.1726)
Virkajan/i et al -0.0101 (0.3858)
Yamasawa et al 0.0100 (0.2524)
Dong et al 0.0198 (0.2709)
Gardes et a! 0.1484 (0.3300)
Lee et a! 0.1570 (0.5077)
Yokoyama et al 0.5596 (0.2782)
Digluseppe et al 0.5710 (0.3156)
Bergan et al 0.7701 (0.3241)
Linder et a! 0.9969 (0.3324)
Gansauge et al 1.0886 (0.4222)
Jinfeng etal 1.1569 (0.4555)
Total (95% Cl)
Test for heterogeneity: y * 
Test for overall effect; Z =
= 37.88, df = 16 (P 
1.63 (P=0.10)
= 0.002), 1* 57.8%
smad4
Toga eta/ 
Tascilar eta/ 
Khorana et al 
Hua et al 
Biankin et al
-0.6733 (0.3276) 
-0.3011 (0.1438) 
-0.1278 (0.2015) 
-0.0619 (0.4042) 
0.8671 (0.4023)
Total (95% Cl)
Test for heterogeneity: /2 = 9.86, df = 4 (P = 0.04), /2 
Test for overall effect: Z - 0.70 (P= 0.49)
59.4%
Weight (%) HR (95% Cl)
1.96 0.53 [0.11, 2.53)
6.63 0.62 [0.34, 1.12]
7.16 0.68 [0.40, 1.16]
5.90 0.77 [0.39, 1.52]
4.26 0.84 [0.34, 2.10]
9.06 0.90 [0.64, 1.26]
5.30 0.99 [0.46, 2.11]
7.53 1.01 [0.62, 1.66]
7.19 1.02 [0.60, 1.73]
6.15 1.16 [0.61, 2.21]
3.84 1.17 [0.43, 3.16]
7.06 1.75 [1.01, 3.02]
6.40 1.77 [0.95, 3.29]
6.25 2.16 [1.14, 4.08]
6.12 2.71 [1.41, 5.20]
4.80 2.97 [1.30, 6.79]
4.40 3.18 [1.30, 7.77]
100.00 1.22 [0.96, 1.56]
17.20 0.51 (0.27, 0.97]
30.10 0.74 [0.56, 0.98]
25.67 0.88 [0.59, 1.31]
13.47 0.94 [0.43, 2.08]
13.55 2.38 [1.08, 5.24]
100.00 0.88 [0.61, 1 .27]
EGFR
Bloomston etal -0.2357 (0.2682) ----- ■- — 29.94 0.79 [0.47, 1.34]
Dong et al 0.0834 (0.3872) -------- ■--------- 22.47 1.09 [0.51, 2.32]
Smeenk et al 0.6575 (0.3804) ------ •--------  22.85 1.93 [0.92, 4.07]
Ueda et al 0.8109 (0.3482) ------- ■------- 24.74 2.25 [1.14, 4.45]
Total (95% Cl) 100.00 1 .35 [0.80, 2.27]
Test for heterogeneity: /2 = 7.20, df = 3 (P = 0.07), I2 = 58.3%
Test for overall effect: Z = 1.13 (P= 0.26)
0.1 0.2 0.5 1 2 5 10
Favours positive Favours negative
Figure 2 Forrest plot to assess overall effect of p53, smad4 and EGFR expression on survival.
studies were rejected for the following reasons: duplicated series of 
patients (Dergham et al, 1997a; Dong et al, 1998b; Nio et al, 1998; 
Nio et al, 1999; Dong et al, 2000; Linder et al, 2001; Nio et al, 
2001a), no dichotomised univariate survival analysis conducted 
(Sessa et al, 1998; Karademir et al, 2000; Evans et al, 2001; Fujioka 
et al, 2001; Gazzaniga et al, 2001; Biankin et al, 2002; Dang et al, 
2002; Hashimoto et al, 2005; Dong ef al, 2007; Smeenk et al, 2007), 
no IHC used in tissue analysis (Weyrer et al, 1996; Li et al, 1999; 
Yamaguchi et al, 2000; Ohshio et al, 2002; Dong et al, 2003), 
unresected cases included in survival analysis (Zhang et al, 1994; 
Aizawa et al, 1996; Lundin et al, 1996; Coppola et al, 1998; 
Dergham et al, 1998; Makinen et al, 1998; Ohshio et al, 1998; Hu 
et al, 1999; Takikita et al, 2009), mix of different tumour types 
included (Sinicrope et al, 1996; Sato et al, 1997; Gansauge et al, 
1998; Yu et al, 2004), only disease-free survival reported 
(Jeong et al, 2005) and insufficient survival data reported 
(Dergham et al, 1997b; Campani et al, 1999; Stipa et al, 2002; 
Hermanova et al, 2009).
The 17 eligible studies included a total of 925 patients with a 
median number of 48 patients per study (range = 26-157) 
(Table 3). Nuclear staining of p53 was used for scoring in all 
cases. Five studies (29%) reported a significant adverse association 
between p53 expression and survival. The median quality 
score was recorded as 65% (range = 45-90%) and the median
proportion of patients exhibiting positive p53 immunostaining was 
47% (range = 25-68%). There was no significant association 
between the IHC cutoff score used and the proportion of cases 
classified as p53 positive (Spearman’s fi = 0.389, P = 0.206). 
Furthermore, there was no significant difference in median 
quality scores between significant and non-significant studies 
(Mann-Whitney, P = 0.243).
Figure 2 illustrates the Forrest plot for the survival data. There 
was no evidence of any significant publication bias (Egger’s test, 
P = 0.298). Significant heterogeneity was demonstrated according 
to Cochran’s y2 test (y2 = 37.88, P = 0.002; I2 = 57.8%). The 
combined HR was recorded as 1.22 (95% Cl = 0.96-1.56), 
indicating no significant overall association between p53 expres­
sion and survival. Of the four studies excluded due to incomplete 
reporting of survival data, only one reported a significant 
association between p53 expression and survival (Stipa et al, 2002).
smad4
The initial search returned 81 studies. Following review of these 
abstracts, five potentially relevant studies were identified, which 
were all found to be eligible for analysis. The combined number of 
patients was 540 with a median of 88 patients per study 
(range = 34-249) (Table 3). The median quality score was 75%
British Journal of Cancer (2011) 104(9). 1440-1451 © 2011 Cancer Research UK
Meta-analysis of IHC prognostic markers
RA Smith et al
0.2 VEGF
0.4
P= 0.269
0.6
0.8
ot ------------------- -------------------------- 1-------------------1--------------------
X
j? 0.1 0.2 0.5 1 2
P= 0.298
Hazard ratio Hazard ratio
1445
Figure 3 Funnel plots to assess publication bias for VEGF, bcl-2, bax and p53 meta-analyses. Note: P-values for result of Egger's regression to assess 
publication bias.
Table 3 Methodological and clinico-pathological data for eligible prognostic studies evaluating p53, smad4 and EGFR
HR Signi- IHC
IHC
cutoff Adjuvant
Reference n (95% Cl) ficant 1 Ab (+ dilution) +ve (%) Male Age N1 T3/T4 Well Mod. Poor therapy
p53
DiGiuseppe et al (1994) 48 1.77 (0.95-3.29) No Novocastra CM-1(1:1000) 26 (54) NS 25 (52) 61 NS NS NS NS NS NS
Yokoyama et al (1994) 57 1.75 (1.01-3.02) Yes Novocastra D07 (1:100) 33 (58) NS NS 64 25 (45) 27 (47) 37 (65) 20 (35) NS
Lee etol (1995) 26 1.17 (0.43-3.16) No Biogenex CM 1 (NS) 7(27) NS 14 (54) NS NS NS 2(8) 20 (77) 4(15) NS
Linder et al (1997) 48 2.71 (1.41-5.20) Yes DAK0D07 (1:50) 22 (46) > 1 36 (68) 66 18 (38) 26 (49) 5(9) 18(34) 30 (57) NS
Virkajarvi et al (1997) 36 0.99 (0.46 - 2.11) No Novocastra CM-I (1 :1000) 15(42) > 1 16 (44) 64 NS NS NS NS NS NS
Naka et al (1998) 32 0.84 (0.34 -2.10) No Novocastra BP53-I2 (1:50) 19 (59) NS 20 (63) 65 23 (72) 13(41) NS NS NS NS
Bold et al (1999) 70 0.62 (0.34-1.12) No Oncogene DO 1 (NS) 33 (47) >25 36 (51) 64 38 (54) NS 15 (22) 37 (56) 15(22) 19 (27)
Gansauge et al (1999) 26 2.97 (1.30-6.79) Yes Oncogene DOI (1:500) 11 (42) NS 12 (50) 59 22 (85) NS NS NS NS 26 (100)
Ahrendt et al (2000) 43 0.77 (0.39-1.52) No DAKO 007 (1:2000) 26 (60) >33 24 (55) 63 23 (53) 22(51) II (26) 23 (55) 8(19) 29 (66)
Bergan et al (2000) 60 2.16 (1.14-4.08) Yes Novocastra D07 (1:100) 15(25) >5 41 (50) 62 18 (30) 21 (35) 25 (42) 23 (38) 12(20) 0(0)
Kawesha et al (2000) 157 0.90 (0.64-1.26) No DAKO DO? (1:300) 64 (41) >5 100 (64) 60 71 (46) NS 21 (13) 77 (49) 59 (38) 13(8)
Gerdes et al (2002) 40 1.16 (0.61-121) No DAKO D07 (1:400) 13(33) > 10 22 (55) NS 16 (40) NS NS NS NS 0(0)
Sanela et al (2002) 52 0.53 (0.11-153) No DAKO DO 7 (1:100) 28 (54) > 10 27 (52) 64 40 (78) 49 (94) 11 (22) 24 (47) 16(31) NS
Yamasawa et al (2002) 72 1.01 (0.62-1.66) No Oncogene DOI (2/tg/ml) 34 (47) >20 34 (47) 65 21 (29) 42 (58) 35 (49) 32 (44) 5(7) 41 (57)
Dong et al (2005a) 59 1.02 (0.60-1.73) No DAKO D07 (1:20) 40 (68) > 10 38 (64) NS 47 (80) NS 19 (32) 21 (36) 19 (32) NS
Magistrelli et al (2006) 67 0.68 (0.40-1.16) No DAKO D07 (1:50) 32 (48) >5 45 (67) 63 34(51) 40 (62) 14(21) 28 (42) 15(22) 30 (45)
jinfeng et al (2007) 32 3.18 (1.30-7.77) Yes DAKO D07 (1:50) 13(41) >10 19 (59) 63 18 (56) 23 (72) 11 (34) 18 (56) 3(10) NS
smad4
Tascilar et al (2001) 249 0.74 (0.56 - 0.98) Yes Santa Cruz B8 (1: 100) 111 (46) NS 139 (56) 65 NS NS NS NS NS NS
Biankin et al (2002) 45 2.38 (1.08-5.24) Yes Santa Cruz B8 (NS) 10 (22) >5 27 (60) 61 21 (47) NS 5(11) 28 (62) 12(27) 8(16)
Hua et al (2003) 34 0.94 (0.43-2.08) No Santa Cruz B8 (1:100) 26 (76) NS 22 (65) 55 14 (41) NS 27 (79) 7(21) NS
Toga et al (2004) 88 0.51 (0.27-0.97) Yes Santa Cruz B8 (1 : 100) 13(15) > 10 43 (49) 66 78 (89) 33 (37) 37 (42) 45 (51) 6(7) 58 (66)
Khorana et al (2005) 124 0.88 (0.59-1.31) No Santa Cruz (1:400) 59 (48) >5 69 (56) 67 56 (45) 69 (58) 23 (19) 52 (43) 45 (38) 88 (79)
EGFR
Dong et al (1998a) 57 1.09 (0.51-2.32) No Oncogene 985/996 (1:20) 39 (68) NS 20 (35) 55 46 (81) NS 18(32) 22 (39) 17 (30) 7(12)
Ueda et al (2004) 76 125 (1.14-4.45) Yes Zymed 3IG7 (1:200) 47 (62) > 10 57 (75) 63 59 (78) NS II (14) 32 (42) 33 (43) NS
Bloomston et al (2006) 71 0.79 (0.47-1.34) No Dakocytomation
2I8C9 (NS)
49 (69) > 1 40 (56) 65 41 (58) 57 (81) 6(9) 45 (63) 20 (28) NS
Smeenk et al (2007) 46 1.93 (0.92-4.07) No DAKO H11 (NS) II (24) > 1 37 (66) 63 29 (52) 34 (61) 6(11) 43 (77) 7(12) 19 (34)
Abbreviations; Cl = confidence interval; EGFR = epidermal growth factor receptor; HR = hazard ratio; IHC = immunohistochemical; NC = non-commercial; NS = not specified. 
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod./Poor refers to tumour differentiation.
(range = 60-95%) and the median proportion of patients exhibit­
ing positive smad4 immunostaining was 45% (range = 15-76%). 
Figure 2 illustrates the Forrest plot. There was evidence of 
significant heterogeneity across the included studies (y2 = 9.86.
P = 0.04; I2 = 59.4%). A combined HR of 0.88 (95% Cl = 0.61- 
1.27) was recorded, indicating no significant overall association 
between smad4 expression and survival in the pooled 
patient group.
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The initial search identified 324 studies. Following review of these 
abstracts, 10 potentially relevant articles were retrieved. Six of 
these studies were rejected for the following reasons: duplicated 
series of patients (Uegaki et al, 1997; Ueda et al, 2006), no 
dichotomised univariate survival analysis conducted (Yamanaka 
et al, 1993; Zhang and Yuan, 2002) and unresected cases included 
in analysis (Gansauge et al, 1998; Takikita et al, 2009). The four 
eligible studies included a total of 250 patients (Table 3). Only a 
single study reported a significant relationship between EGFR 
expression and survival (Ueda et al, 2004). The median quality 
score was 70% (range = 65-70%). Figure 2 illustrates the Forrest 
plot for the pooled data. Significant heterogeneity was demon­
strated (x2 = 7.20, P = 0.07). The combined HR was recorded as 
1.35 (95% Cl = 0.80-2.27), indicating no significant overall 
association between EGFR expression and survival.
DISCUSSION
Previous meta-analyses of studies investigating the prognostic 
value of molecular markers have been published for different 
malignancies. These include VEGF (Delmotte et al, 2002; Kyzas 
et al, 2005a; Des Guetz et al, 2006), bcl-2 (Martin et al, 2003; 
Callagy et al, 2008) and p53 (Kyzas et al, 2005b; Malats et al, 2005). 
To date, no such meta-analysis has been undertaken for any 
studies evaluating immunohistochemical prognostic markers in 
resected pancreatic cancer.
Meta-analysis of prognostic literature is associated with a 
number of inherent limitations. One of these key limitations is 
the general prevalence of retrospective study design in this setting. 
None of the studies included in the current meta-analysis specified 
a prospective design and archived paraffin-embedded tumour 
material was utilised for IHC in all cases. This indicates that 
availability of tissue is invariably the main determinant of study 
size rather than any specific considerations relating to adequate 
statistical power in order to reliably detect a prognostic effect 
for the marker of interest. The availability and adequacy of 
corresponding clinico-pathological data is also a significant 
consideration in retrospective studies of this type and we identified 
several studies reporting incomplete datasets with regard to 
histopathological details. Alongside this, an additional hindrance 
to meta-analysis of prognostic literature is the general lack of 
multivariable survival data. This is usually attributable to the fact 
that the number of patients included in each study is typically 
small, precluding any meaningful attempt at analysing multiple 
covariates.
Additional challenges in the interpretation and comparison of 
immunohistochemical prognostic studies include variability in 
patient selection (i.e. resected and unresected cases, inclusion of 
non-pancreatic periampullary tumours), disparate immunohisto­
chemical criteria used for prognostic classification, bias associated 
with the statistical approach to analysis of survival data 
(e.g. selection of data-driven cutoff values for continuous 
variables), incomplete reporting of survival data, duplicated 
patient series and publication bias arising as a result of selective 
reporting of ‘positive’ studies (Altman, 2001). In order to 
overcome some of these comparative difficulties, specific inclusion 
criteria were applied in order to select studies for meta-analysis. 
Only studies including resected pancreatic adenocarcinoma were 
included in order to avoid any confounding effects on survival 
associated with differing proportions of resected and unresected 
cases. Any studies including periampullary tumours of non- 
pancreatic origin were also excluded due to the disparity in 
survival outcomes characteristically associated with ampullary, 
duodenal and bile duct adenocarcinomas when compared with 
pancreatic adenocarcinoma (Riall et al, 2006). Furthermore, 
in cases where part or all of the same patient series was included
in more than one publication, only the more recent or most 
complete study was included in the analysis in order to avoid 
duplicating the same patient data for the immunohistochemical 
marker of interest. For those studies where insufficient survival 
data was reported to generate indirect calculations for the logHR 
and variance, authors were contacted for additional survival data. 
However, in all cases the authors were either unable to provide 
any supplementary data or no response was received. The only 
supplementary raw data obtained was for two studies previously 
conducted at our own institution (Kawesha et al, 2000; Evans et al, 
2001). Therefore, no subsequent attempt to request individual 
patient survival data for all eligible studies was undertaken, 
although this would have been potentially beneficial.
When analysing the overall relationships between individual 
study size, reported prognostic significance and methodological 
quality scores in the present study, there was a significant trend 
towards superior methodological quality in larger studies as one 
might reasonably expect, despite the fact that study size itself was 
not one of the criteria used for quality scoring. When considering 
the overall effect of potential publication bias in this analysis, only 
a minority of studies (21 out of 50) actually reported a statistically 
significant prognostic result. Furthermore, the funnel plots and 
Egger’s tests for the individual analyses, although more difficult to 
interpret when fewer studies were included, were not generally 
indicative of any strong publication bias.
Vascular endothelial growth factor emerged as the most 
potentially informative immunohistochemical prognostic marker 
from the pooled data. Vascular endothelial growth factor com­
prises four ligands (VEGF-A, VEGF-B, VEGF-C and VEGF-D), 
which exhibit specific binding profiles with three transmembrane 
VEGF receptors (VEGF-I, -II and -III) and promote intracellular 
tyrosine kinase cascades when activated. The VEGF-A (usually 
referred to simply as VEGF) mediates the key pro-angiogenic 
properties of proliferation and migration of endothelial cells along 
with increasing vascular permeability (Yamazaki and Morita, 2006; 
Dallas et al, 2007). Alternate gene splicing results in a number of 
VEGF-A isoforms of differing amino-acid lengths, the smaller of 
which (e.g. 121 and 165) are secreted while the larger (e.g. 189 and 
206) remains cell associated. VEGF-C and VEGF-D are implicated 
in the process of lymphangiogenesis (Achen and Stacker, 2008) 
while the function of VEGF-B is incompletely understood (Nash 
et al, 2006). Pancreatic cancer cells have been demonstrated to 
express both VEGF ligand and its receptors, implicating a potential 
VEGF-mediated autocrine loop in the proliferation of pancreatic 
malignancy (Biichler ef al, 2002).
The results from the present study demonstrate that, despite 
variability between eligible studies as to the relative prognostic 
impact of VEGF expression in resected pancreatic adenocarcino­
ma, the observed survival trend is concordant with that reported 
for other malignancies in similar meta-analyses (Delmotte et al, 
2002; Kyzas et al, 2005a, b; Des Guetz et al, 2006). When comparing 
the value for the pooled HR identified in the present study (1.51 
(95% Cl = 1.18-1.92)) with the above referenced studies, the order 
of magnitude for this effect is also broadly comparable for that 
quoted for both lung cancer (1.48 (95% Cl = 1.27-1.72)) and 
colorectal cancer (1.65 (95% Cl = 1.27-2.14)).
Significant heterogeneity was observed when analysing 
the logHR estimates from the eligible studies. Evaluation of the 
relevant methodological and clinico-pathological characteristics of 
each study revealed a number of potential sources of heterogeneity 
in study methodology. Nine studies reported use of commercially 
available anti-VEGF primary antibodies, all of which exhibit 
broadly comparable binding characteristics with the common 
splice variants of VEGF-A. When analysing the concentrations of 
primary antibody utilised, most studies reported comparable 
dilution ratios. However, the concentration was not specified 
in two studies. This issue is potentially relevant for the 
study reporting use of the lowest primary antibody dilution
British Journal of Cancer (2011) 104(9), 1440-1451 © 2011 Cancer Research UK
Meta-analysis of IHC prognostic markers
RA Smith et al
"|447
(Lim ef al, 2004) as this was one of only two studies, which 
indicated a contradictory prognostic effect when compared with 
the overall group (i.e. a non-significant trend towards adverse 
survival with negative VEGF immunostaining).
When reviewing the immunohistochemical criteria used for 
VEGF scoring, the majority of studies reported a scoring system 
based on cytoplasmic staining of tumour cells. Where the 
distribution of immunostaining used for scoring was not explicitly 
stated in the text (i.e. cytoplasmic, membranous, nuclear, stromal, 
etc.), the figures of representative VEGF staining presented in the 
relevant studies were all strongly indicative of cytoplasmic staining 
being used to define positive VEGF expression in cancer cells. 
All studies with one exception utihsed a system of dichotomising 
patients according to the percentage of positively stained cells 
present. Despite the range of values used to define VEGF positivity 
across the included studies, there was no evidence of any 
significant association between the % cutoff value used and the 
corresponding proportion of VEGF positive patients reported. 
Furthermore, if including only the six studies, which used a 
standardised cutoff value of > 10% for meta-analysis, the 
significance of the association between VEGF staining and 
adverse survival was unchanged (HR = 1.62 (95% Cl = 1.09- 
2.40)—random effects). These observations indicate that differ­
ences in the specific scoring criteria used for immunohistochem­
ical classification appear unlikely to have a significant confounding 
effect in describing the underlying relationship between VEGF 
expression and survival observed for the overall group.
Broadly comparable demographic and histological tumour 
characteristics were observed across the eligible VEGF studies, 
indicating that similar patient populations were evaluated in the 
combined analysis. Data relating to adjuvant therapy was only 
reported in 6 out of 11 studies and the treatment modalities 
included a mix of both chemotherapy and chemoradiation. 
Importantly, no studies reported any policy of selection of patients 
for adjuvant therapy based on VEGF tumour expression 
as immunohistochemical evaluation was undertaken on a retro­
spective basis in all cases. This was equally true for studies 
evaluating the other markers of interest.
Both bcl-2 and bax emerged as potentially relevant immuno­
histochemical prognostic factors. These proteins belong to the 
bcl-2 family and regulate apoptosis by mediating cytosolic release 
of cytochrome C from mitochondria in response to cellular stress. 
Cytochrome C binds to APAF-1 and cleaves caspase-9 into its 
active form, thereby initiating the activation of executioner 
caspases resulting in cytoskeletal degradation and cell death 
(Hamacher et al, 2008). The bcl-2-associated X protein (bax) 
promotes release of cytochrome C and consequently exhibits pro- 
apoptotic properties. In contrast, bcl-2 inhibits mitochondrial 
release of cytochrome C and has anti-apoptotic effects as a result. 
The finding that bax expression is associated with more favourable 
survival in resected pancreatic cancer is, therefore, concordant 
with its physiological role. The observation that the same 
relationship is consistently seen for bcl-2 expression appears 
paradoxical. However, this finding is mirrored in other malig­
nancies (Martin et al, 2003; Callagy et al, 2008) and it is beheved 
that a complex interaction of competitive dimerisations between 
pro- and anti-apoptotic proteins governs the cell’s fate in response 
to apoptotic stimuli (Westphal and Kalthoff, 2003). It is difficult to 
draw any reliable conclusions from the current meta-analysis of 
bcl-2 and bax for the pancreatic literature due to the Umited 
number of evaluable studies. However, the overall trend towards 
both bax and bcl-2 expression being associated with more 
favourable survival outcomes is generally consistent with the 
findings seen in other malignancies.
The tumour suppressor gene pl6 (CDKN2A) has a key role in 
pancreatic carcinogenesis (Schutte et al, 1997). pl6 is a cell-cycle 
checkpoint protein, which binds to cyclin-dependent kinases 
resulting in cell-cycle arrest at the Gl/S checkpoint.
The observation that positive immunostaining for pl6 appears 
to represent a favourable prognostic feature is, therefore, also 
consistent with its tumour suppressor function. However, the 
small number of eligible studies included in this analysis again 
precludes any meaningful conclusions regarding the repro­
ducibility of pl6 expression as a reliable marker of prognosis in 
resected pancreatic cancer.
Of the various factors evaluated in the present study, the tumour 
suppressor protein p53 was found to represent the most 
extensively investigated immunohistochemical prognostic marker. 
It also exhibited a significant degree of heterogeneity in the 
reported association between immunostaining and survival for 
individual studies. Although the overall trend was towards 
overexpression of p53 resulting in adverse survival for the pooled 
data, this did not reach significance and there is no obvious 
explanation for the contradictory results seen between the various 
studies. The majority of studies used either the monoclonal DO-7, 
DO-1 or polyclonal CM-1 primary antibodies, which all exhibit 
immunoreactivity with both wild-type and mutant forms of p53. 
Due to the increased stability of mutant p53, most of the nuclear 
immunostaining seen reflects the presence of the mutant rather 
than wild-type p53 protein. Despite the marked differences 
between studies in terms of the proportion of cases classified as 
p53 positive, reported primary antibody dilutions used and cutoff 
values selected for immunohistochemical scoring, there was no 
clear association between any of these factors and either the 
direction of the prognostic effect or the reported magnitude of the 
HR, which might potentially explain the disparity in survival 
trends. As a result of these findings, immunohistochemical 
overexpression of p53 cannot be recommended as a reliable or 
reproducible marker of prognosis in resected pancreatic cancer 
from the available evidence.
The smad4 (or DPC4) protein is a central component of the 
intracellular signalling pathway for transforming growth factor 
f} (TGF-/1), and loss of smad4 expression represents an important 
event in the progression of PanINs to invasive malignancy 
(Wilentz et al, 2000). The results from the analysis of the five 
studies evaluating smad4 expression again demonstrate unex­
plained heterogeneity in the reporting of the prognostic effect of 
this marker. Biankin et al reported an entirely contradictory 
survival trend to the other four studies with loss of smad4 
expression being associated with significantly improved patient 
survival despite use of the same primary antibody and otherwise 
broadly comparable study methodology and patient groups. This 
survival trend appears at odds with the accepted tumour 
suppressor role of smad4 in mediating the inhibitory signalling 
associated with the TGF-jS pathway. Despite the fact that the 
patient series reported by Biankin et al only accounts for 8% of all 
patients included in the combined analysis and 14% of the 
weighting allocated to the pooled survival data, the discrepancy in 
the results is such that sufficient heterogeneity is introduced to 
require a random effects approach resulting in a non-significant 
result for the overall analysis. These findings further underline the 
difficulties in making any reliable conclusions regarding the 
relative prognostic value of immunohistochemical markers when 
analysed in limited patient series.
Epidermal growth factor receptor is the cell surface receptor for 
a family of extracellular ligands, which include EGF and TGF-a and 
is coded for by the c-erbBl proto-oncogene. Activation of EGFR 
stimulates intracellular tyrosine kinase phosphorylation with 
consequent activation of a number of signalling cascades including 
the MAPK (mitogen-activated protein kinase) and Akt (protein 
kinase) pathways, which promote cell proliferation (Ciardello and 
Tortora, 2008). The analysis of the four eligible studies included in 
the current meta-analysis again fails to make a strong case for 
tumoural overexpression of EGFR representing a reproducible 
prognostic marker. However, the laboratory methodologies 
reported in the four studies demonstrated more marked variability
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(e.g., use of four different EGFR primary antibodies) when 
compared with some of the other analyses.
Despite the inherent limitations of meta-analysing prognostic 
literature, the findings from the present study suggest that VEGF 
represents the most consistently reproducible molecular marker 
with prognostic value in resected pancreatic adenocarcinoma. This 
result is concordant with existing meta-analyses, which implicate a 
similar prognostic role for VEGF expression in other malignancies 
and lend further weight to the assertion that angiogenesis is a key 
determinant in driving pancreatic cancer progression. For several 
of the other markers evaluated in this study, directly contradictory 
prognostic effects were commonly observed with significant 
variability in the proportions of positive immunostaining reported, 
despite often broadly comparable patient groups and study 
methodologies. These results provide further evidence to suggest
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with which these factors can be translated into clinical use (e.g., 
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Manuyakorn et al, 2010).
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